
<html lang="en"     class="pb-page"  data-request-id="628a0d92-6384-46e9-866a-f6ddcba23c4a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.6b00902;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2016.59.issue-18"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I “Gatekeeper” Mutant of cKIT Kinase" /></meta><meta name="dc.Creator" content="Binhua  Li" /></meta><meta name="dc.Creator" content="Aoli  Wang" /></meta><meta name="dc.Creator" content="Juan  Liu" /></meta><meta name="dc.Creator" content="Ziping  Qi" /></meta><meta name="dc.Creator" content="Xiaochuan  Liu" /></meta><meta name="dc.Creator" content="Kailin  Yu" /></meta><meta name="dc.Creator" content="Hong  Wu" /></meta><meta name="dc.Creator" content="Cheng  Chen" /></meta><meta name="dc.Creator" content="Chen  Hu" /></meta><meta name="dc.Creator" content="Wenchao  Wang" /></meta><meta name="dc.Creator" content="Jiaxin  Wu" /></meta><meta name="dc.Creator" content="Zhenquan  Hu" /></meta><meta name="dc.Creator" content="Ling  Ye" /></meta><meta name="dc.Creator" content="Fengming  Zou" /></meta><meta name="dc.Creator" content="Feiyang  Liu" /></meta><meta name="dc.Creator" content="Beilei  Wang" /></meta><meta name="dc.Creator" content="Li  Wang" /></meta><meta name="dc.Creator" content="Tao  Ren" /></meta><meta name="dc.Creator" content="Shaojuan  Zhang" /></meta><meta name="dc.Creator" content="Mingfeng  Bai" /></meta><meta name="dc.Creator" content="Shanchun  Zhang" /></meta><meta name="dc.Creator" content="Jing  Liu" /></meta><meta name="dc.Creator" content="Qingsong  Liu" /></meta><meta name="dc.Description" content="cKIT kinase inhibitors, e.g., imatinib, could induce drug-acquired mutations such as cKIT T670I that rendered drug resistance after chronic treatment. Through a type II kinase inhibitor design appr..." /></meta><meta name="Description" content="cKIT kinase inhibitors, e.g., imatinib, could induce drug-acquired mutations such as cKIT T670I that rendered drug resistance after chronic treatment. Through a type II kinase inhibitor design appr..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 30, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00902" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00902" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00902" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00902" /></link>
        
    
    

<title>Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I “Gatekeeper” Mutant of cKIT Kinase | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00902" /></meta><meta property="og:title" content="Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I “Gatekeeper” Mutant of cKIT Kinase" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0018.jpeg" /></meta><meta property="og:description" content="cKIT kinase inhibitors, e.g., imatinib, could induce drug-acquired mutations such as cKIT T670I that rendered drug resistance after chronic treatment. Through a type II kinase inhibitor design approach we discovered a highly potent type II cKIT kinase inhibitor compound 35 (CHMFL-KIT-8140), which potently inhibited both cKIT wt (IC50 = 33 nM) and cKIT gatekeeper T670I mutant (IC50 = 99 nM). Compound 35 displayed strong antiproliferative effect against GISTs cancer cell lines GIST-T1 (cKIT wt, GI50 = 4 nM) and GIST-5R (cKIT T670I, GI50 = 26 nM). In the cellular context it strongly inhibited c-KIT mediated signaling pathways and induced apoptosis. In the BaF3-TEL-cKIT-T670I isogenic cell inoculated xenograft mouse model, 35 exhibited dose dependent tumor growth suppression efficacy and 100 mg/kg dosage provided 47.7% tumor growth inhibition (TGI) without obvious toxicity. We believe compound 35 would be a good pharmacological tool for exploration of the cKIT-T670I mutant mediated pathology in GISTs." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00902"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00902">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00902&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00902&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00902&amp;href=/doi/10.1021/acs.jmedchem.6b00902" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 8456-8472</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00867" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00914" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of <i>N</i>-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I “Gatekeeper” Mutant of cKIT Kinase</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Binhua++Li">Binhua Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aoli++Wang">Aoli Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Juan++Liu">Juan Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ziping++Qi">Ziping Qi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaochuan++Liu">Xiaochuan Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kailin++Yu">Kailin Yu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Wu">Hong Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cheng++Chen">Cheng Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chen++Hu">Chen Hu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wenchao++Wang">Wenchao Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiaxin++Wu">Jiaxin Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhenquan++Hu">Zhenquan Hu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ling++Ye">Ling Ye</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fengming++Zou">Fengming Zou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Feiyang++Liu">Feiyang Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Beilei++Wang">Beilei Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li++Wang">Li Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tao++Ren">Tao Ren</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shaojuan++Zhang">Shaojuan Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mingfeng++Bai">Mingfeng Bai</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shanchun++Zhang">Shanchun Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Liu">Jing Liu</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qingsong++Liu">Qingsong Liu</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">High Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">University of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">⊥</span> <span class="aff-text">Molecular Imaging Laboratory, Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15219, United States</span></div><div class="aff-info" id="aff5b"><span class="aff-symbol">#</span> <span class="aff-text">Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States</span></div><div class="aff-info" id="aff5c"><span class="aff-symbol">∇</span> <span class="aff-text">University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, United States</span></div><div class="aff-info" id="aff6"><span class="aff-symbol">○</span> <span class="aff-text">Hefei Cosource Medicine Technology Co. LTD., 358 Ganquan Road, Hefei, Anhui 230031, P. R. China</span></div><div class="corresp-info"><strong>*</strong>J.L.: phone, 86-551-65593186; e-mail, <a href="/cdn-cgi/l/email-protection#cba1a2a5aca7a2be8ba3a6ada7e5aaa8e5a8a5"><span class="__cf_email__" data-cfemail="7c1615121b1015093c14111a10521d1f521f12">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>Q.L.: phone, 86-551-65595161; e-mail, <a href="/cdn-cgi/l/email-protection#f687859a9f83cfc1b69e9b909ad89795d89598"><span class="__cf_email__" data-cfemail="5726243b3e226e60173f3a313b793634793439">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00902&amp;href=/doi/10.1021%2Facs.jmedchem.6b00902" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 8456–8472</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 22, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>16 June 2016</li><li><span class="item_label"><b>Published</b> online</span>30 August 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 September 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00902" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00902</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8456%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBinhua%2BLi%252C%2BAoli%2BWang%252C%2BJuan%2BLiu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D18%26contentID%3Dacs.jmedchem.6b00902%26title%3DDiscovery%2Bof%2BN-%2528%25281-%25284-%25283-%25283-%2528%25286%252C7-Dimethoxyquinolin-3-yl%2529oxy%2529phenyl%2529ureido%2529-2-%2528trifluoromethyl%2529phenyl%2529piperidin-4-yl%2529methyl%2529propionamide%2B%2528CHMFL-KIT-8140%2529%2Bas%2Ba%2BHighly%2BPotent%2BType%2BII%2BInhibitor%2BCapable%2Bof%2BInhibiting%2Bthe%2BT670I%2B%25E2%2580%259CGatekeeper%25E2%2580%259D%2BMutant%2Bof%2BcKIT%2BKinase%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8472%26publicationDate%3DSeptember%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00902"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1564</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00902" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I “Gatekeeper” Mutant of cKIT Kinase&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Binhua&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Aoli&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Juan&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Ziping&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Xiaochuan&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Kailin&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Cheng&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Chen&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Wenchao&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Jiaxin&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Zhenquan&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Ling&quot;,&quot;last_name&quot;:&quot;Ye&quot;},{&quot;first_name&quot;:&quot;Fengming&quot;,&quot;last_name&quot;:&quot;Zou&quot;},{&quot;first_name&quot;:&quot;Feiyang&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Beilei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Tao&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Shaojuan&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Mingfeng&quot;,&quot;last_name&quot;:&quot;Bai&quot;},{&quot;first_name&quot;:&quot;Shanchun&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Qingsong&quot;,&quot;last_name&quot;:&quot;Liu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;8456-8472&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00902&quot;},&quot;abstract&quot;:&quot;cKIT kinase inhibitors, e.g., imatinib, could induce drug-acquired mutations such as cKIT T670I that rendered drug resistance after chronic treatment. Through a type II kinase inhibitor design approach we discovered a highly potent type II cKIT kinase inhibitor compound 35 (CHMFL-KIT-8140), which potently inhibited both cKIT wt (IC50 = 33 nM) and cKIT gatekeeper T670I mutant (IC50 = 99 nM). Compound 35 displayed strong antiproliferative effect against GISTs cancer cell lines GIST-T1 (cKIT wt, GI50 = 4 nM) and GIST-5R (cKIT T670I, GI50 = 26 nM). In the cellular context it strongly inhibited c-KIT mediated signaling pathways and induced apoptosis. In the BaF3-TEL-cKIT-T670I isogenic cell inoculated xenograft mouse model, 35 exhibited dose dependent tumor growth suppression efficacy and 100 mg/kg dosage provided 47.7% tumor growth inhibition (TGI) without obvious toxicity. We believe compound 35 would be a good pharmacological tool for exploration of the cKIT-T670I mutant mediated pathology in GISTs.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00902&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00902" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00902&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00902" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00902&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00902" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00902&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00902&amp;href=/doi/10.1021/acs.jmedchem.6b00902" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00902" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00902" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00902%26sid%3Dliteratum%253Aachs%26pmid%3D27545040%26genre%3Darticle%26aulast%3DLi%26date%3D2016%26atitle%3DDiscovery%2Bof%2BN-%2528%25281-%25284-%25283-%25283-%2528%25286%252C7-Dimethoxyquinolin-3-yl%2529oxy%2529phenyl%2529ureido%2529-2-%2528trifluoromethyl%2529phenyl%2529piperidin-4-yl%2529methyl%2529propionamide%2B%2528CHMFL-KIT-8140%2529%2Bas%2Ba%2BHighly%2BPotent%2BType%2BII%2BInhibitor%2BCapable%2Bof%2BInhibiting%2Bthe%2BT670I%2B%25E2%2580%259CGatekeeper%25E2%2580%259D%2BMutant%2Bof%2BcKIT%2BKinase%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D18%26spage%3D8456%26epage%3D8472%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291264" title="Kinase inhibitors">Kinase inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291763" title="Noncovalent interactions">Noncovalent interactions</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/jmcmar.2016.59.issue-18/20160922/jmcmar.2016.59.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">cKIT kinase inhibitors, e.g., imatinib, could induce drug-acquired mutations such as cKIT T670I that rendered drug resistance after chronic treatment. Through a type II kinase inhibitor design approach we discovered a highly potent type II cKIT kinase inhibitor compound <b>35</b> (CHMFL-KIT-8140), which potently inhibited both cKIT wt (IC<sub>50</sub> = 33 nM) and cKIT gatekeeper T670I mutant (IC<sub>50</sub> = 99 nM). Compound <b>35</b> displayed strong antiproliferative effect against GISTs cancer cell lines GIST-T1 (cKIT wt, GI<sub>50</sub> = 4 nM) and GIST-5R (cKIT T670I, GI<sub>50</sub> = 26 nM). In the cellular context it strongly inhibited c-KIT mediated signaling pathways and induced apoptosis. In the BaF3-TEL-cKIT-T670I isogenic cell inoculated xenograft mouse model, <b>35</b> exhibited dose dependent tumor growth suppression efficacy and 100 mg/kg dosage provided 47.7% tumor growth inhibition (TGI) without obvious toxicity. We believe compound <b>35</b> would be a good pharmacological tool for exploration of the cKIT-T670I mutant mediated pathology in GISTs.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20008" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20008" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. There are approximately (1–2)/100 000 newly diagnosed patients with GISTs each year in the U.S.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Almost all GISTs express cKIT kinase and about 80–85% of all GISTs cases are associated with gain-of-function mutations in the cKIT gene.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> c-KIT kinase is a member of the type III transmembrane receptor tyrosine kinase (RTK) family. Under physiological conditions, it gets activated upon binding of the extracellular stem cell factor (SCF). cKIT plays important roles in cellular transformation and differentiation, including proliferation, survival, adhesion, and chemotaxis.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Constitutive activation of the cKIT kinase is critical in the pathogenesis of GISTs.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> Due to the critical role of cKIT kinase to the tumorigenesis of GISTs, it has been extensively explored as an important drug discovery target for anti-GIST therapy.</div><div class="NLM_p">Currently there are two cKIT kinase inhibitors approved for the clinical use for GISTs. Compound <b>1</b> (imatinib,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a><a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) was the first type II kinase inhibitor approved as the first-line treatment for advanced GIST. Unfortunately, approximately 14% of patients are initially insensitive to compound <b>1</b>;<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> furthermore, 46–67% of the responding patients will develop resistance through acquisition of a secondary mutation in the cKIT kinase domain,<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9-11)</a> e.g., the ATP-binding pocket mutants V654A and T670I, within 2 years of compound <b>1</b> treatment. The T670 residue located at the gatekeeper position in cKIT kinase provides one of the key hydrogen bonds for the binding of <b>1</b>. Therefore, mutations at this position have a profound effect for compound <b>1</b>’s binding.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> In addition, experimental evidence supports that cKIT T670I mutant will drive a more aggressive earlier metastasis and shorter progression-free survival.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Compound <b>2</b> (sunitinib), a type I kinase inhibitor, was approved by FDA for the treatment of patients with imatinib-resistant GIST in 2006. Because compound <b>2</b> does not occupy the deep hydrophobic pocket generated by DFG motif flip-out as type II inhibitor compound <b>1</b> does, there is enough space to accommodate the more bulky amino acid residue isoleucine associated with the T670I mutation without affecting <b>2</b>’s binding.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Moreover, a panel of small molecule type II kinase inhibitors have been reported to bear cKIT kinase inhibitory activity such as <b>3</b> (nilotinib),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a><b>4</b> (masitinib),<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a><b>5</b> (sorafenib),<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> etc. Among them compounds <b>3</b> and <b>4</b> significantly lost activity against T670I mutant, while compound <b>5</b> exhibited moderate inhibitory activity. Here, we reported our medicinal chemistry effort that started from a hit compound <b>6</b> to the discovery of a new quinoline scaffold based type II cKIT kinase inhibitor compound <b>35</b> (CHMFL-KIT-8140), which displayed potent in vitro and in vivo activities against cKIT gatekeeper T670I mutant (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of the representative cKIT kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic illustration of discovery of compound <b>35</b> (CHMFL-KIT-8140).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83623" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83623" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Structure–Activity Relationship (SAR) Exploration</h3><div class="NLM_p">During high-throughput screening of our in-house generated kinase inhibitors, we obtained a quinoline scaffold based compound <b>6</b> which exhibited moderate antiproliferative activity against BaF3-TEL-cKIT cell line (GI<sub>50</sub> = 0.4 μM) and BaF3-TEL-cKIT-T670I cell line (GI<sub>50</sub> = 2.7 μM). However, the compound demonstrated a good selectivity window against the parental BaF3 cell line (GI<sub>50</sub> > 10 μM). Therefore, we decided to use <b>6</b> as the starting point for further medicinal chemistry modification. In order to get a view of the structural basis for the SAR exploration, we first made a homology model of cKIT T670I mutant based on the cKIT wt X-ray crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>) and examined the detailed binding information on compounds <b>1</b> and <b>6</b> with cKIT wt/T670I (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). In the cKIT wt, compound <b>1</b> forms four key hydrogen bonds: one in the hinge binding area between the pyridine nitrogen of <b>1</b> and Cys673; one in the linker moiety between the aminopyrimidine nitrogen of <b>1</b> and the gatekeeper residue Thr670; two canonical hydrogen bonds between the Glu640 in the c-Helix and Asp810 in the DFG motif with the amide bond of <b>1</b> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). The mutation of gatekeeper residue Thr670 to the more bulky Ile670 results in loss of one of the key hydrogen bonds, and meanwhile the newly generated steric hindrance impeded compound <b>1</b>’s binding (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B). In comparison, in our model compound <b>6</b> forms three key hydrogen bonds with cKIT wt, i.e., one in the hinge binding area and two in the DFG motif and c-helix area (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>C). Compound <b>6</b> has an O-linked phenyl ring in the gatekeeper area and lacks the hydrogen bond formed between Thr670 with compound <b>1</b>. However, the O-linked phenyl ring in <b>6</b> will be likely to generate enough space to accommodate the more bulky Ile670 if it can orientate into a proper direction, which will make it possible to overcome the T670I mutation (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>D). In addition, the CF3 group in <b>6</b> might form hydrophobic interactions with Leu647, Ile653, Leu783, and Ile808 in cKIT, which could be beneficial to the binding (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>E). On the basis of the analysis and the typical type II kinase inhibitor design approach,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> compound <b>6</b> was divided into four parts: the quinoline hinge binding part, the O-bridged phenyl linker part, the amide mediated hydrogen bonding part, and the tail part that occupies the DFG shifting created hydrophobic pocket (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>F). Since the quinoline occupied hinge binding part is required for binding and the O-bridged phenyl linker part is necessary for overcoming cKIT-T670I mutation, we decided to keep them unchanged. We envisioned that variation of the H-bonding area (R1) and the tail part (R2, R3) might alter the orientation of the O-bridged phenyl linker moiety to achieve higher binding affinity and better selectivity against cKIT-T670I kinase mutant.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Schematic illustration of SAR exploration rationale. (A) Binding mode of compound <b>1</b> with cKIT wt (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>). (B) Binding mode of compound <b>1</b> with cKIT T670I homology model (generated based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>). (C) Binding mode of compound <b>6</b> with cKIT wt (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>, docking model). (D) Binding mode of compound <b>6</b> with cKIT T670I homology model (generated based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>, docking model). (E) Illustration of the hydrophobic interaction between the CF3 group of compound <b>6</b> and Leu647, Ile653, Leu783 and Ile808. (F) Illustration of the chemical modification strategy of compound <b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As the starting point, we first explored the SAR of the hydrogen bonding part (R1). BaF3-TEL-cKIT, BaF3-TEL-cKIT-T670I, and parental BaF3 cells were used to monitor the cKIT wt and cKIT-T670I kinase inhibitory activities. Replacement of the amide group in compound <b>6</b> with urea group (<b>7</b>) significantly increased the activity both to cKIT wt (GI<sub>50</sub> = 0.12 μM) and to cKIT T670I (GI<sub>50</sub> = 0.071 μM) and meanwhile showed a selectivity ratio of approximately 12 against parental BaF3 cells (GI<sub>50</sub> = 1.5 μM) (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). However, switching the amide group to a much larger group, i.e., <i>N</i>,<i>N</i>′-dimethylcyclopropane-1,1-dicarboxamide (<b>8</b>), led to the complete loss of activity to both the c-KIT wt and cKIT-T670I (GI<sub>50</sub> > 10 μM). This might be due to the interaction of the cyclopropane substituent with the Glu640, which abolished the critical hydrogen bonds in this area for the type II binding. We then explored the R2 moiety in the tail part by fixing the R1 as the uera. Removal of the trifluoromethyl group (<b>9</b>) also caused complete activity loss to cKIT wt and cKIT-T670I (GI<sub>50</sub> > 10 μM), which indicated that the hydrophobic interaction between the CF3 group and the hydrophobic environment formed by Leu647, Ile653 Leu783, and Ile808 was important for the binding. In addition, replacement of the phenyl group with a pyridine group (<b>10</b>) resulted in significant activity loss in BaF3-TEL-cKIT-T670I cells (GI<sub>50</sub> > 10 μM). These results indicated that the urea group at the R1 position and the (trifluoromethyl)benzyl group at R2 were preferred for better activity.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR Exploration Focused on the R1/R2 Positons<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0014.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0015.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div><div></div></div><div class="NLM_p">On the basis of compound <b>7</b>, we next focused SAR exploration on the R3 position, which presumably occupies the DFG-out shifting generated hydrophobic pocket and usually will provide the selectivity and higher binding affinity for the type II inhibitors (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Shifting the propionyl group from 4-position (<b>7</b>) to 3-position (<b>11</b>) led to about 13-fold activity loss in BaF3-TEL-cKIT-T670I cells (GI<sub>50</sub> = 0.071 μM versus 0.92 μM). Replacement of the propionyl group in <b>7</b> with acetyl group (<b>12</b>) retained the activities against BaF3-TEL-cKIT cells and BaF3-TEL-cKIT-T670I cells (GI<sub>50</sub> = 0.11 μM and 0.046 μM, respectively) and meanwhile displayed better selectivity against parental BaF3 cells (GI<sub>50</sub> = 7.1 μM). Installment of larger groups such as dimethylbutyl (<b>13</b>), glycine (<b>14</b>), and alanine (<b>15</b>) all led to about 10-fold loss of activity against cKIT T670I mutant. However, the <i>N</i>,<i>N</i>-dimethylglycine (<b>16</b>) gained back the activity against cKIT T670I mutant (GI<sub>50</sub> = 0.053 μM) and displayed better activity against cKIT wt (GI<sub>50</sub> = 0.038 μM) as well as better selectivity to parental BaF3 cells (GI<sub>50</sub> = 2.9 μM) compared to <b>7</b>. Introduction of cyclohexene (<b>17</b>) and pyridine groups (<b>18</b>) both led to about 5- to 10-fold activity loss, while tetrahydropyran group (<b>19</b>) gained back the activity against both cKIT wt (GI<sub>50</sub> = 0.087 μM) and cKIT T670I (GI<sub>50</sub> = 0.083 μM). <i>N</i>-Methylpiperidine (<b>20</b>) and <i>N</i>-ethylpiperidine (<b>21</b>) retained similar potency. <i>N</i>-Acyl (<b>22</b>), <i>N</i>-cyclopropanecarbonyl (<b>23</b>), and Boc (<b>24</b>) substituents caused 2- to 3-fold activity loss, and 2-methylpiperidine group (<b>25</b>) resulted in about 10-fold activity loss against cKIT T670I. Increasing the length or size of the piperidine-derived substituents either narrowed down the selectivity window to parental BaF3 cells (<b>26</b> and <b>27</b>) or decreased the activity against cKIT T670I (<b>28</b> and <b>29</b>). Interestingly, ethyl linked morpholine (<b>30</b>) showed impressive activities against cKIT wt (GI<sub>50</sub> = 0.042 μM) and cKIT T670I (GI<sub>50</sub> = 0.059 μM) and meanwhile kept a good selectivity window to parental BaF3 cells (GI<sub>50</sub> = 3.6 μM). Switching the amide moiety to sulfonamide derivatives with different aliphatic chains such as methyl (<b>31</b>), ethyl (<b>32</b>), and propyl (<b>33</b>) did not improve the antiproliferative efficacy against cKIT T670I mutant either. However, introduction of the cyclopropyl group (<b>34</b>) started to gain back the activity against BaF3-TEL-cKIT-T670I cells (GI<sub>50</sub> = 0.063 μM). Increasing the size of R3 to <i>N</i>-(piperidin-4-ylmethyl)propionamide (<b>35</b>) enhanced the activity against cKIT wt (GI<sub>50</sub> = 0.057 μM) and meanwhile retained the activity against cKIT T670I and remarkably improved the selectivity window to parental BaF3 cells (GI<sub>50</sub> > 10 μM). Unfortunately, further size increase (<b>36</b>) resulted in obvious activity loss compared to compound <b>35</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR Exploration Focused on the R3 Position<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0016.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0017.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div><div></div></div><div class="NLM_p">Since compound <b>35</b> exhibited the best activity and selectivity profile, we then studied its binding modes with cKIT wt and T670I mutant by molecular modeling. In the cKIT wt (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>), compound <b>35</b> adopted a canonical type II binding mode. As expected, the quinoline nitrogen formed a hydrogen bond with the cKIT residue Cys673 in the hinge binding area (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). The two NHs in the urea moiety formed two hydrogen bonds with Glu640 in the c-helix, and the carbonyl formed a hydrogen bond with the Asp810 in the DFG motif. The tail part occupied the hydrophobic pocket generated by the DFG-out shift. In addition, a hydrogen bond was formed between the NH of the amide and the Ile789 in cKIT kinase. In the homology model of cKIT T670I mutant, compound <b>35</b> adopted a similar type II binding mode. The three hydrogen bonds formed via the urea moiety caused the O-bridged phenyl moiety in <b>35</b> to orient to an angle that provided enough space for the bulky residue isoleucine, which could explain its potency against T670I mutant (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Molecular modeling analysis of the binding modes of cKIT wt/T670I with compound <b>35</b>: (A) binding mode of compound <b>35</b> with cKIT wt (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>); (B) binding mode of compound <b>35</b> with cKIT T670I homology model (generated based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Biochemical and Cellular Property Evaluation</h3><div class="NLM_p">We further examined the activity of compound <b>35</b> against a panel of cKIT mutants in the TEL engineered BaF3 systems as well as intact GIST cancer cell lines (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). The results demonstrated that besides cKIT wt and cKIT T670I, compound <b>35</b> was also effective against cKIT L567P (GI<sub>50</sub> = 0.023 μM), cKIT N822K (GI<sub>50</sub> = 0.04 μM), and cKITT670I/V559D (GI<sub>50</sub> = 0.073 μM). However, compound <b>1</b> was only potent against cKIT L567P (GI<sub>50</sub> = 0.01 μM). Compound <b>2</b> was more potent against these mutants, but it also affected the parental BaF3 cells growth (GI<sub>50</sub> = 1.6 μM) which indicated its multiple target feature. In addition, compound <b>35</b> is about 10-fold and 2-fold more potent than compounds <b>1</b> and <b>2</b> against cKIT wt, respectively. Compound <b>35</b> displayed similar antiproliferative effects to compound <b>2</b> against cKIT wt expressing GIST cancer cell line GIST-T1 (GI<sub>50</sub> = 0.004 μM) and is about 7-fold more potent than compound <b>1</b> (GI<sub>50</sub> = 0.027 μM). <b>35</b> also exhibited similar potency to compound <b>2</b> against cKIT T670I expressing GIST cancer cell line GIST-5R (GI<sub>50</sub> = 0.026 μM) and was about 300-fold more active than compound <b>1</b> (GI<sub>50</sub> = 8.3 μM).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Antiproliferative Effects of Compounds <b>1</b>, <b>2</b>, and <b>35</b> against a Variety of BaF3-TEL-cKIT Isogenic Cells and GIST Intact Cell Lines<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">GI<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">compd <b>1</b></th><th class="colsep0 rowsep0" align="center">compd <b>2</b></th><th class="colsep0 rowsep0" align="center">compd <b>35</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.15</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-cKIT</td><td class="colsep0 rowsep0" align="left">0.59 ± 0.050</td><td class="colsep0 rowsep0" align="left">0.11 ± 0.040</td><td class="colsep0 rowsep0" align="left">0.057 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-cKIT-T670I</td><td class="colsep0 rowsep0" align="left">9.6 ± 0.32</td><td class="colsep0 rowsep0" align="left">0.005 ± 0.0001</td><td class="colsep0 rowsep0" align="left">0.063 ± 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-cKIT-V654A</td><td class="colsep0 rowsep0" align="left">0.70 ± 0.015</td><td class="colsep0 rowsep0" align="left">0.006 ± 0.0003</td><td class="colsep0 rowsep0" align="left">0.32 ± 0.040</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-cKIT-L567P</td><td class="colsep0 rowsep0" align="left">0.01 ± 0.001</td><td class="colsep0 rowsep0" align="left">0.003 ± 0.0006</td><td class="colsep0 rowsep0" align="left">0.023 ± 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-cKIT-N822K</td><td class="colsep0 rowsep0" align="left">0.36 ± 0.006</td><td class="colsep0 rowsep0" align="left">0.11 ± 0.018</td><td class="colsep0 rowsep0" align="left">0.04 ± 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-cKIT-D816V</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.42 ± 0.0057</td><td class="colsep0 rowsep0" align="left">0.67 ± 0.015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-cKIT-T670I-V559D</td><td class="colsep0 rowsep0" align="left">5.2 ± 1.1</td><td class="colsep0 rowsep0" align="left">0.007 ± 0.001</td><td class="colsep0 rowsep0" align="left">0.073 ± 0.004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-cKIT-V559D-V654A</td><td class="colsep0 rowsep0" align="left">0.70 ± 0.16</td><td class="colsep0 rowsep0" align="left">0.006 ± 0.0006</td><td class="colsep0 rowsep0" align="left">0.36 ± 0.0001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST-T1 (cKIT wt)</td><td class="colsep0 rowsep0" align="left">0.027 ± 0.0011</td><td class="colsep0 rowsep0" align="left">0.005 ± 0.0002</td><td class="colsep0 rowsep0" align="left">0.004 ± 0.0026</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST-5R (cKIT-T670I)</td><td class="colsep0 rowsep0" align="left">8.3 ± 0.32</td><td class="colsep0 rowsep0" align="left">0.021 ± 0.0001</td><td class="colsep0 rowsep0" align="left">0.026 ± 0.006</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">All GI<sub>50</sub> values were obtained by triple testing.</p></div></div></div><div class="NLM_p">We also used ADP-Glo based biochemical activity assay with the purified kinase proteins to confirm the inhibition activities of compound <b>35</b> against cKIT and cKIT-T670I kinases. The results showed that <b>35</b> inhibited cKIT wt kinase with an IC<sub>50</sub> of 33 nM and inhibited cKIT T670I kinase with an IC<sub>50</sub> of 99 nM (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. ADP-Glo biochemical characterization of compound <b>35</b> against cKIT wt/T670I kinases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To better understand compound <b>35</b>’s selectivity, we examined its kinome wide selectivity profile with KinomeScan technology.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The results demonstrated that compound <b>35</b> bore a good selectivity (<i>S</i> score (1) = 0.03) in a panel of 468 kinases and mutants at 1 μM concentration. Besides high binding affinity to cKIT and cKIT-T670I kinases, it also displayed strong binding against CDKL2, CDKL3, CSF1R, DDR1, FLT3, FLT4, LOK, RET, and PDGFRβ kinases (percent activity remaining less than 1% at 1 μM <b>35</b>) (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.6b00902/suppl_file/jm6b00902_si_001.pdf" class="ext-link">Supporting Information Table 1</a>). Given the fact that KinomeScan is a binding assay and sometimes cannot really reflect the compound’s inhibitory activity, we then used TEL transformed BaF3 system to further test the on-target activity and selectivity of <b>35</b> against other potential off-targets revealed by KinomeScan assay (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). The data showed that compound <b>35</b> also potently inhibited PDGFRβ (GI<sub>50</sub> = 0.005 μM) and displayed apparent activity against FLT3 (GI<sub>50</sub> = 0.099 μM), FLT4 (GI<sub>50</sub> = 0.24 μM), CSF1R (GI<sub>50</sub> = 0.11 μM) as well as RET (GI<sub>50</sub> = 0.12 μM). This is not surprising since cKIT, FLT3, CSF1R, and PDGFR kinases all belong to the type III receptor tyrosine kinase family and the ATP binding pocket of these kinases are highly conserved.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Kinome wide selectivity profiling of compound <b>35</b>. (A) KinomeScan profiling of compound <b>35</b> at a concentration of 1 μM against 468 kinases and mutants. (B) Kinases that maintained activity of less than 1% of control in the presence of 1 μM <b>35</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Antiproliferative Effects of Compound <b>35</b> against KinaseTargets Revealed from the KinomeScan Profiling in Isogenic BaF3 Cell Lines<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">GI<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-CSF1R</td><td class="colsep0 rowsep0" align="left">0.11 ± 0.006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-FLT3</td><td class="colsep0 rowsep0" align="left">0.099 ± 0.0011</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-FLT4</td><td class="colsep0 rowsep0" align="left">0.24 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-RET</td><td class="colsep0 rowsep0" align="left">0.12 ± 0.0057</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-TEL-PDGFRβ</td><td class="colsep0 rowsep0" align="left">0.005 ± 0.0007</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">All GI<sub>50</sub> values were obtained by triple testing.</p></div></div></div><div class="NLM_p">We next investigated compound <b>35</b>’s effects on the cKIT mediated signaling pathways in cKIT wt and cKIT T670I driven GIST cell lines GIST-T1 and GIST-5R, respectively (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). As the results demonstrated, compound <b>35</b> completely blocked cKIT pY703, pY719, pY823 autophosphorylation sites in GIST-T1 cells at the concentration of 100 nM and also remarkably inhibited downstream signaling mediators pAKT (S473), pS6 (S235/236), pERK (T202/204) (EC<sub>50</sub> less than 100 nM). Compound <b>1</b> displayed similar effect on the signaling pathways, which further proved <b>35</b>’s cKIT kinase inhibitory activity. In the imatinib-resistant cell line GIST-5R (cKIT T670I), <b>35</b> also significantly affected cKIT pY703, pY719, pY823 autophosphorylation sites and downstream mediator phosphorylation (EC<sub>50</sub> less than 100 nM). Not surprisingly, compound <b>1</b>’s inhibitory effect was much weaker even at the concentration of 1 μM. In addition, compound <b>35</b> started to induce dose-dependent cell apoptotic death (by examining the cleaved PARP) in both GIST-T1 and GIST-5R cells from the concentration of 30 nM at 24 h, while at the same time point compound <b>1</b> did not cause apparent apoptosis in GIST-5R cells (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of compounds <b>1</b>, <b>2</b>, and <b>35</b> on cKIT mediated signaling pathways in GIST-T1 and GIST-5R cancer cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Effect of compounds <b>1</b>, <b>2</b>, and <b>35</b> on induction of apoptosis in GIST-T1 and GIST-5R cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> In Vivo PK/PD Evaluation</h3><div class="NLM_p">The PK properties of compound <b>35</b> were evaluated using rats model (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). With the intravenous injection compound <b>35</b> exhibited a <i>T</i><sub>1/2</sub> of 2.04 h and <i>C</i><sub>max</sub> of 2563.2 ng/mL. However, in the oral administration there was almost no absorption, which prevented <b>35</b> from the oral application in the animal model. We also tested the solubility of compound <b>35</b>, and the data showed that in the PBS buffer (pH = 7.4) it was 22.8 ± 0.2 μg/mL (about 35 μM) while in the pure water it was 50.8 ± 4.7 μg/mL (about 78 μM). This indicated that <b>35</b> should be fully dissolved at the concentrations we used in the in vitro studies.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Study of Compound <b>35</b> on Sprague Dawley Rats</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center">AUC<sub>(0–<i>t</i>)</sub> (ng mL<sup>–1</sup> h<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center">AUC<sub>(0–∞)</sub> (ng mL<sup>–1</sup> h<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>z</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center">CL<sub>z</sub> (L h<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center">MRT<sub>(0–∞)</sub> (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iv, 1 mg/kg, mean</td><td class="colsep0 rowsep0" align="left">2.04</td><td class="colsep0 rowsep0" align="left">0.017</td><td class="colsep0 rowsep0" align="left">2563.2</td><td class="colsep0 rowsep0" align="left">377.2</td><td class="colsep0 rowsep0" align="left">384.9</td><td class="colsep0 rowsep0" align="left">7.91</td><td class="colsep0 rowsep0" align="left">2.76</td><td class="colsep0 rowsep0" align="left">0.78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SD (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">0.86</td><td class="colsep0 rowsep0" align="left">0.0</td><td class="colsep0 rowsep0" align="left">825.4</td><td class="colsep0 rowsep0" align="left">100.1</td><td class="colsep0 rowsep0" align="left">105.0</td><td class="colsep0 rowsep0" align="left">3.11</td><td class="colsep0 rowsep0" align="left">0.89</td><td class="colsep0 rowsep0" align="left">0.11</td></tr></tbody></table></div></div><div class="NLM_p">We finally tested the antitumor efficacy of compound <b>35</b> in BaF3-TEL-cKIT-T670I cells inoculated xenograft mouse model. On the basis of the PK data, we chose the ip injection method. The results demonstrated that none of the 25, 50, and 100 mg kg<sup>–1</sup> day<sup>–1</sup> treatment affected the mice body weight (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>A). During 10 days of continuous treatment, compound <b>35</b> dose-dependently inhibited the growth of the BaF3-TEL-cKIT-T670I tumor progression and a dosage of 100 mg kg<sup>–1</sup> day<sup>–1</sup> exhibited 47.7% TGI (tumor growth inhibition) (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>B–D). The immunohistochemistry stain showed that in the tumors the inhibitor dose-dependently inhibited the tumor cell proliferation (examined by Ki-67 staining) and induced apoptosis (examined by TUNEL staining) (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>E). Compared to compound <b>1</b>, which has been shown that it could promote but not suppress the cKIT T670I tumor growth, compound <b>35</b> demonstrated a proof of concept that a type II kinase inhibitor could effectively suppress the tumor progression.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0010.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>35</b>’s antitumor efficacy in BaF3-TEL-cKIT-T670I xenograft model. Female nu/nu mice bearing established BaF3-TEL-cKIT-T670I tumor xenografts were treated with compound <b>35</b> at 25, 50, 100 mg kg<sup>–1</sup> d<sup>–1</sup> or vehicle. Daily ip administration was initiated when BaF3-TEL-cKIT-T670I tumors had reached a size of 200–400 mm<sup>3</sup>. Each group contained seven animals. Data of mean ± SEM (A) body weight and (B) tumor size measurements from BaF3-TEL-cKIT-T670I xenograft mice after compound <b>35</b> administration. Initial body weight and tumor size were set as 100%. (C) Representative photographs of tumors in each group after 25, 50, 100 (mg/kg)/d compound <b>35</b> or vehicle treatment. (D) Comparison of the final tumor weight in each group after 10-day treatment period of <b>35</b>. Numbers in columns indicate the mean tumor weight in each group. (ns) <i>p</i> > 0.05, (∗) <i>p</i> < 0.05, (∗∗) <i>p</i> < 0.01. (E) Representative micrographs of hematoxylin and eosin (HE), Ki-67, and TUNEL staining of tumor tissues of <b>35</b> treatment groups in comparison with the vehicle group. Note the specific nuclear staining of cells with morphology consistent with proliferation and apoptosis (E, red arrow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27267" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27267" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of urea compounds <b>7</b>, <b>9</b>, <b>11</b>–<b>36</b> started from nucleophilic substitution of 4-chloro-6,7-dimethoxyquinoline with 3-aminophenol which afforded compound <b>37</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Boc-protected 3- or 4-aminopiperidine analogs (<b>39</b>) reacted with chloronitrobenzene derivatives (<b>38</b>) to provide <b>40</b> in two steps. Urea formation from the two precursors with triphosgene afforded compound <b>41</b>. Acidic deprotection of Boc group (<b>42</b>) and amide bond formation with corresponding acyl chlorides or carboxylic acids furnished the target compounds.</div><figure id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0011.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>7</b>, <b>9</b>, <b>11</b>–<b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i><sup>t</sup></i>BuOK, K<sub>2</sub>CO<sub>3</sub>, DMSO, 100 °C, 12 h; (b) K<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 8 h; (c) H<sub>2</sub>, 10% Pd/C, MeOH, rt, 3 h; (d) triphosgene, Et<sub>3</sub>N, DMAP, DCM, 0 °C to rt, 1 h; (e) 4 M HCl in ethyl acetate, rt, 1 h. (f) For <b>7</b>, <b>9</b>, <b>11</b>–<b>13</b>, and <b>31</b>–<b>35</b>: acyl chloride, Et<sub>3</sub>N, DMF, −50 °C, 5 min. For <b>16</b>–<b>24</b>, <b>26</b>–<b>30</b>, and <b>36</b>: carboxylic acid, HATU, Et<sub>3</sub>N, DMF, rt, overnight. For <b>14</b>, <b>15</b>, and <b>25</b>: (i) carboxylic acid, HATU, Et<sub>3</sub>N, DMF, rt, overnight; (ii) 4 M HCl in ethyl acetate, rt, 1 h.</p></p></figure><div class="NLM_p">Compound <b>10</b> was prepared via a similar approach in different reaction order (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The nucleophilic substitution of trifluoromethyl substituted chloronitrobenzene (<b>38b</b>) and Boc-protected 4-aminopiperidine (<b>39b</b>) was followed by Boc-deprotection (<b>44</b>) and connection with <b>37</b> through triphosgene. Hydrogenation of the nitro group in <b>45</b> provided the amine moiety, which then readily reacted with the propionyl chloride.</div><figure id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0012.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 8 h; (b) 4 M HCl in ethyl acetate, rt, 1 h; (c) <b>37</b>, triphodgene, Et<sub>3</sub>N, DMAP, DCM, 0 °C to rt, 1 h; (d) H<sub>2</sub>, 10% Pd/C, MeOH, rt, 8 h; (e) propionyl chloride, Et<sub>3</sub>N, DMF, −50 °C, 5 min.</p></p></figure><div class="NLM_p">The synthesis of compound <b>8</b> that bears a cyclopropane-1,1-dicarboxamide moiety at the R1 position was achieved by amidation of <b>37</b> with 1-(methoxycarbonyl)cyclopropanecarboxylic acid, which was followed by methyl ester hydrolysis of <b>47</b> and coupling reaction of <b>48</b> with <b>40d</b>. Final Boc deprotection and acylation afforded compound <b>8</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0013.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compound <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HATU, DIPEA, DMF, rt, overnight; (b) 1.0 M NaOH, MeOH, reflux, 2 h; (c) <b>40d</b>, HATU, DIPEA, DMF, rt, overnight; (d) 4 M HCl in ethyl acetate, rt, 1 h; (e) propionyl chloride, Et<sub>3</sub>N, DMF, −50 °C, 5 min.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44801" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44801" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have discovered a new quinoline scaffold based highly potent type II kinase inhibitor compound <b>35</b>, which possessed strong inhibitory activities against both cKIT wt GIST cancer cells (GIST-T1) and cKIT T670I gatekeeper mutant cells (GIST-5R). The compound strongly inhibited cKIT mediated signaling pathways and dose-dependently induced apoptosis. Although <b>35</b> displayed good antitumor efficacies in the cKIT T670I mutant cells mediated xenograft mouse models, the poor oral PK profile prevented it from further development. Further medicinal chemistry effort is needed to improve the PK profile of this series of compounds. We believe compound <b>35</b> will be a useful pharmacological tool for exploration of the cKIT kinase gatekeeper T670I mutant mediated pathology in GISTs.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54880" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54880" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Chemistry</h3><div class="NLM_p">All reagents and solvents were purchased from commercial sources and used as obtained. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded with a Bruker 400 NMR spectrometer and referenced to deuterium dimethyl sulfoxide (DMSO-<i>d</i><sub>6</sub>) or deuterium chloroform (CDCl<sub>3</sub>). Chemical shifts are expressed in ppm. In the NMR tabulation, s indicates singlet; d, doublet; t, triplet; q, quartet; m, multiplet; and br, broad peak. LC/MS were performed on an Agilent 6224 TOF using an ESI source coupled to an Agilent 1260 Infinity HPLC system operating in reverse mode with an Agilent Eclipse Plus C18 1.8 μm, 3.0 mm × 50 mm column. Flash column chromatography was conducted using silica gel (Silicycle 40–64 μm). The purities of all compounds were determined to be above 95% by HPLC.</div><div class="NLM_p last">Compounds <b>7</b>–<b>13</b> and <b>31</b>–<b>35</b> were prepared following the synthetic procedure of <b>7</b>.</div></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)propionamide (<b>7</b>)</h3><div class="NLM_p last">To a solution of <b>42d</b> (30.0 mg, 0.057 mmol), Et<sub>3</sub>N (0.039 mL, 0.171 mmol) in anhydrous DMF (0.5 mL) at −50 °C under Ar was added propionyl chloride (6.3 mg, 0.0682 mmol). After being stirred at −50 °C for 5 min, the reaction mixture was quenched with water and warmed up to room temperature. The mixture was diluted with ethyl acetate and washed with water and brine. The organic phase was dried with MgSO<sub>4</sub>, filtered, and concentrated under vacuum to give the residue which was purified by silica gel flash chromatography with dichloromethane/methanol (10:1) to afford the title compound <b>7</b> as a white solid (8.5 mg, 25%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.02 (s, 2H), 8.51 (d, <i>J</i> = 5.2 Hz, 1H), 7.88 (d, <i>J</i> = 2.2 Hz, 1H), 7.77 (d, <i>J</i> = 7.8 Hz, 1H), 7.60–7.53 (m, 2H), 7.50 (d, <i>J</i> = 8.9 Hz, 2H), 7.47–7.39 (m, 2H), 7.28 (d, <i>J</i> = 8.0 Hz, 1H), 6.90 (dd, <i>J</i> = 8.0, 1.9 Hz, 1H), 6.55 (d, <i>J</i> = 5.2 Hz, 1H), 3.95 (s, 6H), 3.70–3.64 (m, 1H), 2.87–2.84 (m, 2H), 2.79–2.74 (m, 2H), 2.07 (q, <i>J</i> = 7.6 Hz, 2H), 1.80–1.77 (m, 2H), 1.52–1.46 (m, 2H), 1.00 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.55, 159.90, 154.98, 152.99, 149.86, 149.32, 147.26, 141.95, 137.14, 130.96, 125.78, 123.45, 115.73, 114.52, 110.86, 108.34, 104.14, 99.52, 56.16, 53.23, 45.73, 32.77, 29.03, 10.44. LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>33</sub>H<sub>35</sub>F<sub>3</sub>N<sub>5</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 638.2590; found, 638.2593.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>N</i>-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-<i>N</i>-(4-(4-propionamidopiperidin-1-yl)-3-(trifluoromethyl)phenyl)cyclopropane 1,1-Dicarboxamide (<b>8</b>)</h3><div class="NLM_p last">White solid, 19% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.23 (s, 1H), 10.18 (s, 1H), 8.51 (d, <i>J</i> = 5.1 Hz, 1H), 8.03 (d, <i>J</i> = 5.6 Hz, 1H), 7.80–7.75 (m, 2H), 7.66 (d, <i>J</i> = 1.0 Hz, 1H), 7.61 (d, <i>J</i> = 8.4 Hz, 1H), 7.51 (dd, <i>J</i> = 12.8, 7.2 Hz, 2H), 7.41 (d, <i>J</i> = 0.5 Hz, 1H), 7.09 (d, <i>J</i> = 4.0 Hz, 1H), 7.00 (d, <i>J</i> = 7.6 Hz, 1H), 6.55 (d, <i>J</i> = 5.2 Hz, 1H), 3.96 (s, 3H), 3.93 (s, 3H), 3.73–3.64 (m, 1H), 2.86–2.74 (m, 4H), 2.09–2.04 (m, 2H), 1.82–1.76 (m, 2H), 1.57–1.44 (m, 4H), 1.00 (t, <i>J</i> = 7.4 Hz, 3H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>37</sub>H<sub>39</sub>F<sub>3</sub>N<sub>5</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 706.2852; found, 706.2867.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)phenyl)piperidin-4-yl)propionamide (<b>9</b>)</h3><div class="NLM_p last">White solid, 29% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.25 (s, 1H), 8.88 (s, 1H), 8.51 (d, <i>J</i> = 4.9 Hz, 1H), 7.74 (d, <i>J</i> = 7.6 Hz, 1H), 7.56 (s, 1H), 7.51 (s, 1H), 7.44–7.35 (m, 2H), 7.27 (t, <i>J</i> = 7.4 Hz, 3H), 6.85 (t, <i>J</i> = 9.1 Hz, 3H), 6.55 (d, <i>J</i> = 5.0 Hz, 1H), 3.95 (s, 6H), 3.73–3.60 (m, 1H), 3.54–3.50 (m, 2H), 2.72–2.66 (m, 2H), 2.05–2.00 (m, 2H), 1.81–1.78 (m, 2H), 1.52–1.42 (m, 2H), 0.99 (t, <i>J</i> = 7.5 Hz, 3H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>32</sub>H<sub>36</sub>N<sub>5</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 570.2716; found, 570.2733.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>N</i>-(4-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)piperidin-1-yl)-3-(trifluoromethyl)phenyl)propionamide (<b>10</b>)</h3><div class="NLM_p last">White solid, 45% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.11 (s, 1H), 8.78 (s, 1H), 8.50 (d, <i>J</i> = 5.0 Hz, 1H), 8.00 (d, <i>J</i> = 1.5 Hz, 1H), 7.78 (d, <i>J</i> = 7.2 Hz, 1H), 7.59–7.47 (m, 2H), 7.41 (s, 1H), 7.39–7.31 (m, 1H), 7.19 (d, <i>J</i> = 7.8 Hz, 1H), 6.86–6.75 (m, 1H), 6.54 (d, <i>J</i> = 5.0 Hz, 1H), 6.48 (d, <i>J</i> = 6.1 Hz, 1H), 3.96 (s, 6H), 3.65–3.57 (m, 1H), 2.94–2.86 (m, 2H), 2.83–2.73 (m, 2H), 2.33 (dd, <i>J</i> = 14.5, 7.1 Hz, 2H), 1.95–1.87 (m, 2H), 1.59–1.47 (m, 2H), 1.08 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.69, 159.96, 155.01, 154.90, 153.05, 149.32, 147.00, 143.01, 136.92, 130.75, 125.99, 123.90, 117.35, 115.84,114.86, 113.37, 110.03, 108.36, 104.21, 99.55, 56.19, 56.14, 52.91, 33.16, 29.93, 10.00. LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>33</sub>H<sub>35</sub>F<sub>3</sub>N<sub>5</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 638.2590; found, 638.2599.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-3-yl)propionamide (<b>11</b>)</h3><div class="NLM_p last">Yellow solid, 41% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.34 (s, 2H), 8.51 (d, <i>J</i> = 4.5 Hz, 1H), 7.89 (s, 1H), 7.59 (s, 3H), 7.52 (s, 1H), 7.47–7.36 (m, 3H), 7.31 (d, <i>J</i> = 6.9 Hz, 2H), 6.89 (d, <i>J</i> = 7.2 Hz, 1H), 6.56 (d, <i>J</i> = 4.5 Hz, 1H), 3.96 (d, <i>J</i> = 5.3 Hz, 6H), 3.86–3.83 (m, 1H), 3.10–3.07 (m, 1H), 2.96–2.92 (m, 1H), 2.80–2.75 (m, 1H), 2.62–2.57 (m, 1H), 2.07 (q, <i>J</i> = 7.3 Hz, 2H), 1.80–1.72 (m, 2H), 1.61–1.52 (m, 1H), 1.33–1.29 (m, 1H), 0.98 (t, <i>J</i> = 7.4 Hz, 3H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>33</sub>H<sub>35</sub>F<sub>3</sub>N<sub>5</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 638.2590; found, 638.2591.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)acetamide (<b>12</b>)</h3><div class="NLM_p last">White solid, 40% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.56 (s, 2H), 8.56–8.48 (m, 1H), 7.88 (d, <i>J</i> = 10.2 Hz, 2H), 7.53 (dt, <i>J</i> = 16.7, 4.3 Hz, 4H), 7.46–7.39 (m, 2H), 7.29 (dd, <i>J</i> = 7.6, 1.1 Hz, 1H), 6.89 (dd, <i>J</i> = 7.8, 1.1 Hz, 1H), 6.57 (d, <i>J</i> = 5.1 Hz, 1H), 3.96 (s, 6H), 3.75–3.62 (m, 1H), 2.88–2.85 (m, 2H), 2.81–2.70 (m, 2H), 1.81 (s, 3H), 1.80–1.77 (m, 2H), 1.57–1.45 (m, 2H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>32</sub>H<sub>33</sub>F<sub>3</sub>N<sub>5</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 624.2434; found, 624.2452.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)-3,3-dimethylbutanamide (<b>13</b>)</h3><div class="NLM_p">White solid, 43% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.69 (s, 2H), 8.51 (d, <i>J</i> = 8.0 Hz, 1H), 7.91 (d, <i>J</i> = 1.0 Hz, 1H), 7.75 (dd, <i>J</i> = 9.6, 2.9 Hz, 1H), 7.59–7.49 (m, 4H), 7.45–7.40 (m, 2H), 7.28 (dd, <i>J</i> = 8.3, 3.0 Hz, 1H), 6.88 (dd, <i>J</i> = 9.2, 3.7 Hz, 1H), 6.55–6.53 (m, 1H), 3.96 (s, 6H), 3.76–3.66 (m, 1H), 2.86–2.84 (m, 3H), 2.81–2.70 (m, 2H), 1.95 (s, 2H), 1.83–1.73 (m, 2H), 1.58–1.45 (m, 3H), 1.05 (s, 9H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>36</sub>H<sub>41</sub>F<sub>3</sub>N<sub>5</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 680.3060; found, 680.3062.</div><div class="NLM_p last">Compounds <b>14</b>–<b>15</b> and <b>25</b> were prepared following the synthetic procedure of <b>14</b>. Compounds <b>16</b>–<b>24</b>, <b>26</b>–<b>30</b>, and <b>36</b> were prepared following the first step (amide bond formation) of the synthetic procedure of <b>14</b>.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 2-Amino-<i>N</i>-(1-(4-(3-(3-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)acetamide Hydrochloride (<b>14</b>)</h3><div class="NLM_p last">To a solution of <b>42d</b> (20 mg, 0.034 mmol), Et<sub>3</sub>N (0.024 mL, 0.170 mmol), and HATU (20 mg, 0.052 mmol) in DMF (0.5 mL) was added (<i>tert</i>-butoxycarbonyl)glycine (10 mg, 0.052 mmol). The reaction mixture was stirred at room temperature overnight and then diluted with ethyl acetate and washed with water and brine. The organic phase was separated and dried with MgSO<sub>4</sub>, then filtered and concentrated. The residue was purified by silica gel flash chromatography with dichloromethane/methanol (10:1) to offer the Boc-prodected compound as a white solid (5.7 mg, 22%), which was then treated with 4.0 M HCl in ethyl acetate (5 mL) at room temperature for about 1 h. The reaction mixture was concentrated under vacuum to provide the product <b>14</b> as a white solid (5 mg, 97%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.18 (s, 1H), 10.09 (s, 1H), 8.81 (d, <i>J</i> = 9.9 Hz, 1H), 8.61–8.52 (m, 1H), 8.18 (d, <i>J</i> = 11.1 Hz, 2H), 7.89 (d, <i>J</i> = 2.2 Hz, 1H), 7.78 (d, <i>J</i> = 2.7 Hz, 2H), 7.71 (d, <i>J</i> = 1.4 Hz, 1H), 7.60–7.49 (m, 3H), 7.38 (dd, <i>J</i> = 7.5, 2.7 Hz, 1H), 7.02 (dd, <i>J</i> = 9.8, 5.4 Hz, 1H), 6.91 (d, <i>J</i> = 5.0 Hz, 1H), 4.05 (s, 6H), 3.89–3.68 (m, 3H), 2.93–2.87 (m, 2H), 2.83–2.76 (m, 2H), 1.87–1.79 (m, 2H), 1.59–1.49 (m, 2H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>32</sub>H<sub>34</sub>F<sub>3</sub>N<sub>6</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 639.2543; found, 639.2557.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (<i>R</i>)-2-Amino-<i>N</i>-(1-(4-(3-(3-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)propanamide Hydrochloride (<b>15</b>)</h3><div class="NLM_p last">White solid, 35% yield in two steps. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.18 (s, 1H), 10.08 (s, 1H), 8.87–8.76 (m, 1H), 8.57 (d, <i>J</i> = 7.3 Hz, 1H), 8.27 (d, <i>J</i> = 1.2 Hz, 2H), 7.89 (s, 1H), 7.78 (d, <i>J</i> = 0.6 Hz, 2H), 7.71 (d, <i>J</i> = 0.6 Hz, 1H), 7.61–7.48 (m, 2H), 7.40–7.34 (m, 1H), 7.07–6.98 (m, 1H), 6.95–6.85 (m, 1H), 4.05 (s, 6H), 3.88–3.69 (m, 2H), 3.04 (t, <i>J</i> = 11.4 Hz, 1H), 2.98–2.85 (m, 2H), 2.84–2.73 (m, 2H), 1.82 (dd, <i>J</i> = 18.1, 11.0 Hz, 2H), 1.64–1.49 (m, 2H), 1.28–1.15 (m, 3H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>33</sub>H<sub>36</sub>F<sub>3</sub>N<sub>6</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 653.2699; found, 653.2671.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)-2-(dimethylamino)acetamide (<b>16</b>)</h3><div class="NLM_p last">White solid, 42% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.76 (s, 2H), 8.50 (d, <i>J</i> = 5.1 Hz, 1H), 8.06 (d, <i>J</i> = 13.1 Hz, 1H), 7.86 (s, 1H), 7.59–7.50 (m, 4H), 7.43 (t, <i>J</i> = 7.5 Hz, 2H), 7.28 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 6.88 (dd, <i>J</i> = 8.3, 1.7 Hz, 1H), 6.55 (dd, <i>J</i> = 3.1, 1.9 Hz, 1H), 3.96 (s, 6H), 3.79–3.71 (m, 1H), 2.89–2.86 (m, 2H), 2.82–2.75 (m, 2H), 2.59 (s, 2H), 2.41 (s, 6H), 1.85–1.75 (m, 2H), 1.63–1.54 (m, 2H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>34</sub>H<sub>38</sub>F<sub>3</sub>N<sub>6</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 667.2856; found, 667.2873.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)cyclohex-1-ene-1-carboxamide (<b>17</b>)</h3><div class="NLM_p last">White solid, 19 yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.48 (d, <i>J</i> = 8.4 Hz, 2H), 8.55 (d, <i>J</i> = 4.9 Hz, 1H), 7.87 (s, 1H), 7.64–7.49 (m, 5H), 7.43 (d, <i>J</i> = 11.7 Hz, 2H), 7.29 (dd, <i>J</i> = 11.3, 3.5 Hz, 1H), 6.95–6.87 (m, 1H), 6.61 (d, <i>J</i> = 5.4 Hz, 1H), 6.52 (d, <i>J</i> = 5.3 Hz, 1H), 3.98 (s, 6H), 3.84–3.72 (m, 1H), 3.12–3.03 (m, 1H), 2.87 (dd, <i>J</i> = 12.4, 5.0 Hz, 2H), 2.78 (dt, <i>J</i> = 9.5, 4.3 Hz, 2H), 2.20–2.07 (m, 4H), 1.78–1.72 (m, 2H), 1.67–1.56 (m, 5H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>37</sub>H<sub>39</sub>F<sub>3</sub>N<sub>5</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 690.2903; found, 690.2929.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)nicotinamide (<b>18</b>)</h3><div class="NLM_p last">White solid, 39% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.88 (d, <i>J</i> = 4.4 Hz, 2H), 9.04 (d, <i>J</i> = 1.1 Hz, 1H), 8.71 (d, <i>J</i> = 7.4 Hz, 1H), 8.61 (d, <i>J</i> = 8.2 Hz, 1H), 8.54 (dd, <i>J</i> = 3.5, 2.1 Hz, 1H), 8.23 (dd, <i>J</i> = 8.7, 3.5 Hz, 1H), 7.87 (d, <i>J</i> = 1.2 Hz, 1H), 7.62–7.48 (m, 5H), 7.44 (t, <i>J</i> = 5.7 Hz, 2H), 7.29 (dd, <i>J</i> = 8.3, 2.7 Hz, 1H), 6.90 (dd, <i>J</i> = 8.6, 1.7 Hz, 1H), 6.59–6.57 (m, 1H), 3.97 (s, 6H), 2.95–2.81 (m, 5H), 1.91–1.85 (m, 2H), 1.81–1.71 (m, 2H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>36</sub>H<sub>34</sub>F<sub>3</sub>N<sub>6</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 687.2543; found, 687.2570.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)tetrahydro-2<i>H</i>-pyran-4-carboxamide (<b>19</b>)</h3><div class="NLM_p last">Light yellow solid, 32% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.45 (s, 2H), 8.51–8.50 (m, 1H), 7.87 (s, 1H), 7.79 (dd, <i>J</i> = 7.5, 0.5 Hz, 1H), 7.57 (d, <i>J</i> = 10.0 Hz, 2H), 7.53–7.46 (m, 2H), 7.43 (d, <i>J</i> = 10.3 Hz, 2H), 7.33–7.25 (m, 1H), 6.88 (dd, <i>J</i> = 8.1, 0.9 Hz, 1H), 6.57–6.52 (m, 1H), 3.96 (s, 6H), 3.86 (dd, <i>J</i> = 11.5, 0.9 Hz, 2H), 3.74–3.62 (m, 1H), 3.34–3.25 (m, 2H), 2.90–2.85 (m, 2H), 2.78–2.72 (m, 2H), 2.37–2.31 (m, 1H), 1.81–1.73 (m, 2H), 1.62–1.50 (m, 6H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>36</sub>H<sub>39</sub>F<sub>3</sub>N<sub>5</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 694.2852; found, 694.2879.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)-1-methylpiperidine-4-carboxamide (<b>20</b>)</h3><div class="NLM_p last">White solid, 37% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.46 (s, 2H), 8.50 (d, <i>J</i> = 4.9 Hz, 1H), 7.87 (d, <i>J</i> = 0.7 Hz, 2H), 7.57 (d, <i>J</i> = 9.9 Hz, 2H), 7.50 (d, <i>J</i> = 12.0 Hz, 2H), 7.46–7.37 (m, 2H), 7.28 (d, <i>J</i> = 8.8 Hz, 1H), 6.89–6.87 (m, 1H), 6.54 (d, <i>J</i> = 4.8 Hz, 1H), 3.95 (s, 6H), 3.72–3.64 (m, 1H), 3.16–3.05 (m, 2H), 2.88–2.85 (m, 3H), 2.78–2.72 (m, 2H), 2.54 (s, 6H), 2.25–2.15 (m, 2H), 1.79–1.70 (m, 6H), 1.57–1.49 (m, 2H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>37</sub>H<sub>42</sub>F<sub>3</sub>N<sub>6</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 707.3169; found, 707.3151.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)-1-ethylpiperidine-4-carboxamide (<b>21</b>)</h3><div class="NLM_p last">White solid, 35% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.51 (s, 2H), 8.50 (d, <i>J</i> = 5.6 Hz, 1H), 7.87–7.83 (m, 2H), 7.57 (dd, <i>J</i> = 10.3, 0.8 Hz, 2H), 7.51–7.48 (m, 2H), 7.43 (dd, <i>J</i> = 10.4, 1.9 Hz, 2H), 7.29–7.25 (m, 1H), 6.89 (dd, <i>J</i> = 5.3, 4.2 Hz, 1H), 6.55 (dd, <i>J</i> = 4.8, 1.0 Hz, 1H), 3.96 (s, 6H), 3.72–3.63 (m, 1H), 3.03–2.97 (m, 2H), 2.90–2.85 (m, 2H), 2.78–2.72 (m, 2H), 2.38–2.32 (m, 3H), 2.27–2.12 (m, 3H), 1.81–1.68 (m, 6H), 1.57–1.48 (m, 2H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>38</sub>H<sub>44</sub>F<sub>3</sub>N<sub>6</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 721.3325; found, 721.3347.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 1-Acetyl-<i>N</i>-(1-(4-(3-(3-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)piperidine-4-carboxamide (<b>22</b>)</h3><div class="NLM_p last">White solid, 35% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.23 (s, 2H), 8.51 (d, <i>J</i> = 4.9 Hz, 1H), 7.87 (d, <i>J</i> = 0.8 Hz, 1H), 7.83 (d, <i>J</i> = 7.8 Hz, 1H), 7.56 (d, <i>J</i> = 7.9 Hz, 2H), 7.50 (d, <i>J</i> = 9.1 Hz, 2H), 7.43 (d, <i>J</i> = 11.6 Hz, 2H), 7.28 (d, <i>J</i> = 8.4 Hz, 1H), 6.89 (dd, <i>J</i> = 7.7, 1.2 Hz, 1H), 6.58–6.52 (m, 1H), 4.39–4.33 (m, 1H), 3.95 (s, 6H), 3.84–3.80 (m, 1H), 3.72–3.64 (m, 1H), 3.05–2.97 (m, 1H), 2.89–2.85 (m, 2H), 2.78–2.73 (m, 2H), 2.37–2.30 (m, 1H), 1.99 (s, 3H), 1.79–1.75 (m, 2H), 1.70–1.63 (m, 2H), 1.52–1.47 (m, 3H), 1.41–1.33 (m, 1H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>38</sub>H<sub>42</sub>F<sub>3</sub>N<sub>6</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 735.3118; found, 735.3129.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 1-(Cyclopropanecarbonyl)-<i>N</i>-(1-(4-(3-(3-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)piperidine-4-carboxamide (<b>23</b>)</h3><div class="NLM_p last">White solid, 46% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.35 (s, 2H), 8.53 (d, <i>J</i> = 4.1 Hz, 1H), 7.90–7.80 (m, 2H), 7.52 (dd, <i>J</i> = 18.4, 10.7 Hz, 4H), 7.46–7.39 (m, 2H), 7.29 (d, <i>J</i> = 8.1 Hz, 1H), 6.96–6.86 (m, 1H), 6.58 (d, <i>J</i> = 3.8 Hz, 1H), 4.41–4.20 (m, 2H), 3.97 (s, 6H), 3.75–3.62 (m, 1H), 3.16–3.01 (m, 1H), 2.87 (d, <i>J</i> = 9.8 Hz, 2H), 2.81–2.71 (m, 2H), 2.61 (dd, <i>J</i> = 14.4, 8.7 Hz, 1H), 2.38 (dd, <i>J</i> = 16.2, 10.8 Hz, 1H), 1.99–1.93 (m, 1H), 1.84–1.62 (m, 5H), 1.60–1.46 (m, 3H), 1.41–1.33 (m, 1H), 0.76–0.65 (m, 4H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>40</sub>H<sub>44</sub>F<sub>3</sub>N<sub>6</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 761.3274; found, 761.3286.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>tert</i>-Butyl 3-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)carbamoyl)piperidine-1-carboxylate (<b>24</b>)</h3><div class="NLM_p last">White solid, 45% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.24 (s, 2H), 8.51 (d, <i>J</i> = 4.8 Hz, 1H), 7.93–7.85 (m, 1H), 7.61–7.54 (m, 2H), 7.50 (d, <i>J</i> = 10.0 Hz, 2H), 7.42 (t, <i>J</i> = 9.6 Hz, 2H), 7.32–7.25 (m, 1H), 6.89 (dd, <i>J</i> = 7.1, 0.8 Hz, 1H), 6.55 (d, <i>J</i> = 4.1 Hz, 1H), 3.96 (s, 6H), 3.89–3.83 (m, 1H), 3.71–3.65 (m, 1H), 2.90–2.85 (m, 3H), 2.80–2.72 (m, 5H), 2.24–2.17 (m, 1H), 1.85–1.74 (m, 3H), 1.67–1.64 (m, 1H), 1.58–1.47 (m, 4H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>41</sub>H<sub>48</sub>F<sub>3</sub>N<sub>6</sub>O<sub>7</sub> [M + H]<sup>+</sup>: 793.3537; found, 793.3529.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)-2-methylpiperidine-4-carboxamide Hydrochloride (<b>25</b>)</h3><div class="NLM_p last">White solid, 61% yield in two steps. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.18 (s, 1H), 10.06 (s, 1H), 8.81 (d, <i>J</i> = 6.2 Hz, 1H), 8.03–7.94 (m, 1H), 7.87 (s, 1H), 7.77 (s, 2H), 7.73–7.68 (m, 1H), 7.53 (dd, <i>J</i> = 19.8, 8.7 Hz, 3H), 7.42–7.32 (m, 1H), 7.06–6.97 (m, 1H), 6.90 (d, <i>J</i> = 5.9 Hz, 1H), 4.05 (s, 6H), 3.72–3.62 (m, 1H), 3.47–3.41 (m, 1H), 3.32–3.20 (m, 1H), 3.14–3.04 (m, 1H), 2.91–2.83 (m, 2H), 2.75–2.73 (m, 2H), 1.84–1.71 (m, 4H), 1.61–1.46 (m, 3H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>37</sub>H<sub>42</sub>F<sub>3</sub>N<sub>6</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 707.3169; found, 707.3151.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)-2-(piperidin-1-yl)acetamide (<b>26</b>)</h3><div class="NLM_p last">White solid, 26% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.36 (s, 2H), 8.51 (d, <i>J</i> = 4.6 Hz, 1H), 7.87 (d, <i>J</i> = 0.5 Hz, 1H), 7.61–7.47 (m, 4H), 7.43 (t, <i>J</i> = 6.1 Hz, 2H), 7.27 (d, <i>J</i> = 3.3 Hz, 1H), 6.93–6.85 (m, 1H), 6.60–6.51 (m, 1H), 3.96 (s, 6H), 3.79–3.72 (m, 1H), 3.03–2.73 (m, 6H), 2.48–2.40 (m, 2H), 1.84–1.73 (m, 2H), 1.64–1.56 (m, 6H), 1.43–1.36 (m, 2H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>37</sub>H<sub>42</sub>F<sub>3</sub>N<sub>6</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 707.3169; found, 707.3147.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)-2-(3-methylpiperidin-1-yl)acetamide (<b>27</b>)</h3><div class="NLM_p last">White solid, 19% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.53 (s, 2H), 8.51 (d, <i>J</i> = 6.6 Hz, 1H), 7.86 (d, <i>J</i> = 0.8 Hz, 1H), 7.62–7.48 (m, 4H), 7.42 (d, <i>J</i> = 2.9 Hz, 2H), 7.28 (dd, <i>J</i> = 9.0, 3.6 Hz, 1H), 6.92–6.85 (m, 1H), 6.61–6.52 (m, 1H), 3.96 (s, 6H), 3.78–3.72 (m, 1H), 3.13–2.97 (m, 1H), 2.93–2.73 (m, 6H), 2.06–1.98 (m, 1H), 1.84–1.74 (m, 4H), 1.67–1.55 (m, 5H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>38</sub>H<sub>44</sub>F<sub>3</sub>N<sub>6</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 721.3325; found, 721.3319.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)-3-(piperidin-1-yl)propanamide (<b>28</b>)</h3><div class="NLM_p last">White solid, 18% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.82 (d, <i>J</i> = 9.0 Hz, 2H), 8.53 (d, <i>J</i> = 4.0 Hz, 1H), 8.23 (dd, <i>J</i> = 10.1, 6.4 Hz, 1H), 7.86 (d, <i>J</i> = 1.7 Hz, 1H), 7.56–7.50 (m, 4H), 7.47–7.40 (m, 2H), 7.34–7.25 (m, 2H), 6.90 (d, <i>J</i> = 6.1 Hz, 1H), 6.59 (d, <i>J</i> = 4.1 Hz, 1H), 3.97 (s, 6H), 3.76–3.69 (m, 1H), 3.25–3.21 (m, 2H), 2.94–2.83 (m, 5H), 2.82–2.73 (m, 3H), 2.71–2.64 (m, 2H), 2.05–1.97 (m, 2H), 1.72–1.64 (m, 1H), 1.60–1.48 (m, 3H), 1.40–1.34 (m, 2H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>38</sub>H<sub>44</sub>F<sub>3</sub>N<sub>6</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 721.3325; found, 721.3347.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)-3-(1-methylpiperidin-2-yl)propanamide (<b>29</b>)</h3><div class="NLM_p last">White solid, 35% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.50 (s, 2H), 8.50 (d, <i>J</i> = 4.7 Hz, 1H), 7.89 (dd, <i>J</i> = 11.1, 2.8 Hz, 2H), 7.57 (d, <i>J</i> = 9.4 Hz, 2H), 7.53–7.45 (m, 2H), 7.40 (d, <i>J</i> = 9.2 Hz, 2H), 7.29 (dd, <i>J</i> = 8.0, 0.4 Hz, 1H), 6.89–6.87 (m, 1H), 6.54 (d, <i>J</i> = 4.8 Hz, 1H), 3.96 (s, 6H), 3.69–3.66 (m, 1H), 3.02–2.94 (m, 1H), 2.86 (dd, <i>J</i> = 8.8, 1.7 Hz, 2H), 2.75–2.71 (m, 2H), 2.39 (s, 3H), 2.15–2.04 (m, 2H), 1.90–1.77 (m, 4H), 1.73–1.61 (m, 3H), 1.60–1.45 (m, 4H), 1.39–1.20 (m, 3H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>39</sub>H<sub>46</sub>F<sub>3</sub>N<sub>6</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 735.3482; found, 735.3463.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)-3-morpholinopropanamide (<b>30</b>)</h3><div class="NLM_p last">White solid, 40% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.55 (s, 2H), 8.51 (d, <i>J</i> = 5.0 Hz, 1H), 8.00 (d, <i>J</i> = 7.2 Hz, 1H), 7.86 (d, <i>J</i> = 1.2 Hz, 1H), 7.57 (d, <i>J</i> = 12.5 Hz, 2H), 7.53–7.46 (m, 2H), 7.42 (t, <i>J</i> = 7.7 Hz, 2H), 7.29 (d, <i>J</i> = 7.7 Hz, 1H), 6.88 (d, <i>J</i> = 7.8 Hz, 1H), 6.56 (d, <i>J</i> = 5.0 Hz, 1H), 3.96 (s, 6H), 3.77–3.71 (m, 2H), 3.52–3.39 (m, 2H), 2.94–2.84 (m, 3H), 2.82–2.66 (m, 5H), 2.35–2.33 (m, 1H), 1.82–1.78 (m, 2H), 1.59–1.48 (m, 2H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>37</sub>H<sub>42</sub>F<sub>3</sub>N<sub>6</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 723.3118; found, 723.3130.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methanesulfonamide (<b>31</b>)</h3><div class="NLM_p last">White solid, 31% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.14 (s, 2H), 8.50 (d, <i>J</i> = 5.2 Hz, 1H), 7.90 (s, 1H), 7.67–7.60 (m, 1H), 7.58 (s, 1H), 7.52 (s, 1H), 7.49–7.32 (m, 4H), 7.18–7.13 (m, 1H), 6.86 (dd, <i>J</i> = 7.3, 0.8 Hz, 1H), 6.57–6.51 (m, 1H), 3.96 (s, 6H), 3.55–3.49 (m, 1H), 2.94 (s, 3H), 2.89–2.86 (m, 2H), 2.79–2.73 (m, 2H), 1.91–1.89 (m, 2H), 1.64–1.55 (m, 2H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>31</sub>H<sub>33</sub>F<sub>3</sub>N<sub>5</sub>O<sub>6</sub>S [M + H]<sup>+</sup>: 660.2104; found, 660.2137.</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)ethanesulfonamide (<b>32</b>)</h3><div class="NLM_p last">White solid, 23% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.59 (s, 2H), 8.50 (d, <i>J</i> = 4.4 Hz, 1H), 7.87 (s, 1H), 7.57 (d, <i>J</i> = 12.3 Hz, 2H), 7.52–7.46 (m, 2H), 7.44–7.39 (m, 2H), 7.29 (dd, <i>J</i> = 8.0, 0.6 Hz, 1H), 7.20 (dd, <i>J</i> = 7.3, 1.3 Hz, 1H), 6.88 (dd, <i>J</i> = 7.3, 1.2 Hz, 1H), 6.56–6.51 (m, 1H), 3.96 (s, 6H), 3.25–3.19 (m, 1H), 3.06–2.99 (m, 2H), 2.88–2.85 (m, 2H), 2.78–2.71 (m, 2H), 1.91–1.83 (m, 2H), 1.64–1.55 (m, 2H), 1.24–1.16 (m, 3H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>32</sub>H<sub>35</sub>F<sub>3</sub>N<sub>5</sub>O<sub>6</sub>S [M + H]<sup>+</sup>: 674.2260; found, 674.2267.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)propane-1-sulfonamide (<b>33</b>)</h3><div class="NLM_p last">White solid, 16% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.51 (s, 2H), 8.50 (d, <i>J</i> = 3.4 Hz, 1H), 7.88 (d, <i>J</i> = 1.6 Hz, 1H), 7.62–7.54 (m, 2H), 7.49 (dd, <i>J</i> = 11.9, 8.2 Hz, 2H), 7.42 (t, <i>J</i> = 7.5 Hz, 2H), 7.33–7.28 (m, 1H), 7.22–7.16 (m, 1H), 6.88 (dd, <i>J</i> = 9.6, 4.8 Hz, 1H), 6.54 (d, <i>J</i> = 8.9 Hz, 1H), 3.96 (s, 6H), 3.29–3.18 (m, 1H), 3.05–2.96 (m, 2H), 2.91–2.83 (m, 2H), 2.78–2.71 (m, 2H), 1.90–1.84 (m, 2H), 1.72–1.66 (m, 2H), 1.62–1.54 (m, 2H), 1.01–0.97 (m, 3H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>33</sub>H<sub>37</sub>F<sub>3</sub>N<sub>5</sub>O<sub>6</sub>S [M + H]<sup>+</sup>: 688.2417; found, 688.2450.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>N</i>-(1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)cyclopropanesulfonamide (<b>34</b>)</h3><div class="NLM_p last">White solid, 63% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.58 (s, 2H), 8.50 (d, <i>J</i> = 4.9 Hz, 1H), 7.96 (s, 1H), 7.87 (d, <i>J</i> = 1.1 Hz, 1H), 7.61–7.54 (m, 2H), 7.52–7.47 (m, 2H), 7.42 (t, <i>J</i> = 7.6 Hz, 2H), 7.32–7.26 (m, 1H), 7.21 (d, <i>J</i> = 8.4 Hz, 1H), 6.88 (dd, <i>J</i> = 8.4, 1.1 Hz, 1H), 6.55 (d, <i>J</i> = 4.9 Hz, 1H), 3.96 (s, 6H), 3.31–3.27 (m, 1H), 2.87–2.85 (m, 1H), 2.81–2.77 (m, 2H), 2.62–2.56 (m, 2H), 1.95–1.90 (m, 2H), 1.67–1.57 (m, 2H), 1.00–0.90 (m, 4H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>33</sub>H<sub>35</sub>F<sub>3</sub>N<sub>5</sub>O<sub>6</sub>S [M + H]<sup>+</sup>: 686.2260; found, 686.2247.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>N</i>-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (<b>35</b>)</h3><div class="NLM_p last">White solid, 51% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.28 (s, 2H), 8.54 (s, 1H), 7.84 (d, <i>J</i> = 21.4 Hz, 2H), 7.55 (d, <i>J</i> = 17.2 Hz, 3H), 7.43 (s, 3H), 7.30 (s, 1H), 6.90 (d, <i>J</i> = 6.3 Hz, 1H), 6.59 (s, 1H), 3.97 (s, 6H), 3.51–3.43 (m, 1H), 2.99 (s, 2H), 2.89–2.85 (m, 2H), 2.67–2.63 (m, 2H), 2.10 (d, <i>J</i> = 7.1 Hz, 2H), 1.70–1.67 (m, 2H), 1.53–1.49 (m, 1H), 1.01 (t, <i>J</i> = 6.9 Hz, 3H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>34</sub>H<sub>37</sub>F<sub>3</sub>N<sub>5</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 652.2747; found, 652.2757.</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>N</i>-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)-3-(1-methylpiperidin-2-yl)propanamide (<b>36</b>)</h3><div class="NLM_p last">White solid, 20% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.77 (s, 1H), 9.71 (s, 1H), 8.50 (d, <i>J</i> = 4.5 Hz, 1H), 7.85 (s, 1H), 7.56 (d, <i>J</i> = 6.7 Hz, 2H), 7.52 (s, 1H), 7.46–7.42 (m, 3H), 7.29 (d, <i>J</i> = 5.9 Hz, 1H), 6.88 (d, <i>J</i> = 6.1 Hz, 1H), 6.56 (s, 1H), 3.96 (s, 6H), 3.56–3.47 (m, 1H), 3.10 (d, <i>J</i> = 3.5 Hz, 2H), 3.05–2.83 (m, 11H), 2.73–2.66 (m, 3H), 2.32–1.94 (m, 2H), 1.83–1.71 (m, 4H), 1.57–1.49 (m, 2H), 1.36–1.17 (m, 4H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>40</sub>H<sub>48</sub>F<sub>3</sub>N<sub>6</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 749.3638; found, 749.3651.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 3-((6,7-Dimethoxyquinolin-4-yl)oxy)aniline (<b>37</b>)</h3><div class="NLM_p">To a solution of 3-aminophenol (1.65 g, 13.4 mmol) in DMSO (15 mL) was added <i><sup>t</sup></i>Bu-OK (1.51 g, 13.4 mmol) at room temperature. After stirring for 2 h, 4-chloro-6,7-dimethoxylquinoline (2.0 g, 8.9 mmol) and K<sub>2</sub>CO<sub>3</sub> (738 mg, 5.34 mmol) were added, then the reaction mixture was heated to 100 °C and stirred for 12 h. After being cooled down to room temperature, the mixture was diluted with ethyl acetate and washed with saturated NaHCO<sub>3</sub> (aq). The diluted mixture was then filtered through Celite to remove the emulsion. The organic phase was collected and washed with 1.0 M NaOH (aq) and brine, then dried with anhydrous MgSO<sub>4</sub>. The filtrate was concentrated to give the residue which was purified by silica gel flash chromatography with dichloromethane/methanol (20:1) to afford the product <b>37</b> as a light yellow solid (2.48 g, 89% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.49 (d, <i>J</i> = 5.2 Hz, 1H), 7.47 (s, 1H), 7.39 (s, 1H), 7.13 (t, <i>J</i> = 8.0 Hz, 1H), 6.55–6.49 (m, 2H), 6.38–6.34 (m, 2H), 5.39 (s, 2H), 3.94 (s, 3H), 3.93 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 160.13, 155.59, 152.93, 151.33, 149.70, 149.29, 146.91, 130.88, 111.51, 108.27, 107.83, 105.98, 104.14, 99.50, 56.13, 56.07. LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>17</sub>H<sub>17</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 297.1239; found, 297.1243.</div><div class="NLM_p last">Compounds <b>40b</b>–<b>d</b> were prepared following the synthetic procedure of <b>40a</b>.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>tert</i>-Butyl (1-(4-Aminophenyl)piperidin-4-yl)carbamate (<b>40a</b>)</h3><div class="NLM_p last">To a solution of 1-chloro-4-nitrobenzene (2.0 g, 12.69 mmol) and K<sub>2</sub>CO<sub>3</sub> (5.3 g, 38.09 mmol) in DMF (60 mL) was added <i>tert</i>-butyl piperidin-4-ylcarbamate (2.5 g, 12.69 mmol). The mixture was stirred at 100 °C for 8 h. The solvent was removed under vacuum after it was allowed to cool down to room temperature. The residue was dissolved in ethyl acetate, washed with water and brine, dried with MgSO<sub>4</sub>, and then concentrated to afford the crude nitrobenzene product as a light yellow solid, which was used in the next step without further purification. LC–MS (ESI, <i>m</i>/<i>z</i>): 322.2906 [M + H]<sup>+</sup>. To a solution of the crude nitrobenzene in methanol (50 mL) was added 10% Pd/C (2.0 g, 20% w/w) at room temperature. The reaction mixture was stirred under hydrogen balloon for 3 h and then filtered through Celite. The filtrate was concentrated to give the residue which was purified by silica gel flash chromatography with dichloromethane/methanol (20:1) to afford compound <b>40a</b> as a brown solid (1.2 g, 32% yield in two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.83 (d, <i>J</i> = 7.4 Hz, 1H), 6.69 (d, <i>J</i> = 7.8 Hz, 2H), 6.48 (d, <i>J</i> = 7.8 Hz, 2H), 4.64 (s, 2H), 3.33–3.28 (m, 3H), 2.55–2.51 (m, 2H), 1.83–1.71 (m, 2H), 1.55–1.45 (m, 2H), 1.40 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 155.37, 143.15, 142.58, 119.11, 115.19, 77.93, 50.72, 47.87, 32.41, 28.73. LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>16</sub>H<sub>26</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 292.2025; found, 292.2037.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>tert</i>-Butyl 1-(4-Amino-2-(trifluoromethyl)phenyl)piperidin-3-ylcarbamate (<b>40b</b>)</h3><div class="NLM_p last">Light yellow solid, 91% yield. White solid, 76% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.16 (d, <i>J</i> = 7.7 Hz, 1H), 6.88–6.71 (m, 2H), 5.34 (s, 2H), 3.47 (d, <i>J</i> = 2.7 Hz, 1H), 2.86 (d, <i>J</i> = 8.4 Hz, 1H), 2.68 (d, <i>J</i> = 8.1 Hz, 1H), 2.39 (s, 1H), 1.76 (d, <i>J</i> = 8.8 Hz, 1H), 1.67 (d, <i>J</i> = 9.4 Hz, 1H), 1.53 (d, <i>J</i> = 5.3 Hz, 1H), 1.37 (s, 9H), 1.23 (d, <i>J</i> = 36.0 Hz, 1H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>17</sub>H<sub>25</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 360.1899; found, 360.1902.</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>tert</i>-Butyl (1-(4-Amino-2-(trifluoromethyl)phenyl)piperidin-4-yl)methylcarbamate (<b>40c</b>)</h3><div class="NLM_p last">White solid, 69% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.19 (d, <i>J</i> = 17.3 Hz, 1H), 6.80 (dd, <i>J</i> = 29.7, 13.0 Hz, 3H), 5.30 (s, 2H), 2.86 (d, <i>J</i> = 5.0 Hz, 2H), 2.77 (d, <i>J</i> = 9.4 Hz, 2H), 2.59 (t, <i>J</i> = 10.7 Hz, 2H), 1.63 (d, <i>J</i> = 11.2 Hz, 2H), 1.39 (s, 9H), 1.19 (dd, <i>J</i> = 21.4, 10.5 Hz, 2H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>18</sub>H<sub>27</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 374.2055; found, 374.2063.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>tert</i>-Butyl (1-(4-Amino-2-(trifluoromethyl)phenyl)piperidin-4-yl)carbamate (<b>40d</b>)</h3><div class="NLM_p">Yellow solid, 76% yield in two steps. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.24 (d, <i>J</i> = 8.5 Hz, 1H), 6.85–6.81 (m, 2H), 6.77 (d, <i>J</i> = 8.5 Hz, 1H), 5.32 (s, 2H), 3.36–3.27 (m, 1H), 2.78–2.76 (m, 2H), 2.69–2.66 (m, 2H), 1.76–1.73 (m, 2H), 1.57–1.43 (m, 2H), 1.39 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 155.39, 146.72, 141.36, 126.80, 126.53, 126.06, 125.83, 123.35, 118.14, 111.17, 111.11, 77.88, 53.45, 47.70, 33.06, 28.72. LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>17</sub>H<sub>25</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 360.1899; found, 360.1910.</div><div class="NLM_p last">Compounds <b>41b</b>–<b>d</b> were prepared following the synthetic procedure of <b>41a</b>.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>tert</i>-Butyl (1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)phenyl)piperidin-4-yl)carbamate (<b>41a</b>)</h3><div class="NLM_p last">To a solution of triphosgene (114 mg, 0.38 mmol) in anhydrous DCM (30 mL) was added a solution of <b>37</b> (300 mg, 0.97 mmol), Et<sub>3</sub>N (0.2 mL, 1.46 mmol), and DMAP (12 mg, 0.09 mmol) in anhydrous DCM (10 mL) at 0 °C under argon. After stirring for 0.5 h, a solution of <b>40a</b> (283 mg, 0.97 mmol), Et<sub>3</sub>N (0.2 mL, 1.46 mmol), and DMAP (12 mg, 0.09 mmol) in anhydrous DCM (10 mL) was added to the above reaction mixture at 0 °C under argon. Then the mixture was warmed to room temperature and stirred for 1 h. The reaction mixture was concentrated and the residue was purified by silica gel flash chromatography with dichloromethane/methanol (20:1) to afford the title compound <b>41a</b> as an off-white solid (418 mg, 69% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.68 (s, 1H), 8.47 (d, <i>J</i> = 5.2 Hz, 1H), 8.39 (s, 1H), 7.57 (s, 1H), 7.47 (d, <i>J</i> = 1.9 Hz, 1H), 7.42 (s, 1H), 7.33–7.15 (m, 5H), 6.92–6.78 (m, 4H), 6.36 (d, <i>J</i> = 5.2 Hz, 1H), 3.96 (s, 6H), 3.51 (d, <i>J</i> = 12.4 Hz, 3H), 2.63 (t, <i>J</i> = 11.9 Hz, 3H), 2.07 (s, 3H), 1.80 (d, <i>J</i> = 1.7 Hz, 3H), 1.59–1.44 (m, 3H), 1.39 (s, 12H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>34</sub>H<sub>40</sub>N<sub>5</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 614.2979; found, 614.2986.</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>tert</i>-Butyl 1-(4-(3-(3-(6,7-Dimethoxyquinolin-4-yloxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-3-ylcarbamate (<b>41b</b>)</h3><div class="NLM_p last">White solid, 57% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.17 (s, 2H), 8.53 (d, <i>J</i> = 5.1 Hz, 1H), 8.33 (s, 1H), 7.86 (s, 1H), 7.29 (d, <i>J</i> = 7.6 Hz, 1H), 6.90 (d, <i>J</i> = 7.4 Hz, 1H), 6.71 (d, <i>J</i> = 18.7 Hz, 1H), 6.58 (d, <i>J</i> = 5.0 Hz, 1H), 3.97 (s, 6H), 3.66–3.41 (m, 3H), 2.96 (t, <i>J</i> = 17.1 Hz, 1H), 2.88–2.68 (m, 1H), 2.58 (d, <i>J</i> = 8.8 Hz, 2H), 2.44 (t, <i>J</i> = 13.0 Hz, 1H), 2.00 (dd, <i>J</i> = 23.7, 10.1 Hz, 1H), 1.89–1.66 (m, 3H), 1.56 (d, <i>J</i> = 22.9 Hz, 1H), 1.36 (s, 9H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>35</sub>H<sub>39</sub>F<sub>3</sub>N<sub>5</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 682.2852; found, 682.2869.</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> <i>tert</i>-Butyl (1-(4-(3-(3-(6,7-Dimethoxyquinolin-4-yloxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methylcarbamate (<b>41c</b>)</h3><div class="NLM_p last">White solid, 68% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.21 (d, <i>J</i> = 8.9 Hz, 2H), 8.54 (d, <i>J</i> = 5.0 Hz, 1H), 8.32 (s, 1H), 7.86 (s, 1H), 7.56 (d, <i>J</i> = 17.4 Hz, 3H), 7.43 (t, <i>J</i> = 8.1 Hz, 3H), 7.29 (d, <i>J</i> = 7.4 Hz, 1H), 6.90 (d, <i>J</i> = 7.5 Hz, 2H), 6.60 (d, <i>J</i> = 5.1 Hz, 1H), 3.96 (s, 6H), 3.53 (d, <i>J</i> = 1.4 Hz, 2H), 2.87 (s, 4H), 2.65 (t, <i>J</i> = 10.5 Hz, 2H), 1.67 (d, <i>J</i> = 10.9 Hz, 2H), 1.47 (d, <i>J</i> = 6.1 Hz, 2H), 1.42 (d, <i>J</i> = 28.5 Hz, 9H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>36</sub>H<sub>41</sub>F<sub>3</sub>N<sub>5</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 696.3009; found, 696.3030.</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>tert</i>-Butyl (1-(4-(3-(3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)carbamate (<b>41d</b>)</h3><div class="NLM_p">Yellow solid, 91% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.97 (s, 2H), 8.51 (d, <i>J</i> = 5.1 Hz, 1H), 7.86 (s, 1H), 7.65–7.37 (m, 6H), 7.29 (d, <i>J</i> = 8.1 Hz, 1H), 6.88 (t, <i>J</i> = 7.6 Hz, 2H), 6.56 (d, <i>J</i> = 5.2 Hz, 1H), 3.95 (d, <i>J</i> = 6.4 Hz, 6H), 3.39 (s, 8H), 2.89–2.84 (m, 2H), 2.74–2.69 (m, 2H), 1.79–1.77 (m, 1H), 1.55–1.48 (m, 2H), 1.39 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.92, 155.39, 154.98, 152.99, 149.85, 149.29, 147.28, 146.99, 141.94, 137.09, 130.93, 125.76, 123.43, 116.63, 115.74, 114.51, 110.88, 108.30, 104.13, 99.51, 77.95, 56.14, 55.35, 53.25, 47.57, 32.90, 28.72. LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>35</sub>H<sub>39</sub>F<sub>3</sub>N<sub>5</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 682.2852; found, 682.2861.</div><div class="NLM_p last">Compounds <b>42b</b>–<b>d</b> were prepared following the synthetic procedure of <b>42a</b>.</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 1-(4-(4-Aminopiperidin-1-yl)phenyl)-3-(3-(6,7-dimethoxyquinolin-4-yloxy)phenyl)urea Hydrochloride (<b>42a</b>)</h3><div class="NLM_p last">Compound <b>41a</b> (400 mg, 0.637 mmol) was dissolved in 4 M HCl in ethyl acetate (5 mL) at room temperature. The resulting mixture was stirred for 1 h and then concentrated to afford the product <b>42a</b> as an off white solid (424 mg, 96%) which was used directly in the next step. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.99 (d, <i>J</i> = 3.7 Hz, 2H), 8.78 (d, <i>J</i> = 0.8 Hz, 1H), 8.66 (d, <i>J</i> = 0.4 Hz, 3H), 7.80 (dd, <i>J</i> = 34.2, 3.7 Hz, 4H), 7.58 (d, <i>J</i> = 17.0 Hz, 3H), 7.34 (dd, <i>J</i> = 30.4, 2.4 Hz, 2H), 6.74 (s, 1H), 4.03 (s, 6H), 3.70–3.66 (m, 4H), 3.55–3.53 (m, 1H), 2.30–2.25 (m, 4H), 2.05 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.16, 156.51, 152.99, 151.60, 150.96, 143.16, 141.24, 139.97, 137.35, 136.42, 132.91, 122.91, 122.69, 118.83, 116.68, 115.53, 110.86, 103.34, 100.75, 100.13, 57.09, 56.92, 27.31, 15.19. LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>29</sub>H<sub>32</sub>N<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 514.2454; found, 514.2451.</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 1-(4-(3-Aminopiperidin-1-yl)-3-(trifluoromethyl)phenyl)-3-(3-(6,7-dimethoxyquinolin-4-yloxy)phenyl)urea Hydrochloride (<b>42b</b>)</h3><div class="NLM_p last">Off-white solid, 56% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.15 (s, 2H), 8.51 (d, <i>J</i> = 5.0 Hz, 1H), 7.87 (s, 1H), 7.57 (s, 2H), 7.52 (s, 1H), 7.41 (d, <i>J</i> = 6.8 Hz, 3H), 7.30 (d, <i>J</i> = 7.7 Hz, 1H), 6.89 (d, <i>J</i> = 7.5 Hz, 1H), 6.56 (d, <i>J</i> = 4.9 Hz, 1H), 3.95 (s, 6H), 2.91 (d, <i>J</i> = 8.5 Hz, 2H), 2.86–2.68 (m, 4H), 2.58 (d, <i>J</i> = 10.0 Hz, 1H), 2.37 (t, <i>J</i> = 9.1 Hz, 1H), 1.81 (d, <i>J</i> = 7.8 Hz, 1H), 1.70 (d, <i>J</i> = 10.8 Hz, 1H), 1.54 (d, <i>J</i> = 9.8 Hz, 1H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.91, 155.01, 153.02, 149.87, 149.30, 147.11, 142.01, 137.06, 130.91, 125.71, 123.45, 115.73, 114.45, 110.83, 108.35, 104.15 99.54, 62.68, 56.15, 54.64, 48.62, 33.44 (s, 1H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>30</sub>H<sub>31</sub>F<sub>3</sub>N<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 582.2328; found, 582.2319.</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 1-(4-(4-(Aminomethyl)piperidin-1-yl)-3-(trifluoromethyl)phenyl)-3-(3-(6,7-dimethoxyquinolin-4-yloxy)phenyl)urea Hydrochloride (<b>42c</b>)</h3><div class="NLM_p last">Off -white solid, 45% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.40 (s, 2H), 8.50 (d, <i>J</i> = 4.2 Hz, 1H), 7.87 (s, 1H), 7.57 (s, 2H), 7.51 (s, 1H), 7.41 (s, 3H), 7.31 (d, <i>J</i> = 7.0 Hz, 1H), 6.87 (d, <i>J</i> = 7.0 Hz, 1H), 6.55 (d, <i>J</i> = 4.1 Hz, 1H), 3.95 (d, <i>J</i> = 5.7 Hz, 6H), 3.42 (s, 1H), 2.86 (d, <i>J</i> = 8.2 Hz, 2H), 2.64 (t, <i>J</i> = 10.3 Hz, 2H), 2.53 (s, 1H), 1.73 (d, <i>J</i> = 10.6 Hz, 2H), 1.36 (s, 1H), 1.21 (d, <i>J</i> = 9.3 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.96 (s, 1H), 154.96, 153.08, 149.87 149.29, 147.51, 146.98, 142.17, 137.11, 130.86, 125.48, 123.40, 116.73, 115.75, 114.36, 110.85, 108.30, 104.13, 99.55, 56.15, 54.27, 47.62, 38.25, 30.70 LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>31</sub>H<sub>33</sub>F<sub>3</sub>N<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 596.2485; found, 596.2488.</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 1-(4-(4-Aminopiperidin-1-yl)-3-(trifluoromethyl)phenyl)-3-(3-(6,7-dimethoxyquinolin-4-yloxy)phenyl)urea Hydrochloride (<b>42d</b>)</h3><div class="NLM_p last">Light yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.18 (s, 1H), 10.09 (s, 1H), 8.80 (d, <i>J</i> = 6.4 Hz, 1H), 8.31 (s, 2H), 7.88 (s, 1H), 7.81–7.63 (m, 3H), 7.53 (dd, <i>J</i> = 23.3, 8.0 Hz, 3H), 7.37 (d, <i>J</i> = 8.0 Hz, 1H), 7.02 (d, <i>J</i> = 7.8 Hz, 1H), 6.88 (d, <i>J</i> = 6.5 Hz, 1H), 4.04 (d, <i>J</i> = 3.6 Hz, 6H), 3.12–3.02 (m, 1H), 2.92–2.89 (m, 2H), 2.80–2.75(m, 2H), 2.01–1.98 (m, 2H), 1.69–1.64 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.46, 153.15, 143.02, 142.58, 137.44, 131.48, 126.05, 122.75, 115.81, 114.46, 110.54, 103.67, 100.79, 100.02, 56.95, 52.09, 47.81, 45.74, 30.74. LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>30</sub>H<sub>31</sub>F<sub>3</sub>N<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 582.2328; found, 582.2331.</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> <i>tert</i>-Butyl 1-(4-Nitro-2-(trifluoromethyl)phenyl)piperidin-4-ylcarbamate (<b>43</b>)</h3><div class="NLM_p last">To a solution of <b>38b</b> (2.0 g, 8.86 mmol) and K<sub>2</sub>CO<sub>3</sub> (3.67 g, 26.58 mmol) in DMF (60 mL) was added <b>39b</b> (1.77 g, 8.86 mmol). The mixture was stirred at 100 °C for 8 h, and then the solvent was removed under vacuum after it was allowed to cool down to room temperature. The residue was dissolved in ethyl acetate, washed with water and brine, dried with MgSO<sub>4</sub>, and then concentrated under vacuum to afford the crude product <b>43</b> as a light yellow solid (2.7 g, 79%), which was used in the next step without further purification. LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>17</sub>H<sub>23</sub>F<sub>3</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 390.1641; found, 390.1633.</div></div><div id="sec5_1_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 1-(4-Nitro-2-(trifluoromethyl)phenyl)piperidin-4-amine Hydrochloride (<b>44</b>)</h3><div class="NLM_p last">Compound <b>43</b> (400 mg, 0.637 mmol) was dissolved in 4 M HCl in ethyl acetate (5 mL) at room temperature. The resulting mixture was stirred for 1 h and then concentrated to afford the product <b>44</b> as an off white solid (455 mg), which used in the next step with no further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.63–8.29 (m, 5H), 7.57 (d, <i>J</i> = 8.7 Hz, 1H), 3.32 (d, <i>J</i> = 10.8 Hz, 2H), 3.22 (s, 1H), 2.99 (t, <i>J</i> = 11.2 Hz, 2H), 2.08 (d, <i>J</i> = 10.6 Hz, 2H), 1.73 (d, <i>J</i> = 11.0 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 157.14, 142.06, 128.92, 124.27, 51.15, 47.39, 30.13 (s, 5H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>12</sub>H<sub>15</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 290.1116; found, 290.1109.</div></div><div id="sec5_1_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 1-(3-(6,7-Dimethoxyquinolin-4-yloxy)phenyl)-3-(1-(4-nitro-2-(trifluoromethyl)phenyl)piperidin-4-yl)urea (<b>45</b>)</h3><div class="NLM_p last">To a solution of triphosgene (133 mg, 0.448 mmol) in anhydrous DCM (20 mL) was added a solution of <b>37</b> (365 mg, 1.12 mmol), Et<sub>3</sub>N (0.2 mL, 1.46 mmol), and DMAP (12 mg, 0.09 mmol) in anhydrous DCM (10 mL) at 0 °C under argon. After stirring for 0.5 h, a solution of <b>44</b> (332 mg, 1.12 mmol), Et<sub>3</sub>N (0.2 mL, 1.46 mmol), and DMAP (12 mg, 0.09 mmol) in anhydrous DCM (10 mL) was added to the above reaction mixture at 0 °C under argon. Then the mixture was warmed to room temperature and stirred for 1 h. The reaction mixture was concentrated and the residue was purified by silica gel flash chromatography with dichloromethane/methanol (20:1) to afford the title compound <b>45</b> as an off-white solid (480 mg, 70% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.61 (s, 1H), 8.51 (s, 1H), 8.39 (s, 2H), 7.52 (dd, <i>J</i> = 30.8, 10.3 Hz, 4H), 7.38 (dd, <i>J</i> = 16.4, 8.4 Hz, 2H), 7.18 (d, <i>J</i> = 8.0 Hz, 1H), 6.81 (d, <i>J</i> = 7.7 Hz, 1H), 6.55 (s, 1H), 6.38 (d, <i>J</i> = 6.4 Hz, 1H), 3.95 (d, <i>J</i> = 7.5 Hz, 6H), 3.69 (s, 1H), 3.29 (d, <i>J</i> = 11.6 Hz, 2H), 3.03 (t, <i>J</i> = 10.9 Hz, 2H), 2.06–1.88 (m, 2H), 1.55 (d, <i>J</i> = 11.1 Hz, 2H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>30</sub>H<sub>29</sub>F<sub>3</sub>N<sub>5</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 612.2070; found, 612.2097.</div></div><div id="sec5_1_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 1-(1-(4-Amino-2-(trifluoromethyl)phenyl)piperidin-4-yl)-3-(3-(6,7-dimethoxyquinolin-4-yloxy)phenyl)urea (<b>46</b>)</h3><div class="NLM_p last">To a solution of the compound <b>45</b> (480 mg, 0.78 mmol) in methanol (20 mL) was added 10% Pd/C (96 mg, 20% w/w) at room temperature. The reaction mixture was stirred under hydrogen balloon for 8 h and then filtered through Celite. The filtrate was concentrated to give the residue which was purified by silica gel flash chromatography with dichloromethane/methanol (20:1) to afford compound <b>46</b> as an off white solid (185 mg, 41% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.57 (s, 1H), 8.50 (s, 1H), 7.50 (s, 2H), 7.37 (dd, <i>J</i> = 17.7, 9.4 Hz, 2H), 7.24 (d, <i>J</i> = 8.1 Hz, 1H), 7.17 (d, <i>J</i> = 7.6 Hz, 1H), 6.88–6.71 (m, 3H), 6.54 (s, 1H), 6.30 (s, 1H), 5.33 (s, 2H), 3.95 (d, <i>J</i> = 7.8 Hz, 6H), 3.51 (s, 1H), 2.72 (dd, <i>J</i> = 21.5, 11.5 Hz, 4H), 1.84 (d, <i>J</i> = 9.9 Hz, 2H), 1.49 (d, <i>J</i> = 10.1 Hz, 2H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>30</sub>H<sub>31</sub>F<sub>3</sub>N<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 582.2328; found, 582.2350.</div></div><div id="sec5_1_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Methyl 1-((3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)carbamoyl)cyclopropane-1-carboxylate (<b>47</b>)</h3><div class="NLM_p last">To a solution of <b>37</b> (200 mg, 0.675 mmol) in DMF (5 mL) was added 1-(methoxycarbonyl)cyclopropane-1-carboxylic acid (116 mg, 0.809 mmol), HATU (333 mg, 0.878 mmol), and DIPEA (0.35 mL, 2.025 mmol). The reaction mixture was allowed to stir at room temperature overnight. The solvent was removed under vacuum to give the residue which was diluted with ethyl acetate and washed with brine. The organic phase was collected and dried over MgSO<sub>4</sub>, then filtered through Celite and concentrated. The residue was purified by silica gel flash chromatography with dichloromethane/methanol (20:1) to afford compound <b>47</b> as an off white solid (271 mg, 95% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.50 (d, <i>J</i> = 4.6 Hz, 1H), 7.68 (s, 1H), 7.56 (s, 1H), 7.42 (d, <i>J</i> = 12.5 Hz, 3H), 6.95 (d, <i>J</i> = 0.9 Hz, 1H), 6.54 (d, <i>J</i> = 4.4 Hz, 1H), 4.06 (s, 6H), 3.74 (s, 3H), 1.81 (s, 2H), 1.70 (s, 2H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>23</sub>H<sub>23</sub>N<sub>2</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 423.1556; found, 423.1561.</div></div><div id="sec5_1_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> <i>tert</i>-Butyl (1-(4-(1-((3-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)carbamoyl)cyclopropane-1-carboxamido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)carbamate (<b>49</b>)</h3><div class="NLM_p last">To a solution of <b>47</b> (270 mg, 0.639 mmol) in MeOH (10 mL) was added 1.0 M NaOH (aq, 1 mL). The mixture was stirred under reflux for about 2 h. After being cooled down to room temperature, the reaction mixture was concentrated under vacuum to give the crude product <b>48</b>, which was used in the next step without further purification. LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>22</sub>H<sub>21</sub>N<sub>2</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 409.1400; found, 409.1411. To a solution of <b>48</b> (130 mg, 0.318 mmol), <b>40d</b> (114 mg, 0.318 mmol), and DIPEA (0.11 mL, 0.636 mmol) in DMF (3 mL) was added HATU (183 mg, 0.477 mmol) at room temperature and the reaction mixture was stirred overnight. The solvent was removed under vacuum to give the residue that was diluted with ethyl acetate and washed with water and brine. The organic phase was collected and dried with MgSO<sub>4</sub>, then filtered and concentrated to give the crude product which was purified by silica gel flash chromatography with dichloromethane/methanol (20:1) to afford the title compound <b>49</b> as an off white solid (150 mg, 63% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.34 (s, 1H), 9.05 (s, 1H), 8.51 (s, 1H), 7.75 (s, 1H), 7.68 (d, <i>J</i> = 9.4 Hz, 1H), 7.60 (d, <i>J</i> = 1.7 Hz, 1H), 7.56 (s, 1H), 7.45 (s, 2H), 7.37 (s, 1H), 7.31 (d, <i>J</i> = 15.0 Hz, 2H), 6.99 (d, <i>J</i> = 14.6 Hz, 1H), 6.55 (d, <i>J</i> = 5.9 Hz, 1H), 4.06 (s, 6H), 3.65–3.55 (m, 1H), 3.05–2.97 (m, 2H), 2.83–2.75 (m, 2H), 2.06–2.02 (m, 2H), 1.98–1.92 (m, 2H), 1.73–1.69 (m, 2H), 1.63–1.58 (m, 2H), 1.48 (s, 9H). LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>39</sub>H<sub>43</sub>F<sub>3</sub>N<sub>5</sub>O<sub>7</sub> [M + H]<sup>+</sup>: 750.3115; found, 750.3119.</div></div><div id="sec5_1_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> <i>N</i>-(4-(4-Aminopiperidin-1-yl)-3-(trifluoromethyl)phenyl)-<i>N</i>-(3-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)cyclopropane 1,1-Dicarboxamide (<b>50</b>)</h3><div class="NLM_p last">Compound <b>49</b> (400 mg, 0.637 mmol,) was dissolved in 4 M HCl in ethyl acetate (5 mL) at room temperature. The resulting mixture was stirred for 1 h, and then concentrated to afford the product <b>50</b> as an off white solid (151 mg, 99%) which was used directly in the next step. LC–MS (ESI, <i>m</i>/<i>z</i>) calcd for C<sub>34</sub>H<sub>35</sub>F<sub>3</sub>N<sub>5</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 650.2590; found, 650.2593.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Cell Lines, Antibodies, and Chemicals</h3><div class="NLM_p">The human GIST-T1 cell line was purchased from Cosmo Bio Co., Ltd. (Tokyo, Japan). GIST-5R cell line was kindly provided by Prof. Brian Rubin, Department of Molecular Genetics, Lerner Research Institute, and Department of Anatomic Pathology and Taussing Cancer Center, Cleveland Clinic, Cleveland, OH 44195. GIST-T1 and GIST-5R cell lines were maintained in DMEM (Corning, USA) supplemented with 10% FBS, 1% penicillin/streptomycin. Isogenic BaF3 cells lines were cultured in RPMI 1640 media (Corning, USA) with 10% fetal bovine serum (FBS) and supplemented with 2% <span class="smallcaps smallerCapital">l</span>-glutamine and 1% penicillin/streptomycin. All cell lines were maintained in culture media at 37 °C with 5% CO<sub>2</sub>.</div><div class="NLM_p">The following antibodies were purchased from Cell Signaling Technology (Danvers, MA): AKT (pan) (C67E7) rabbit mAb (no. 4691), Phospho-AKT (Thr308) (244F9) rabbit mAb (no. 4056), Phospho-AKT (Ser473) (D9E) XP rabbit mAb (no. 4060), GAPDH (D16H11) XP rabbit mAb, PARP (46D11) rabbit mAb (no. 9532), caspase-3 (8G10) rabbit mAb (no. 9665), Phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (197G2) rabbit mAb (no. 4377), p44/42 MAPK (ERK1/2) (137F5) rabbit mAb (no. 4695), cKIT (Ab81) mouse mAb (no. 3308), Phospho-cKIT (Tyr703) (D12E12) rabbit mAb (no. 3073), Phospho-cKIT (Tyr719) antibody (no. 3391), rabbit (polyclonal) anti-cKIT (pY 823) Phospho specific antibody, Phospho-STAT3 (Tyr705) (D3A7) XP rabbit mAb (Biotinylated) (no. 4093), STAT3 (D3Z2G) rabbit mAb no. 12640, Phospho-S6 ribosomal protein (Ser235/236) antibody (no. 2211), S6 ribosomal protein (5G10) rabbit mAb no. 2217.</div><div class="NLM_p last">Imatinib and sunitinib and were purchased from Shanghai Haoyuan Chemexpress Inc. (Shanghai, China)</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> General Procedure for Antiproliferation Assays</h3><div class="NLM_p last">Cells were grown in 96-well culture plates (3000/well). The compounds of various concentrations were added into the plates. Cell proliferation was determined after treatment with compounds for 72 h. Cell viability was measured using the CellTiter-Glo assay (Promega, USA) according to the manufacturer’s instructions, and luminescence was measured in a multilabel reader (Envision, PerkinElmer, USA). Data were normalized to control groups (DMSO) and represented by the mean of three independent measurements with standard error of <20%. GI<sub>50</sub> values were calculated using Prism 5.0 (GraphPad Software, San Diego, CA).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> TEL-Isogenic Cell Generation</h3><div class="NLM_p last">Retroviral constructs for BaF3-cKIT mutants were made based on the pMSCVpuro (Clontech) backbone. For TEL-cKIT vector, the first 1 kb of human TEL gene with an artificial myristoylation sequence (MGCGCSSHPEDD) was cloned into the pMSCVpuro retroviral vector, followed by a 3xFLAG tag sequence and a stop codon. Then, the kinase domain coding sequence of cKIT was inserted in-frame between TEL and 3xFLAG sequences. For full-length expression vectors, the coding sequences of cKIT variants were directly cloned in pMSCVpuro vector with a 3xFLAG tag at the C-terminal end. All mutagenesis were performed using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) following the manufacturer’s instructions. Retrovirus was packaged in HEK293T cells by transfecting cKIT-containing MSCV vectors together with two helper plasmids. Virus supernatants were harvested 48 h after transfection and filtered before infection. Then BaF3 cells were infected with harvested virus supernatants using spinoculation protocol and stable cell lines were obtained by puromycin selection for 48 h. The IL-3 concentrations in the culture medium were gradually withdrawn until cells were able to grow in the absence of IL-3.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> cKIT Protein Purification</h3><div class="NLM_p last">The sequences encoding wt cKIT and T670I cKIT residues 544–935 with a Histag were cloned into baculovirus expression vector pFASTHTA. The proteins were expressed by infecting SF9 cells with high titer viral stocks for 48h. Cells were harvested and lysed in 25 mM Tris pH7.4, 250 mM NaCl, 1 mM PMSF. The supernatant was loaded to Ni-NTA column (QIAGEN, 1018244). Then the proteins were step-eluted with the same buffer with 250 mM imidazole. The eluted proteins were loaded on a Superdex-200 column equilibrated in 25 mM Tris (pH 7.4), 250 mM NaCl, 1 mM DTT, and 1 mM EDTA. Peak fractions were concentrated to 2 mg/mL and flash-frozen.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Kinase Biochemical Assay</h3><div class="NLM_p last">The ADP-Glo kinase assay (Promega, Madison, WI) was used to screen compound <b>35</b> for its cKIT, cKIT T670I inhibition effects. The kinase reaction system contains 9 μL cKIT (40 ng/μL) or cKIT T670I (20 ng/μL), 1 μL of serially diluted compound <b>35</b>, and 10 μL substrate Poly(4:1 Glu, Tyr) peptide (0.4 μg/μL) (Promega, Madison, WI) with 100 μM ATP (Promega, Madison, WI). The reaction in each tube was started immediately by adding ATP and kept going for 1 h under 37 °C. After the tube was cooled for 5 min at room temperature, 5 μL solvent reactions were carried out in a 384-well plate. Then 5 μL of ADP-Glo reagent was added into each well to stop the reaction and consume the remaining ATP within 40 min. At the end, 10 μL of kinase detection reagent was added into the well and incubated for 30 min to produce a luminescence signal. The luminescence signal was measured with an automated plate reader (Envision, PE, USA), and the dose–response curve was fitted using Prism 5.0 (GraphPad Software Inc., San Diego, CA).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Signaling Pathway Study</h3><div class="NLM_p last">GIST-T1 and GIST-5R cells were cultured in 10% FBS-containing DMEM medium. The serially diluted compound <b>35</b> was added to cells for 1 h. The cells were collected and lysed. The cell lysates were analyzed by Western blotting. Western blotting was performed by standard methods, as previously described.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Apoptosis Effect Examination</h3><div class="NLM_p last">GIST-T1 and GIST-5R cells were cultured in 10% FBS-containing DMEM medium. The serially diluted compound <b>35</b> was added to cells for 24 h. Then, apoptosis of GIST-T1 and GIST-5R cells was detected by Western blot using PARP and GAPDH antibodies (Cell Signaling Technology).</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> In Vivo Pharmacokinetics Study</h3><div class="NLM_p last">Compound <b>35</b> was dissolved in 55% saline containing 5% DMSO and 40% PEG400 by vortex. The final concentration of the stock solution was 1 mg/mL for administration. Six 8 week old male Sprague-Dawely rats were fasted overnight before starting drug treatment via intravenous and oral administration. Animal blood collection time points were as follows. For groups 1, 3, 5 (intravenous): 1 min, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h before and after administration was selected. For groups 2, 4, 6 (oral): 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h before and after dosing. Each time about 0.2 mL of blood was collected through the jugular vein adding heparin for anticoagulation and kept on ice. Then plasma was separated by centrifugation at 8000 rpm for 6 min at 2–8 °C. The obtained plasma was stored at −80 °C before analysis. After finishing the test, all surviving animals will be transferred to the repository or euthanasia (CO<sub>2</sub> asphyxiation).</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> BaF3-TEL-cKIT-T670I Xenograft Model</h3><div class="NLM_p last">Five week old female nu/nu mice were purchased from the Shanghai Experimental Center, Chinese Academy of Sciences (Shanghai, China). All animals were maintained in a specific pathogen-free facility and used according to the animal care regulations of Hefei Institutes of Physical Science, Chinese Academy of Sciences (Hefei, China), and all efforts were made to minimize animal suffering. To obtain orthotopic xenograft of human mammary tumor in the mice, cells were harvested during exponential growth. One million BaF3-TEL-cKIT-T670I cells in PBS were suspended in a 1:1 mixture with Matrigel (BD Biosciences) and injected into the subcutaneous space on the right flank of nu/nu mice. Daily ip injection was initiated when BaF3-TEL-cKIT-T670I tumors had reached a size of 200–400 mm<sup>3</sup>. Animals were then randomized into treatment groups of 7 mice each for efficacy studies. Compound <b>35</b> was delivered daily in a HKI solution (0.5% methocellulose/0.4% Tween80 in ddH<sub>2</sub>O) by ip injection. A range of doses of <b>35</b> or its vehicle was administered, as indicated in the <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a> legend. Body weight and tumor growth were measured daily after <b>35</b> treatment. Tumor volumes were calculated as follows: tumor volume (mm<sup>3</sup>) = [(<i>W</i><sup>2</sup> × <i>L</i>)/2] in which width (<i>W</i>) is defined as the smaller of the two measurements and length (<i>L</i>) is defined as the larger of the two measurements.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> HE Staining</h3><div class="NLM_p last">HE staining was carried out according to the previous report.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> First, the sections were hydrated and then the slide was dipped into a Coplin jar containing Mayer’s hematoxylin and agitated for 30 s. After rinsing the slide in H<sub>2</sub>O for 1 min, it was stained with 1% eosin Y solution for 10–30 s with agitation. Subsequently, the sections were dehydrated with two changes of 95% alcohol and two changes of 100% alcohol for 30 s each, and then the alcohol was extracted with two changes of xylene. Finally, one or two drops of mounting medium was added and covered with a coverslip.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Ki-67 Staining</h3><div class="NLM_p last">For IHC demonstration of Ki-67, tissue sections were quenched for endogenous peroxides and placed in an antigen retrieval solution (0.01 M citrate buffer, pH 6.0) for 15 min in a microwave oven at 100 °C at 600 W. After incubation in the casein block, mouse mAb anti-Ki-67 (ZSGB-BIO, China) was applied to the sections at dilutions of 1:50. Incubations with primary antibodies lasted overnight at 4 °C. The secondary detection system was used to visualize antibody binding. Staining was developed with DAB, and the slides were counterstained with hematoxylin, dehydrated, and mounted.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> TUNEL Staining</h3><div class="NLM_p last">TUNEL staining was performed using the POD in Situ Cell Death Detection kit (Roche, USA). Briefly, sections were deparaffinized in xylene, rehydrated in decreasing concentration of ethanol, and then treated by nuclease free proteinase K for 15 min at room temperature before endogenous peroxidase was blocked in 3% H<sub>2</sub>O<sub>2</sub> in methanol. Terminal deoxynucleotidyl transferase (TdT) in reaction buffer was applied to sections for 1 h at 37 °C. Following washes, the slides were covered by converter-POD solution for 30 min at 37 °C. Apoptotic cells were detected after incubation in 3,3′-diaminobenzidine (DAB) chromogen (Beyotime Biotechnology, China) for approximately 8 min, and the slides were counterstained with hematoxylin.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Molecular Modeling</h3><div class="NLM_p last">The crystal structure of cKIT/imatinib complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>) was used for docking. Alternative coordinates of the side chains were manually confirmed. Missing side chains were automatically added using AmberTools15.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The protonation and tautomeric state at physiological pH were confirmed by software Reduce,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and the receptor side chain coordinates were further optimized by Yeti<sup>X</sup> 8.3.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The cKIT(T670I) mutant coordinates were generated by first replacing Thr670 with alanine, then changing the residue name to ILE and automatically adding the missing coordinates by AmberTools15 based on the local environment. The coordinates of compounds <b>1</b> and <b>35</b> were generated and preoptimized by Bio<sup>X</sup> 4.6,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and the atomic AM1-BCC partial charges were calculated by antechamber within AmberTools15. Template-based induced-fit docking for the two compounds with both cKIT and cKIT(T670I) was performed by Yeti<sup>X</sup> 8.3.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00902">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45752" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45752" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00902" class="ext-link">10.1021/acs.jmedchem.6b00902</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Table S1 listing DiscoverX’s KinomeScan selectivity profiling data of compound <b>35</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00902/suppl_file/jm6b00902_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00902/suppl_file/jm6b00902_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00902/suppl_file/jm6b00902_si_001.pdf">jm6b00902_si_001.pdf (745.73 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00902/suppl_file/jm6b00902_si_002.csv">jm6b00902_si_002.csv (5.09 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00902" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43720" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43720" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Liu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#adc7c4c3cac1c4d8edc5c0cbc183ccce83cec3"><span class="__cf_email__" data-cfemail="c8a2a1a6afa4a1bd88a0a5aea4e6a9abe6aba6">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingsong Liu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy
of Sciences, Hefei, Anhui 230088, P.
R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6011130c0915595720080d060c4e01034e030e"><span class="__cf_email__" data-cfemail="7a0b0916130f434d3a12171c16541b19541914">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Binhua Li</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aoli Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juan Liu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ziping Qi</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaochuan Liu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kailin Yu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Wu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheng Chen</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chen Hu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenchao Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiaxin Wu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhenquan Hu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ling Ye</span> - <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy
of Sciences, Hefei, Anhui 230088, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fengming Zou</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feiyang Liu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230036, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Beilei Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tao Ren</span> - <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy
of Sciences, Hefei, Anhui 230088, P.
R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shaojuan Zhang</span> - <span class="hlFld-Affiliation affiliation">Molecular
Imaging Laboratory, Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15219, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Bioengineering, University
of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States</span>; 
    <span class="hlFld-Affiliation affiliation">University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingfeng Bai</span> - <span class="hlFld-Affiliation affiliation">Molecular
Imaging Laboratory, Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15219, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Bioengineering, University
of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States</span>; 
    <span class="hlFld-Affiliation affiliation">University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shanchun Zhang</span> - <span class="hlFld-Affiliation affiliation">CHMFL-HCMTC
Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei, Anhui 230031, P.
R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Hefei
Cosource Medicine Technology Co. LTD., 358 Ganquan Road, Hefei, Anhui 230031, P. R. China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>B.L., A.W., J.L., Z.Q., and X.L. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Dr. Shanchun Zhang is a shareholder of Hefei Cosource Medicine Technology Co. LTD.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e5816-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48334" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48334" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Q.L. is supported by the Joint Funds of Research on Major Science Facilities, Key Program of the National NSFC (Grant U1432250). W.W., J.L., and Q.L. are supported by the grant of “Cross-Disciplinary Collaborative Teams Program for Science, Technology and Innovation (2014–2016)” from Chinese Academy of Sciences. We are grateful for the China “Thousand Talents Program” support for Q.L. and “Hundred Talents Program” of the Chinese Academy of Sciences support for J.L. and W.W. Also, J.L. is supported by the National Program for Support of Top-Notch Young Professionals. Q.L. is also supported by the CAS/SAFEA international partnership program for creative research teams.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i84" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i84"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i85" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i85"> Abbreviations Used</h2><tr><td class="NLM_term">GIST</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumor</p></td></tr><tr><td class="NLM_term">KIT</td><td class="NLM_def"><p class="first last">v-kit Hardy–Zuckerman 4 feline sarcoma viral oncogene homologue</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term"><sup><i>t</i></sup>BuOK</td><td class="NLM_def"><p class="first last">potassium <i>tert</i>-butoxide</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dimethyl chloride</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">GI<sub>50</sub></td><td class="NLM_def"><p class="first last">half growth inhibition concentration</p></td></tr><tr><td class="NLM_term">HE</td><td class="NLM_def"><p class="first last">hematoxylin and eosin</p></td></tr><tr><td class="NLM_term">TUNEL</td><td class="NLM_def"><p class="first last">terminal deoxynucleotidyl transferase dUTP nick end labeling</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s modified Eagle medium</p></td></tr><tr><td class="NLM_term">pMSCV</td><td class="NLM_def"><p class="first last">plasmid murine stem cell virus</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i86">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62323" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62323" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 25 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Miettinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasota, J.</span><span> </span><span class="NLM_article-title">Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis</span> <span class="citation_source-journal">Virchows Arch.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">438</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.1007/s004280000338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1007%2Fs004280000338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=11213830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1Kquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2001&pages=1-12&author=M.+Miettinenauthor=J.+Lasota&title=Gastrointestinal+stromal+tumors%2D%2Ddefinition%2C+clinical%2C+histological%2C+immunohistochemical%2C+and+molecular+genetic+features+and+differential+diagnosis&doi=10.1007%2Fs004280000338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis</span></div><div class="casAuthors">Miettinen, Markku; Lasota, Jerzy</div><div class="citationInfo"><span class="NLM_cas:title">Virchows Archiv</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">438</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">VARCEM</span>;
        ISSN:<span class="NLM_cas:issn">0945-6317</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review with 81 refs.  Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal (GI) tract.  They are defined here as KIT (CD117, stem cell factor receptor)-pos. mesenchymal spindle cell or epithelioid neoplasms primary in the GI tract, omentum, and mesentery.  GISTs typically present in older individuals and are most common in the stomach (60-70%), followed by small intestine (20-25%), colon and rectum (5%), and esophagus (<5%).  Benign tumors outnumber the malignant ones by a wide margin.  Approx. 70% of GISTs are pos. for CD34, 20-30% are pos. for smooth muscle actin (SMA), 10% are pos. for S100 protein and <5% are pos. for desmin.  The expression of CD34 and SMA is often reciprocal.  GISTs commonly have activating mutations in exon 11 (or rarely exon 9 and exon 13) of the KIT gene that encodes a tyrosine kinase receptor for the growth factor named stem cell factor or mast cell growth factor.  Ligand-independent activation of KIT appears to be a strong candidate for mol. pathogenesis of GISTs, and it may be a target for future treatment for such tumors.  Other genetic changes in GISTs discovered using comparative genomic hybridization include losses in 14q and 22q in both benign and malignant GISTs and occurrence in various gains predominantly in malignant GISTs.  GISTs have phenotypic similarities with the interstitial cells of Cajal and, therefore, a histogenetic origin from these cells has been suggested.  An alternative possibility, origin of pluripotential stem cells, is also possible; this is supported by the same origin of Cajal cells and smooth muscle and by the common SMA expression in GISTs.  GISTs differ clin. and pathogenetically from true leiomyosarcomas (very rare in the GI tract) and leiomyomas.  The latter occur in the GI tract, predominantly in the esophagus (intramural tumors) and the colon and rectum (muscularis mucosae tumors).  They also differ from schwannomas that are benign S100-pos. spindle cell tumors usually presenting in the stomach.  GI autonomic nerve tumors (GANTs) are probably a subset of GIST.  Other mesenchymal tumors that have to be sepd. from GISTs include inflammatory myofibroblastic tumors in children, desmoid, and dedifferentiated liposarcoma.  Angiosarcomas and metastatic melanomas, both of which are often KIT-pos., should not be confused with GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeixqNq3cd-7Vg90H21EOLACvtfcHk0lg0ISaY1_ID9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1Kquw%253D%253D&md5=d2600b6aa118b36339ace603c1c9b87f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2Fs004280000338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs004280000338%26sid%3Dliteratum%253Aachs%26aulast%3DMiettinen%26aufirst%3DM.%26aulast%3DLasota%26aufirst%3DJ.%26atitle%3DGastrointestinal%2520stromal%2520tumors--definition%252C%2520clinical%252C%2520histological%252C%2520immunohistochemical%252C%2520and%2520molecular%2520genetic%2520features%2520and%2520differential%2520diagnosis%26jtitle%3DVirchows%2520Arch.%26date%3D2001%26volume%3D438%26spage%3D1%26epage%3D12%26doi%3D10.1007%2Fs004280000338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Lennartsson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronnstrand, L.</span><span> </span><span class="NLM_article-title">Stem cell factor receptor/c-Kit: from basic science to clinical implications</span> <span class="citation_source-journal">Physiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">1619</span><span class="NLM_x">–</span> <span class="NLM_lpage">1649</span><span class="refDoi"> DOI: 10.1152/physrev.00046.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1152%2Fphysrev.00046.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=23073628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhsl2lsbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=1619-1649&author=J.+Lennartssonauthor=L.+Ronnstrand&title=Stem+cell+factor+receptor%2Fc-Kit%3A+from+basic+science+to+clinical+implications&doi=10.1152%2Fphysrev.00046.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Stel cell factor receptor/c-Kit: from basic science to clinical implications</span></div><div class="casAuthors">Lennartsson, Johan; Roennstrand, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1619-1649</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  Stem cell factor (SCF) is a dimeric mol. that exerts its biol. functions by binding to and activating the receptor tyrosine kinase c-Kit.  Activation of c-Kit leads to its autophosphorylation and initiation of signal transduction.  Signaling proteins are recruited to activated c-Kit by certain interaction domains (e.g., SH2 and PTB) that specifically bind to phosphorylated tyrosine residues in the intracellular region of c-Kit.  Activation of c-Kit signaling has been found to mediate cell survival, migration, and proliferation depending on the cell type.  Signaling from c-Kit is crucial for normal hematopoiesis, pigmentation, fertility, gut movement, and some aspects of the nervous system.  Deregulated c-Kit kinase activity has been found in a no. of pathol. conditions, including cancer and allergy.  The observation that gain-of-function mutations in c-Kit can promote tumor formation and progression has stimulated the development of therapeutics agents targeting this receptor, e.g., the clin. used inhibitor imatinib mesylate.  Also other clin. used multiselective kinase inhibitors, for instance, sorafenib and sunitinib, have c-Kit included in their range of targets.  Furthermore, loss-of-function mutations in c-Kit have been obsd. and shown to give rise to a condition called piebaldism.  This review provides a summary of our current knowledge regarding structural and functional aspects of c-Kit signaling both under normal and pathol. conditions, as well as advances in the development of low-mol.-wt. mols. inhibiting c-Kit function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiAi_V1Wivd7Vg90H21EOLACvtfcHk0lhpeB0qRxOhxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhsl2lsbnK&md5=b874bfb881938c505b6718732950be51</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00046.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00046.2011%26sid%3Dliteratum%253Aachs%26aulast%3DLennartsson%26aufirst%3DJ.%26aulast%3DRonnstrand%26aufirst%3DL.%26atitle%3DStem%2520cell%2520factor%2520receptor%252Fc-Kit%253A%2520from%2520basic%2520science%2520to%2520clinical%2520implications%26jtitle%3DPhysiol.%2520Rev.%26date%3D2012%26volume%3D92%26spage%3D1619%26epage%3D1649%26doi%3D10.1152%2Fphysrev.00046.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Linnekin, D.</span><span> </span><span class="NLM_article-title">Early signaling pathways activated by c-Kit in hematopoietic cells</span> <span class="citation_source-journal">Int. J. Biochem. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1053</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span><span class="refDoi"> DOI: 10.1016/S1357-2725(99)00078-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1016%2FS1357-2725%2899%2900078-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10582339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADyaK1MXmsVWitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1999&pages=1053-1074&author=D.+Linnekin&title=Early+signaling+pathways+activated+by+c-Kit+in+hematopoietic+cells&doi=10.1016%2FS1357-2725%2899%2900078-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Early signaling pathways activated by c-Kit in hematopoietic cells</span></div><div class="casAuthors">Linnekin, D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1053-1074</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 171 refs.  C-Kit is a receptor tyrosine kinase that binds stem cell factor (SCF).  Structurally, c-Kit contains five Ig-like domains extracellularly and a catalytic domain divided into two regions by a 77 amino acid insert intracellularly.  Studies in white spotting and steel mice have shown that functional SCF and c-Kit are crit. in the survival and development of stem cells involved in hematopoiesis, pigmentation and reprodn.  Mutations in c-Kit are assocd. with a variety of human diseases.  Interaction of SCF with c-Kit rapidly induces receptor dimerization and increases in autophosphorylation activity.  Downstream of c-Kit, multiple signal transduction components are activated, including phosphatidylinositol-3-kinase, Src family members, the JAK/STAT pathway and the Ras-Raf-MAP kinase cascade.  Structure-function studies have begun to address the role of these signaling components in SCF-mediated responses.  This review will focus on the biochem. mechanism of action of SCF in hematopoietic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-8E1wr3VU-rVg90H21EOLACvtfcHk0lhpeB0qRxOhxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsVWitrc%253D&md5=f8fc51c696dbb65c6885bd55d0e0bde8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1357-2725%2899%2900078-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1357-2725%252899%252900078-3%26sid%3Dliteratum%253Aachs%26aulast%3DLinnekin%26aufirst%3DD.%26atitle%3DEarly%2520signaling%2520pathways%2520activated%2520by%2520c-Kit%2520in%2520hematopoietic%2520cells%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D1999%26volume%3D31%26spage%3D1053%26epage%3D1074%26doi%3D10.1016%2FS1357-2725%2899%2900078-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Hirota, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isozaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiguro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muhammad Tunio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, Y.</span><span> </span><span class="NLM_article-title">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">580</span><span class="refDoi"> DOI: 10.1126/science.279.5350.577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1126%2Fscience.279.5350.577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=9438854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=577-580&author=S.+Hirotaauthor=K.+Isozakiauthor=Y.+Moriyamaauthor=K.+Hashimotoauthor=T.+Nishidaauthor=S.+Ishiguroauthor=K.+Kawanoauthor=M.+Hanadaauthor=A.+Kurataauthor=M.+Takedaauthor=G.+Muhammad+Tunioauthor=Y.+Matsuzawaauthor=Y.+Kanakuraauthor=Y.+Shinomuraauthor=Y.+Kitamura&title=Gain-of-function+mutations+of+c-kit+in+human+gastrointestinal+stromal+tumors&doi=10.1126%2Fscience.279.5350.577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span></div><div class="casAuthors">Hirota, Seiichi; Isozaki, Koji; Moriyama, Yasuhiro; Hashimoto, Koji; Nishida, Toshirou; Ishiguro, Shingo; Kawano, Kiyoshi; Hanada, Masato; Kurata, Akihiko; Takeda, Masashi; Muhammad Tunio, Ghulam; Matsuzawa, Yuji; Kanakura, Yuzuru; Shinomura, Yasuhisa; Kitamura, Yukihiko</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5350</span>),
    <span class="NLM_cas:pages">577-580</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the human digestive tract, but their mol. etiol. and cellular origin are unknown.  Sequencing of c-kit complementary DNA, which encodes a proto-oncogenic receptor tyrosine kinase (KIT), from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains.  All of the corresponding mutant KIT proteins were constitutively activated without the KIT ligand, stem cell factor (SCF).  Stable transfection of the mutant c-kit complementary DNAs induced malignant transformation of Ba/F3 murine lymphoid cells, suggesting that the mutations contribute to tumor development.  GISTs may originate from the interstitial cells of Cajal (ICCs) because the development of ICCs is dependent on the SCF-KIT interaction and because, like GISTs, these cells express both KIT and CD34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLlGnWQ79KELVg90H21EOLACvtfcHk0liU4HG_aJHfHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D&md5=b66b6b8a389b064f73fba13ca84e8650</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.279.5350.577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.279.5350.577%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DS.%26aulast%3DIsozaki%26aufirst%3DK.%26aulast%3DMoriyama%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DIshiguro%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DK.%26aulast%3DHanada%26aufirst%3DM.%26aulast%3DKurata%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DMuhammad%2BTunio%26aufirst%3DG.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DShinomura%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26atitle%3DGain-of-function%2520mutations%2520of%2520c-kit%2520in%2520human%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D1998%26volume%3D279%26spage%3D577%26epage%3D580%26doi%3D10.1126%2Fscience.279.5350.577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duensing, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreevey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">PDGFRA activating mutations in gastrointestinal stromal tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">708</span><span class="NLM_x">–</span> <span class="NLM_lpage">710</span><span class="refDoi"> DOI: 10.1126/science.1079666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1126%2Fscience.1079666" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=708-710&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=A.+Duensingauthor=L.+McGreeveyauthor=C.+J.+Chenauthor=N.+Josephauthor=S.+Singerauthor=D.+J.+Griffithauthor=A.+Haleyauthor=A.+Townauthor=G.+D.+Demetriauthor=C.+D.+Fletcherauthor=J.+A.+Fletcher&title=PDGFRA+activating+mutations+in+gastrointestinal+stromal+tumors&doi=10.1126%2Fscience.1079666"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.1079666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1079666%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DDuensing%26aufirst%3DA.%26aulast%3DMcGreevey%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DJoseph%26aufirst%3DN.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DGriffith%26aufirst%3DD.%2BJ.%26aulast%3DHaley%26aufirst%3DA.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DPDGFRA%2520activating%2520mutations%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D708%26epage%3D710%26doi%3D10.1126%2Fscience.1079666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarlomo-Rikala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tervahartiala, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">1052</span><span class="NLM_x">–</span> <span class="NLM_lpage">1056</span><span class="refDoi"> DOI: 10.1056/NEJM200104053441404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1056%2FNEJM200104053441404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=11287975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=1052-1056&author=H.+Joensuuauthor=P.+J.+Robertsauthor=M.+Sarlomo-Rikalaauthor=L.+C.+Anderssonauthor=P.+Tervahartialaauthor=D.+Tuvesonauthor=S.+Silbermanauthor=R.+Capdevilleauthor=S.+Dimitrijevicauthor=B.+Drukerauthor=G.+D.+Demetri&title=Effect+of+the+tyrosine+kinase+inhibitor+STI571+in+a+patient+with+a+metastatic+gastrointestinal+stromal+tumor&doi=10.1056%2FNEJM200104053441404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor</span></div><div class="casAuthors">Joensuu H; Roberts P J; Sarlomo-Rikala M; Andersson L C; Tervahartiala P; Tuveson D; Silberman S; Capdeville R; Dimitrijevic S; Druker B; Demetri G D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1052-6</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYZ86Vmj15i5otVjB3IRIyfW6udTcc2eZxFV1NDoBvYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D&md5=d361debf544b136b28889449118225e3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJM200104053441404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200104053441404%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DSarlomo-Rikala%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DL.%2BC.%26aulast%3DTervahartiala%26aufirst%3DP.%26aulast%3DTuveson%26aufirst%3DD.%26aulast%3DSilberman%26aufirst%3DS.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DEffect%2520of%2520the%2520tyrosine%2520kinase%2520inhibitor%2520STI571%2520in%2520a%2520patient%2520with%2520a%2520metastatic%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D1052%26epage%3D1056%26doi%3D10.1056%2FNEJM200104053441404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Abbeele, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiese, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span> </span><span class="NLM_article-title">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x">, </span> <span class="NLM_fpage">472</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span><span class="refDoi"> DOI: 10.1056/NEJMoa020461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1056%2FNEJMoa020461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=12181401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2002&pages=472-480&author=G.+D.+Demetriauthor=M.+von+Mehrenauthor=C.+D.+Blankeauthor=A.+D.+Van+den+Abbeeleauthor=B.+Eisenbergauthor=P.+J.+Robertsauthor=M.+C.+Heinrichauthor=D.+A.+Tuvesonauthor=S.+Singerauthor=M.+Janicekauthor=J.+A.+Fletcherauthor=S.+G.+Silvermanauthor=S.+L.+Silbermanauthor=R.+Capdevilleauthor=B.+Kieseauthor=B.+Pengauthor=S.+Dimitrijevicauthor=B.+J.+Drukerauthor=C.+Corlessauthor=C.+D.+Fletcherauthor=H.+Joensuu&title=Efficacy+and+safety+of+imatinib+mesylate+in+advanced+gastrointestinal+stromal+tumors&doi=10.1056%2FNEJMoa020461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span></div><div class="casAuthors">Demetri, George D.; von Mehren, Margaret; Blanke, Charles D.; Van den Abbeele, Annick D.; Eisenberg, Burton; Roberts, Peter J.; Heinrich, Michael C.; Tuveson, David A.; Singer, Samuel; Janicek, Milos; Fletcher, Jonathan A.; Silverman, Stuart G.; Silberman, Sandra L.; Capdeville, Renaud; Kiese, Beate; Peng, Bin; Dimitrijevic, Sasa; Druker, Brian J.; Corless, Christopher; Fletcher, Christopher D. M.; Joensuu, Heikki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">472-480</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Constitutive activation of KIT receptor tyrosine kinase is crit. in the pathogenesis of gastrointestinal stromal tumors.  Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclin. models and preliminary clin. studies to have activity against such tumors.  We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor.  We assessed antitumor response and the safety and tolerability of the drug.  Pharmacokinetics were assessed in a subgroup of patients.  A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily.  Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for tech. reasons, response could not be evaluated in 7 patients (4.8 percent).  No patient had a complete response to the treatment.  The median duration of response had not been reached after a median follow-up of 24 wk after the onset of response.  Early resistance to imatinib was noted in 20 patients (13.6 percent).  Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common.  Gastrointestinal or intraabdominal hemorrhage occurred in approx. 5 percent of patients.  There were no significant differences in toxic effects or response between the two doses.  Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia.  Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor.  Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVE0HpuuKXXrVg90H21EOLACvtfcHk0ljh2G1JW3rI6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D&md5=95c9ea076dd2b0e053ae2061cb3f5d24</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa020461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa020461%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DJanicek%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DSilverman%26aufirst%3DS.%2BG.%26aulast%3DSilberman%26aufirst%3DS.%2BL.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DKiese%26aufirst%3DB.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DCorless%26aufirst%3DC.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DJoensuu%26aufirst%3DH.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520imatinib%2520mesylate%2520in%2520advanced%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D347%26spage%3D472%26epage%3D480%26doi%3D10.1056%2FNEJMoa020461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalcberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeCesne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issels, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Oosterom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogendoorn, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Glabbeke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertulli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span> </span><span class="NLM_article-title">Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1127</span><span class="NLM_x">–</span> <span class="NLM_lpage">1134</span><span class="refDoi"> DOI: 10.1016/S0140-6736(04)17098-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1016%2FS0140-6736%2804%2917098-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2004&pages=1127-1134&author=J.+Verweijauthor=P.+G.+Casaliauthor=J.+Zalcbergauthor=A.+LeCesneauthor=P.+Reichardtauthor=J.+Y.+Blayauthor=R.+Isselsauthor=A.+van+Oosteromauthor=P.+C.+Hogendoornauthor=M.+Van+Glabbekeauthor=R.+Bertulliauthor=I.+Judson&title=Progression-free+survival+in+gastrointestinal+stromal+tumours+with+high-dose+imatinib%3A+randomised+trial&doi=10.1016%2FS0140-6736%2804%2917098-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2804%2917098-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252804%252917098-0%26sid%3Dliteratum%253Aachs%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DZalcberg%26aufirst%3DJ.%26aulast%3DLeCesne%26aufirst%3DA.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DIssels%26aufirst%3DR.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%26aulast%3DHogendoorn%26aufirst%3DP.%2BC.%26aulast%3DVan%2BGlabbeke%26aufirst%3DM.%26aulast%3DBertulli%26aufirst%3DR.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DProgression-free%2520survival%2520in%2520gastrointestinal%2520stromal%2520tumours%2520with%2520high-dose%2520imatinib%253A%2520randomised%2520trial%26jtitle%3DLancet%26date%3D2004%26volume%3D364%26spage%3D1127%26epage%3D1134%26doi%3D10.1016%2FS0140-6736%2804%2917098-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Antonescu, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besmer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hom, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koryotowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leversha, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desantis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMatteo, R. P.</span><span> </span><span class="NLM_article-title">Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">4182</span><span class="NLM_x">–</span> <span class="NLM_lpage">4190</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-2245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1158%2F1078-0432.CCR-04-2245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=15930355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=4182-4190&author=C.+R.+Antonescuauthor=P.+Besmerauthor=T.+Guoauthor=K.+Arkunauthor=G.+Homauthor=B.+Koryotowskiauthor=M.+A.+Levershaauthor=P.+D.+Jeffreyauthor=D.+Desantisauthor=S.+Singerauthor=M.+F.+Brennanauthor=R.+G.+Makiauthor=R.+P.+DeMatteo&title=Acquired+resistance+to+imatinib+in+gastrointestinal+stromal+tumor+occurs+through+secondary+gene+mutation&doi=10.1158%2F1078-0432.CCR-04-2245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation</span></div><div class="casAuthors">Antonescu, Cristina R.; Besmer, Peter; Guo, Tianhua; Arkun, Knarik; Hom, Glory; Koryotowski, Beata; Leversha, Margaret A.; Jeffrey, Philip D.; Desantis, Diann; Singer, Samuel; Brennan, Murray F.; Maki, Robert G.; DeMatteo, Ronald P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4182-4190</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GIST) have an activating mutation in either KIT or PDGFRA.  Imatinib is a selective tyrosine kinase inhibitor and achieves a partial response or stable disease in about 80% of patients with metastatic GIST.  It is now clear that some patients with GIST develop resistance to imatinib during chronic therapy.  To identify the mechanism of resistance, we studied 31 patients with GIST who were treated with imatinib and then underwent surgical resection.  There were 13 patients who were nonresistant to imatinib, 3 with primary resistance, and 15 with acquired resistance after initial benefit from the drug.  There were no secondary mutations in KIT or PDGFRA in the nonresistant or primary resistance groups.  In contrast, secondary mutations were found in 7 of 15 (46%) patients with acquired resistance, each of whom had a primary mutation in KIT exon 11.  Most secondary mutations were located in KIT exon 17.  KIT phosphorylation was heterogeneous and did not correlate with clin. response to imatinib or mutation status.  That acquired resistance to imatinib in GIST commonly occurs via secondary gene mutation in the KIT kinase domain has implications for strategies to delay or prevent imatinib resistance and to employ newer targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOQf6NfYqwnrVg90H21EOLACvtfcHk0lgohT7No3NDLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D&md5=f0f8000b2c362c7d1dcc74a2a7aaa067</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2245%26sid%3Dliteratum%253Aachs%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DArkun%26aufirst%3DK.%26aulast%3DHom%26aufirst%3DG.%26aulast%3DKoryotowski%26aufirst%3DB.%26aulast%3DLeversha%26aufirst%3DM.%2BA.%26aulast%3DJeffrey%26aufirst%3DP.%2BD.%26aulast%3DDesantis%26aufirst%3DD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DBrennan%26aufirst%3DM.%2BF.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26atitle%3DAcquired%2520resistance%2520to%2520imatinib%2520in%2520gastrointestinal%2520stromal%2520tumor%2520occurs%2520through%2520secondary%2520gene%2520mutation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D4182%26epage%3D4190%26doi%3D10.1158%2F1078-0432.CCR-04-2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Debiec-Rychter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciot, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mentens, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vranckx, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasag, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prenen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roesel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagemeijer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Oosterom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marynen, P.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span><span class="refDoi"> DOI: 10.1053/j.gastro.2004.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1053%2Fj.gastro.2004.11.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2005&pages=270-279&author=M.+Debiec-Rychterauthor=J.+Coolsauthor=H.+Dumezauthor=R.+Sciotauthor=M.+Stulauthor=N.+Mentensauthor=H.+Vranckxauthor=B.+Wasagauthor=H.+Prenenauthor=J.+Roeselauthor=A.+Hagemeijerauthor=A.+Van+Oosteromauthor=P.+Marynen&title=Mechanisms+of+resistance+to+imatinib+mesylate+in+gastrointestinal+stromal+tumors+and+activity+of+the+PKC412+inhibitor+against+imatinib-resistant+mutants&doi=10.1053%2Fj.gastro.2004.11.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2004.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2004.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DDebiec-Rychter%26aufirst%3DM.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DDumez%26aufirst%3DH.%26aulast%3DSciot%26aufirst%3DR.%26aulast%3DStul%26aufirst%3DM.%26aulast%3DMentens%26aufirst%3DN.%26aulast%3DVranckx%26aufirst%3DH.%26aulast%3DWasag%26aufirst%3DB.%26aulast%3DPrenen%26aufirst%3DH.%26aulast%3DRoesel%26aufirst%3DJ.%26aulast%3DHagemeijer%26aufirst%3DA.%26aulast%3DVan%2BOosterom%26aufirst%3DA.%26aulast%3DMarynen%26aufirst%3DP.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520imatinib%2520mesylate%2520in%2520gastrointestinal%2520stromal%2520tumors%2520and%2520activity%2520of%2520the%2520PKC412%2520inhibitor%2520against%2520imatinib-resistant%2520mutants%26jtitle%3DGastroenterology%26date%3D2005%26volume%3D128%26spage%3D270%26epage%3D279%26doi%3D10.1053%2Fj.gastro.2004.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDougall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Molecular correlates of imatinib resistance in gastrointestinal stromal tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4764</span><span class="NLM_x">–</span> <span class="NLM_lpage">4774</span><span class="refDoi"> DOI: 10.1200/JCO.2006.06.2265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1200%2FJCO.2006.06.2265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=16954519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFynsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=4764-4774&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=C.+D.+Blankeauthor=G.+D.+Demetriauthor=H.+Joensuuauthor=P.+J.+Robertsauthor=B.+L.+Eisenbergauthor=M.+von+Mehrenauthor=C.+D.+Fletcherauthor=K.+Sandauauthor=K.+McDougallauthor=W.+B.+Ouauthor=C.+J.+Chenauthor=J.+A.+Fletcher&title=Molecular+correlates+of+imatinib+resistance+in+gastrointestinal+stromal+tumors&doi=10.1200%2FJCO.2006.06.2265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular correlates of imatinib resistance in gastrointestinal stromal tumors</span></div><div class="casAuthors">Heinrich, Michael C.; Corless, Christopher L.; Blanke, Charles D.; Demetri, George D.; Joensuu, Heikki; Roberts, Peter J.; Eisenberg, Burton L.; von Mehren, Margaret; Fletcher, Christopher D. M.; Sandau, Katrin; McDougall, Karen; Ou, Wen-bin; Chen, Chang-Jie; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">4764-4774</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of the KIT or platelet-derived growth factor alpha (PDGFRA) kinases, which are targets for imatinib.  In clin. studies, 75% to 90% of patients with advanced GISTs experience clin. benefit from imatinib.  However, imatinib resistance is an increasing clin. problem.  Patients and Methods One hundred forty-seven patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clin. study of imatinib.  Specimens from pretreatment and/or imatinib-resistant tumors were analyzed to identify mol. correlates of imatinib resistance.  Secondary kinase mutations of KIT or PDGFRA that were identified in imatinib-resistant GISTs were biochem. profiled for imatinib sensitivity.  Results Mol. studies were performed using specimens from 10 patients with primary and 33 patients with secondary resistance.  Imatinib-resistant tumors had levels of activated KIT that were similar to or greater than those typically found in untreated GISTs.  Secondary kinase mutations were rare in GISTs with primary resistance but frequently found in GISTs with secondary resistance (10% v 67%, P = .002).  Evidence for clonal evolution and/or polyclonal secondary kinase mutations was seen in three (18.8%) of 16 patients.  Secondary kinase mutations were nonrandomly distributed and were assocd. with decreased imatinib sensitivity compared with typical KIT exon 11 mutations.  Using RNAi technol., we demonstrated that imatinib-resistant GIST cells remain dependent on KIT kinase activity for activation of crit. downstream signaling pathways.  Conclusion Different mol. mechanisms are responsible for primary and secondary imatinib resistance in GISTs.  These findings have implications for future approaches to the growing problem of imatinib resistance in patients with advanced GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw_n35sjCddLVg90H21EOLACvtfcHk0ljhF7RuJSLh6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFynsrrN&md5=25f7b94dd02d55c2fb56cea499cb7ab8</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.06.2265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.06.2265%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DEisenberg%26aufirst%3DB.%2BL.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DSandau%26aufirst%3DK.%26aulast%3DMcDougall%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DW.%2BB.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DMolecular%2520correlates%2520of%2520imatinib%2520resistance%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D4764%26epage%3D4774%26doi%3D10.1200%2FJCO.2006.06.2265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNitto, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">English, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greig, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacques, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunney, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quenzer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmett, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">1542</span><span class="NLM_x">–</span> <span class="NLM_lpage">1547</span><span class="refDoi"> DOI: 10.1073/pnas.0812413106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1073%2Fpnas.0812413106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=19164557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=1542-1547&author=K.+S.+Gajiwalaauthor=J.+C.+Wuauthor=J.+Christensenauthor=G.+D.+Deshmukhauthor=W.+Diehlauthor=J.+P.+DiNittoauthor=J.+M.+Englishauthor=M.+J.+Greigauthor=Y.+A.+Heauthor=S.+L.+Jacquesauthor=E.+A.+Lunneyauthor=M.+McTigueauthor=D.+Molinaauthor=T.+Quenzerauthor=P.+A.+Wellsauthor=X.+Yuauthor=Y.+Zhangauthor=A.+Zouauthor=M.+R.+Emmettauthor=A.+G.+Marshallauthor=H.+M.+Zhangauthor=G.+D.+Demetri&title=KIT+kinase+mutants+show+unique+mechanisms+of+drug+resistance+to+imatinib+and+sunitinib+in+gastrointestinal+stromal+tumor+patients&doi=10.1073%2Fpnas.0812413106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span></div><div class="casAuthors">Gajiwala, Ketan S.; Wu, Joe C.; Christensen, James; Deshmukh, Gayatri D.; Diehl, Wade; DiNitto, Jonathan P.; English, Jessie M.; Greig, Michael J.; He, You-Ai; Jacques, Suzanne L.; Lunney, Elizabeth A.; McTigue, Michele; Molina, Dave; Quenzer, Terri; Wells, Peter A.; Yu, Xiu; Zhang, Yan; Zou, Aihua; Emmett, Mark R.; Marshall, Alan G.; Zhang, Hui-Min; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1542-1547</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GISTs) exhibit aberrant activation of the receptor tyrosine kinase (RTK) KIT.  The efficacy of the inhibitors imatinib mesylate and sunitinib malate in GIST patients has been linked to their inhibition of these mutant KIT proteins.  However, patients on imatinib can acquire secondary KIT mutations that render the protein insensitive to the inhibitor.  Sunitinib has shown efficacy against certain imatinib-resistant mutants, although a subset that resides in the activation loop, including D816H/V, remains resistant.  Biochem. and structural studies were undertaken to det. the mol. basis of sunitinib resistance.  Our results show that sunitinib targets the autoinhibited conformation of WT KIT and that the D816H mutant undergoes a shift in conformational equil. toward the active state.  These findings provide a structural and enzymol. explanation for the resistance profile obsd. with the KIT inhibitors.  Prospectively, they have implications for understanding oncogenic kinase mutants and for circumventing drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkwFxa-p-iWbVg90H21EOLACvtfcHk0ljhF7RuJSLh6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D&md5=dd226c914c6f9a258426c0f4984a5258</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0812413106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0812413106%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DDeshmukh%26aufirst%3DG.%2BD.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DEnglish%26aufirst%3DJ.%2BM.%26aulast%3DGreig%26aufirst%3DM.%2BJ.%26aulast%3DHe%26aufirst%3DY.%2BA.%26aulast%3DJacques%26aufirst%3DS.%2BL.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMolina%26aufirst%3DD.%26aulast%3DQuenzer%26aufirst%3DT.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DA.%26aulast%3DEmmett%26aufirst%3DM.%2BR.%26aulast%3DMarshall%26aufirst%3DA.%2BG.%26aulast%3DZhang%26aufirst%3DH.%2BM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DKIT%2520kinase%2520mutants%2520show%2520unique%2520mechanisms%2520of%2520drug%2520resistance%2520to%2520imatinib%2520and%2520sunitinib%2520in%2520gastrointestinal%2520stromal%2520tumor%2520patients%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D1542%26epage%3D1547%26doi%3D10.1073%2Fpnas.0812413106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Wardelmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merkelbach-Bruse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schildhaus, H. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinicke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speidel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietsch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buettner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pink, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenberger, P.</span><span> </span><span class="NLM_article-title">Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1743</span><span class="NLM_x">–</span> <span class="NLM_lpage">1749</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-1211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1158%2F1078-0432.CCR-05-1211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=16551858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1Cjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1743-1749&author=E.+Wardelmannauthor=S.+Merkelbach-Bruseauthor=K.+Paulsauthor=N.+Thomasauthor=H.+U.+Schildhausauthor=T.+Heinickeauthor=N.+Speidelauthor=T.+Pietschauthor=R.+Buettnerauthor=D.+Pinkauthor=P.+Reichardtauthor=P.+Hohenberger&title=Polyclonal+evolution+of+multiple+secondary+KIT+mutations+in+gastrointestinal+stromal+tumors+under+treatment+with+imatinib+mesylate&doi=10.1158%2F1078-0432.CCR-05-1211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate</span></div><div class="casAuthors">Wardelmann, Eva; Merkelbach-Bruse, Sabine; Pauls, Katharina; Thomas, Nadja; Schildhaus, Hans-Ulrich; Heinicke, Thomas; Speidel, Nicola; Pietsch, Torsten; Buettner, Reinhard; Pink, Daniel; Reichardt, Peter; Hohenberger, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1743-1749</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GIST) are characterized by a strong KIT receptor activation most often resulting from KIT mutations.  In a smaller subgroup of tumors without KIT mutations, analogous activating mutations are found in the platelet-derived growth factor receptor α (PDGFRα) gene.  Both PDGFRα and KIT receptors are targets of the tyrosine kinase inhibitor imatinib (Glivec) which has improved the treatment of advanced GISTs significantly.  However, a subgroup of tumors show a secondary progress under therapy with imatinib after initial response.  One possible mechanism of secondary resistance is the development of newly acquired KIT mutations.  In the present study, we evaluated the frequency of such secondary KIT mutations in a series of GIST patients in which tumor tissue was resected under treatment.  We examd. one to seven different tumor areas in 32 cases (total of 104 samples) and found up to four newly acquired KIT mutations in 14 patients (43.8%).  These were always located in exons encoding the first or second tyrosine kinase domain (exon 13, 14, or 17).  Mutations were found only in a subset of samples analyzed from each case whereas others retained the wild-type sequence in the same region.  There was never more than one new mutation in the same sample.  Consistent with a secondary clonal evolution, the primary mutation was always detectable in all samples from each tumor.  According to our results, the identification of newly acquired KIT mutations in addn. to the primary mutation is dependent on the no. of tissue samples analyzed and has high implications for further therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhLaWTAFjP7Vg90H21EOLACvtfcHk0lgd6WXfuOe82Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1Cjs7Y%253D&md5=e39c95f452672224e49e8c5515b139c1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1211%26sid%3Dliteratum%253Aachs%26aulast%3DWardelmann%26aufirst%3DE.%26aulast%3DMerkelbach-Bruse%26aufirst%3DS.%26aulast%3DPauls%26aufirst%3DK.%26aulast%3DThomas%26aufirst%3DN.%26aulast%3DSchildhaus%26aufirst%3DH.%2BU.%26aulast%3DHeinicke%26aufirst%3DT.%26aulast%3DSpeidel%26aufirst%3DN.%26aulast%3DPietsch%26aufirst%3DT.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DPink%26aufirst%3DD.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DHohenberger%26aufirst%3DP.%26atitle%3DPolyclonal%2520evolution%2520of%2520multiple%2520secondary%2520KIT%2520mutations%2520in%2520gastrointestinal%2520stromal%2520tumors%2520under%2520treatment%2520with%2520imatinib%2520mesylate%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D1743%26epage%3D1749%26doi%3D10.1158%2F1078-0432.CCR-05-1211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenstein, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span><span class="refDoi"> DOI: 10.1016/j.ccr.2005.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1016%2Fj.ccr.2005.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=15710326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=129-141&author=E.+Weisbergauthor=P.+W.+Manleyauthor=W.+Breitensteinauthor=J.+Bruggenauthor=S.+W.+Cowan-Jacobauthor=A.+Rayauthor=B.+Huntlyauthor=D.+Fabbroauthor=G.+Fendrichauthor=E.+Hall-Meyersauthor=A.+L.+Kungauthor=J.+Mestanauthor=G.+Q.+Daleyauthor=L.+Callahanauthor=L.+Catleyauthor=C.+Cavazzaauthor=A.+Mohammedauthor=D.+Neubergauthor=R.+D.+Wrightauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Characterization+of+AMN107%2C+a+selective+inhibitor+of+native+and+mutant+Bcr-Abl&doi=10.1016%2Fj.ccr.2005.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Breitenstein, Werner; Brueggen, Josef; Cowan-Jacob, Sandra W.; Ray, Arghya; Huntly, Brian; Fabbro, Doriano; Fendrich, Gabriele; Hall-Meyers, Elizabeth; Kung, Andrew L.; Mestan, Juergen; Daley, George Q.; Callahan, Linda; Catley, Laurie; Cavazza, Cara; Mohammed, Azam; Neuberg, Donna; Wright, Renee D.; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL).  We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a no. of imatinib-resistant Bcr-Abl mutants.  Crystallog. anal. of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl.  Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.  AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow6QF3qX2uO7Vg90H21EOLACvtfcHk0lgd6WXfuOe82Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D&md5=d28e1a54b982951f8d3e6ef1d2d3b2eb</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBruggen%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DHuntly%26aufirst%3DB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DCallahan%26aufirst%3DL.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DCavazza%26aufirst%3DC.%26aulast%3DMohammed%26aufirst%3DA.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DCharacterization%2520of%2520AMN107%252C%2520a%2520selective%2520inhibitor%2520of%2520native%2520and%2520mutant%2520Bcr-Abl%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D129%26epage%3D141%26doi%3D10.1016%2Fj.ccr.2005.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Adenis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bui-Nguyen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouche, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertucci, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isambert, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bompas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaigneau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domont, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray-Coquard, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blesius, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Tine, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulusu, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubreuil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansfield, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moussy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermine, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Cesne, A.</span><span> </span><span class="NLM_article-title">Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1762</span><span class="NLM_x">–</span> <span class="NLM_lpage">1769</span><span class="refDoi"> DOI: 10.1093/annonc/mdu237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1093%2Fannonc%2Fmdu237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=25122671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FhsFagtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1762-1769&author=A.+Adenisauthor=J.+Y.+Blayauthor=B.+Bui-Nguyenauthor=O.+Boucheauthor=F.+Bertucciauthor=N.+Isambertauthor=E.+Bompasauthor=L.+Chaigneauauthor=J.+Domontauthor=I.+Ray-Coquardauthor=A.+Blesiusauthor=B.+A.+Van+Tineauthor=V.+R.+Bulusuauthor=P.+Dubreuilauthor=C.+D.+Mansfieldauthor=Y.+Acinauthor=A.+Moussyauthor=O.+Hermineauthor=A.+Le+Cesne&title=Masitinib+in+advanced+gastrointestinal+stromal+tumor+%28GIST%29+after+failure+of+imatinib%3A+a+randomized+controlled+open-label+trial&doi=10.1093%2Fannonc%2Fmdu237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial</span></div><div class="casAuthors">Adenis A; Blay J-Y; Ray-Coquard I; Bui-Nguyen B; Bouche O; Bertucci F; Isambert N; Bompas E; Chaigneau L; Domont J; Blesius A; Le Cesne A; Van Tine B A; Bulusu V R; Dubreuil P; Mansfield C D; Acin Y; Moussy A; Hermine O</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1762-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Masitinib is a highly selective tyrosine kinase inhibitor with activity against the main oncogenic drivers of gastrointestinal stromal tumor (GIST).  Masitinib was evaluated in patients with advanced GIST after imatinib failure or intolerance.  PATIENTS AND METHODS:  Prospective, multicenter, randomized, open-label trial.  Patients with inoperable, advanced imatinib-resistant GIST were randomized (1 : 1) to receive masitinib (12 mg/kg/day) or sunitinib (50 mg/day 4-weeks-on/2-weeks-off) until progression, intolerance, or refusal.  Primary efficacy analysis was noncomparative, testing whether masitinib attained a median progression-free survival (PFS) (blind centrally reviewed RECIST) threshold of >3 months according to the lower bound of the 90% unilateral confidence interval (CI).  Secondary analyses on overall survival (OS) and PFS were comparative with results presented according to a two-sided 95% CI.  RESULTS:  Forty-four patients were randomized to receive masitinib (n = 23) or sunitinib (n = 21).  Median follow-up was 14 months.  Patients receiving masitinib experienced less toxicity than those receiving sunitinib, with significantly lower occurrence of severe adverse events (52% versus 91%, respectively, P = 0.008).  Median PFS (central RECIST) for the noncomparative primary analysis in the masitinib treatment arm was 3.71 months (90% CI 3.65).  Secondary analyses showed that median OS was significantly longer for patients receiving masitinib followed by post-progression addition of sunitinib when compared against patients treated directly with sunitinib in second-line [hazard ratio (HR) = 0.27, 95% CI 0.09-0.85, P = 0.016].  This improvement was sustainable as evidenced by 26-month follow-up OS data (HR = 0.40, 95% CI 0.16-0.96, P = 0.033); an additional 12.4 months survival advantage being reported for the masitinib treatment arm.  Risk of progression while under treatment with masitinib was in the same range as for sunitinib (HR = 1.1, 95% CI 0.6-2.2, P = 0.833).  CONCLUSIONS:  Primary efficacy analysis ensured the masitinib treatment arm could satisfy a prespecified PFS threshold.  Secondary efficacy analysis showed that masitinib followed by the standard of care generated a statistically significant survival benefit over standard of care.  Encouraging median OS and safety data from this well-controlled and appropriately designed randomized trial indicate a positive benefit-risk ratio.  Further development of masitinib in imatinib-resistant/intolerant patients with advanced GIST is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxkpR-5bcD_eb6AVA-44PTfW6udTcc2ebtoGUvPJA6E7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FhsFagtA%253D%253D&md5=a2aae8942a25c3f43682342282f40402</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu237%26sid%3Dliteratum%253Aachs%26aulast%3DAdenis%26aufirst%3DA.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DBui-Nguyen%26aufirst%3DB.%26aulast%3DBouche%26aufirst%3DO.%26aulast%3DBertucci%26aufirst%3DF.%26aulast%3DIsambert%26aufirst%3DN.%26aulast%3DBompas%26aufirst%3DE.%26aulast%3DChaigneau%26aufirst%3DL.%26aulast%3DDomont%26aufirst%3DJ.%26aulast%3DRay-Coquard%26aufirst%3DI.%26aulast%3DBlesius%26aufirst%3DA.%26aulast%3DVan%2BTine%26aufirst%3DB.%2BA.%26aulast%3DBulusu%26aufirst%3DV.%2BR.%26aulast%3DDubreuil%26aufirst%3DP.%26aulast%3DMansfield%26aufirst%3DC.%2BD.%26aulast%3DAcin%26aufirst%3DY.%26aulast%3DMoussy%26aufirst%3DA.%26aulast%3DHermine%26aufirst%3DO.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26atitle%3DMasitinib%2520in%2520advanced%2520gastrointestinal%2520stromal%2520tumor%2520%2528GIST%2529%2520after%2520failure%2520of%2520imatinib%253A%2520a%2520randomized%2520controlled%2520open-label%2520trial%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26spage%3D1762%26epage%3D1769%26doi%3D10.1093%2Fannonc%2Fmdu237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Guo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agaram, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hom, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Adamo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMatteo, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besmer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonescu, C. R.</span><span> </span><span class="NLM_article-title">Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">4874</span><span class="NLM_x">–</span> <span class="NLM_lpage">4881</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-0484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1158%2F1078-0432.CCR-07-0484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=17699867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGmtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=4874-4881&author=T.+Guoauthor=N.+P.+Agaramauthor=G.+C.+Wongauthor=G.+Homauthor=D.+D%E2%80%99Adamoauthor=R.+G.+Makiauthor=G.+K.+Schwartzauthor=D.+Veachauthor=B.+D.+Clarksonauthor=S.+Singerauthor=R.+P.+DeMatteoauthor=P.+Besmerauthor=C.+R.+Antonescu&title=Sorafenib+inhibits+the+imatinib-resistant+KITT670I+gatekeeper+mutation+in+gastrointestinal+stromal+tumor&doi=10.1158%2F1078-0432.CCR-07-0484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor</span></div><div class="casAuthors">Guo, Tianhua; Agaram, Narasimhan P.; Wong, Grace C.; Hom, Glory; D'Adamo, David; Maki, Robert G.; Schwartz, Gary K.; Veach, Darren; Clarkson, Bayard D.; Singer, Samuel; DeMatteo, Ronald P.; Besmer, Peter; Antonescu, Cristina R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4874-4881</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Resistance is commonly acquired in patients with metastatic gastrointestinal stromal tumor who are treated with imatinib mesylate, often due to the development of secondary mutations in the KIT kinase domain.  We sought to investigate the efficacy of second-line tyrosine kinase inhibitors, such as sorafenib, dasatinib, and nilotinib, against the commonly obsd. imatinib-resistant KIT mutations (KITV654A, KITT670I, KITD820Y, and KITN822K) expressed in the Ba/F3 cellular system.  EXPTL. DESIGN: In vitro drug screening of stable Ba/F3 KIT mutants recapitulating the genotype of imatinib-resistant patients harboring primary and secondary KIT mutations was investigated.  Comparison was made to imatinib-sensitive Ba/F3 KIT mutant cells as well as Ba/F3 cells expressing only secondary KIT mutations.  The efficacy of drug treatment was evaluated by proliferation and apoptosis assays, in addn. to biochem. inhibition of KIT activation.  RESULTS: Sorafenib was potent against all imatinib-resistant Ba/F3 KIT double mutants tested, including the gatekeeper secondary mutation KITWK557-8del/T670I, which was resistant to other kinase inhibitors.  Although all three drugs tested decreased cell proliferation and inhibited KIT activation against exon 13 (KITV560del/V654A) and exon 17 (KITV559D/D820Y) double mutants, nilotinib did so at lower concns.  CONCLUSIONS: Our results emphasize the need for tailored salvage therapy in imatinib-refractory gastrointestinal stromal tumors according to individual mol. mechanisms of resistance.  The Ba/F3 KITWK557-8del/T670I cells were sensitive only to sorafenib inhibition, whereas nilotinib was more potent on imatinib-resistant KITV560del/V654A and KITV559D/D820Y mutant cells than dasatinib and sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqllTJoDeevKbVg90H21EOLACvtfcHk0lg5xpafwEBktw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGmtLw%253D&md5=f1643671ada85f1bcd05faa04cd88b52</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0484%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DAgaram%26aufirst%3DN.%2BP.%26aulast%3DWong%26aufirst%3DG.%2BC.%26aulast%3DHom%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Adamo%26aufirst%3DD.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DVeach%26aufirst%3DD.%26aulast%3DClarkson%26aufirst%3DB.%2BD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26atitle%3DSorafenib%2520inhibits%2520the%2520imatinib-resistant%2520KITT670I%2520gatekeeper%2520mutation%2520in%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D4874%26epage%3D4881%26doi%3D10.1158%2F1078-0432.CCR-07-0484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1230</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span><span class="refDoi"> DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+type+II+binding+mode%3A+A+privileged+approach+for+kinase+inhibitor+focused+drug+discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0ljffEFDM9eUnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520type%2520II%2520binding%2520mode%253A%2520A%2520privileged%2520approach%2520for%2520kinase%2520inhibitor%2520focused%2520drug%2520discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1051</span><span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0lgacG30Uh5niA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Grunewald, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mühlenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuler, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span> </span><span class="NLM_article-title">Effect of secondary KIT mutations on growth of GIST cells in the absence of selective pressure by imatinib in isogenic models of imatinib resistance</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">No. 15, May 20 Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">10555</span><div class="note"><p class="first last">(ASCO Annual Meeting Abstracts)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=10555&issue=No.+15%2C+May+20+Suppl.&author=S.+Grunewaldauthor=T.+M%C3%BChlenbergauthor=B.+Rubinauthor=M.+H.+Schulerauthor=J.+A.+Fletcherauthor=S.+Bauer&title=Effect+of+secondary+KIT+mutations+on+growth+of+GIST+cells+in+the+absence+of+selective+pressure+by+imatinib+in+isogenic+models+of+imatinib+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrunewald%26aufirst%3DS.%26aulast%3DM%25C3%25BChlenberg%26aufirst%3DT.%26aulast%3DRubin%26aufirst%3DB.%26aulast%3DSchuler%26aufirst%3DM.%2BH.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DBauer%26aufirst%3DS.%26atitle%3DEffect%2520of%2520secondary%2520KIT%2520mutations%2520on%2520growth%2520of%2520GIST%2520cells%2520in%2520the%2520absence%2520of%2520selective%2520pressure%2520by%2520imatinib%2520in%2520isogenic%2520models%2520of%2520imatinib%2520resistance%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3DNo.%252015%252C%2520May%252020%2520Suppl%26spage%3D10555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Duensing, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medeiros, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McConarty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panigrahy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3999</span><span class="NLM_x">–</span> <span class="NLM_lpage">4006</span><span class="refDoi"> DOI: 10.1038/sj.onc.1207525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1038%2Fsj.onc.1207525" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=3999-4006&author=A.+Duensingauthor=F.+Medeirosauthor=B.+McConartyauthor=N.+E.+Josephauthor=D.+Panigrahyauthor=S.+Singerauthor=C.+D.+Fletcherauthor=G.+D.+Demetriauthor=J.+A.+Fletcher&title=Mechanisms+of+oncogenic+KIT+signal+transduction+in+primary+gastrointestinal+stromal+tumors+%28GISTs%29&doi=10.1038%2Fsj.onc.1207525"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207525%26sid%3Dliteratum%253Aachs%26aulast%3DDuensing%26aufirst%3DA.%26aulast%3DMedeiros%26aufirst%3DF.%26aulast%3DMcConarty%26aufirst%3DB.%26aulast%3DJoseph%26aufirst%3DN.%2BE.%26aulast%3DPanigrahy%26aufirst%3DD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DMechanisms%2520of%2520oncogenic%2520KIT%2520signal%2520transduction%2520in%2520primary%2520gastrointestinal%2520stromal%2520tumors%2520%2528GISTs%2529%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D3999%26epage%3D4006%26doi%3D10.1038%2Fsj.onc.1207525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Pollard, J. W.</span><span> </span><span class="NLM_article-title">Trophic macrophages in development and disease</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1038/nri2528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1038%2Fnri2528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=19282852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFCisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=259-270&author=J.+W.+Pollard&title=Trophic+macrophages+in+development+and+disease&doi=10.1038%2Fnri2528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Trophic macrophages in development and disease</span></div><div class="casAuthors">Pollard, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">259-270</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Specialized phagocytes are found in the most primitive multicellular organisms.  Their roles in homeostasis and in distinguishing self from non-self have evolved with the complexity of organisms and their immune systems.  Equally important, but often overlooked, are the roles of macrophages in tissue development.  As discussed in this Review, these include functions in branching morphogenesis, neuronal patterning, angiogenesis, bone morphogenesis and the generation of adipose tissue.  In each case, macrophage depletion impairs the formation of the tissue and compromises its function.  I argue that in several diseases, the unrestrained acquisition of these developmental macrophage functions exacerbates pathol.  For example, macrophages enhance tumor progression and metastasis by affecting tumor-cell migration and invasion, as well as angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR03M07hzbU7Vg90H21EOLACvtfcHk0lj1GyqKNc1v4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFCisbc%253D&md5=d29685d4cbb8d8bdd296f8b8ff869d36</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnri2528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2528%26sid%3Dliteratum%253Aachs%26aulast%3DPollard%26aufirst%3DJ.%2BW.%26atitle%3DTrophic%2520macrophages%2520in%2520development%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D9%26spage%3D259%26epage%3D270%26doi%3D10.1038%2Fnri2528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Case, D. A.; Babin, V.; Berryman, J. T.; Betz, R. M.; Cai, Q.; Cerutti, D. S.; Cheatham, T. A.,  III; Darden, T. A.; Duke, R. E.; Gohlke, H.; Gietz, A. W.; Gusarov, S.; Homeyer, N.; Jonowski, P.; Kaus, J.; Kolossváry, I.; Kovalenko, A.; Lee, T. S.; LeGrand, S.; Luchko, T.; Luo, R.; Madei, B.; Merz, K. M.; Paesani, F.; Roe, D. R.; Roitberg, A.; Sagui, C.; Salomon-Ferrer, R.; Seabra, G.; Simmerling, C. L.; Smith, W.; Swails, J.; Walker, R. C.; Wang, J.; Wolf, R. M.; Wu, X.; Kollman, P. A.</span>AMBER14; <span class="NLM_publisher-name">University of California</span>: <span class="NLM_publisher-loc">San Francisco, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=D.+A.+Case&author=V.+Babin&author=J.+T.+Berryman&author=R.+M.+Betz&author=Q.+Cai&author=D.+S.+Cerutti&author=T.+A.+Cheatham&author=T.+A.+Darden&author=R.+E.+Duke&author=H.+Gohlke&author=A.+W.+Gietz&author=S.+Gusarov&author=N.+Homeyer&author=P.+Jonowski&author=J.+Kaus&author=I.+Kolossv%C3%A1ry&author=A.+Kovalenko&author=T.+S.+Lee&author=S.+LeGrand&author=T.+Luchko&author=R.+Luo&author=B.+Madei&author=K.+M.+Merz&author=F.+Paesani&author=D.+R.+Roe&author=A.+Roitberg&author=C.+Sagui&author=R.+Salomon-Ferrer&author=G.+Seabra&author=C.+L.+Simmerling&author=W.+Smith&author=J.+Swails&author=R.+C.+Walker&author=J.+Wang&author=R.+M.+Wolf&author=X.+Wu&author=P.+A.+Kollman&title=AMBER14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DCase%26aufirst%3DD.%2BA.%26jtitle%3DAMBER14%26pub%3DUniversity%2520of%2520California%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Word, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovell, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. C.</span><span> </span><span class="NLM_article-title">Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">1735</span><span class="NLM_x">–</span> <span class="NLM_lpage">1747</span><span class="refDoi"> DOI: 10.1006/jmbi.1998.2401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1006%2Fjmbi.1998.2401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=9917408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADyaK1MXhtV2ht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1999&pages=1735-1747&author=J.+M.+Wordauthor=S.+C.+Lovellauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=Asparagine+and+glutamine%3A+using+hydrogen+atom+contacts+in+the+choice+of+side-chain+amide+orientation&doi=10.1006%2Fjmbi.1998.2401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Asparagine and Glutamine: Using Hydrogen Atom Contacts in the Choice of Side-chain Amide Orientation</span></div><div class="casAuthors">Word, J. Michael; Lovell, Simon C.; Richardson, Jane S.; Richardson, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1735-1747</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Small-probe contact dot surface anal., with all explicit hydrogen atoms added and their van der Waals contacts included, was used to choose between the two possible orientations for each of 1554 asparagine (Asn) and glutamine (Gln) side-chain amide groups in a dataset of 100 unrelated, high-quality protein crystal structures at 0.9 to 1.7 Å resoln.  For the movable-H groups, each connected, closed set of local H-bonds was optimized for both H-bonds and van der Waals overlaps.  In addn. to the Asn/Gln "flips", this process included rotation of OH, SH, NH3+, and methionine Me H atoms, flip and protonation state of histidine rings, interaction with bound ligands, and a simple model of water interactions.  However, except for switching N and O identity for amide flips (or N and C identity for His flips), no non-H atoms were shifted.  Even in these very high-quality structures, about 20 % of the Asn/Gln side-chains required a 180° flip to optimize H-bonding and/or to avoid NH2 clashes with neighboring atoms (incorporating a conservative score penalty which, for marginal cases, favors the assignment in the original coordinate file).  The programs Reduce, Probe, and Mage provide not only a suggested amide orientation, but also a numerical score comparison, a categorization of the marginal cases, and a direct visualization of all relevant interactions in both orientations.  Visual examn. allowed confirmation of the raw score assignment for about 40 % of those Asn/Gln flips placed within the "marginal" penalty range by the automated algorithm, while uncovering only a small no. of cases whose automated assignment was incorrect because of special circumstances not yet handled by the algorithm.  It seems that the H-bond and the at.-clash criteria independently look at the same structural realities: when both criteria gave a clear answer, they agreed every time.  But consideration of van der Waals clashes settled many addnl. cases for which H-bonding was either absent or approx. equiv. for the two main alternatives.  With this extra information, 86 % of all side-chain amide groups could be oriented quite unambiguously.  In the absence of further exptl. data, it would probably be inappropriate to assign many more than this.  Some of the remaining 14 % are ambiguous because of coordinate error or inadequacy of the theor. model, but the great majority of ambiguous cases probably occur as a dynamic mix of both flip states in the actual protein mol.  The software and the 100 coordinate files with all H atoms added and optimized and with amide flips cor. are publicly available.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC6MEkiSKy07Vg90H21EOLACvtfcHk0lj1GyqKNc1v4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhtV2ht7g%253D&md5=a3bd044a8652a5ac03e2eb7b9414c2e0</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1998.2401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1998.2401%26sid%3Dliteratum%253Aachs%26aulast%3DWord%26aufirst%3DJ.%2BM.%26aulast%3DLovell%26aufirst%3DS.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DAsparagine%2520and%2520glutamine%253A%2520using%2520hydrogen%2520atom%2520contacts%2520in%2520the%2520choice%2520of%2520side-chain%2520amide%2520orientation%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1999%26volume%3D285%26spage%3D1735%26epage%3D1747%26doi%3D10.1006%2Fjmbi.1998.2401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Rossato, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smieško, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spreafico, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vedani, A.</span><span> </span><span class="NLM_article-title">Probing small-molecule binding to cytochrome P450 2D6 and 2C9: An in silico protocol for generating toxicity alerts</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">2088</span><span class="NLM_x">–</span> <span class="NLM_lpage">2101</span><span class="refDoi"> DOI: 10.1002/cmdc.201000358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1002%2Fcmdc.201000358" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=2088-2101&author=G.+Rossatoauthor=B.+Ernstauthor=M.+Smie%C5%A1koauthor=M.+Spreaficoauthor=A.+Vedani&title=Probing+small-molecule+binding+to+cytochrome+P450+2D6+and+2C9%3A+An+in+silico+protocol+for+generating+toxicity+alerts&doi=10.1002%2Fcmdc.201000358"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000358%26sid%3Dliteratum%253Aachs%26aulast%3DRossato%26aufirst%3DG.%26aulast%3DErnst%26aufirst%3DB.%26aulast%3DSmie%25C5%25A1ko%26aufirst%3DM.%26aulast%3DSpreafico%26aufirst%3DM.%26aulast%3DVedani%26aufirst%3DA.%26atitle%3DProbing%2520small-molecule%2520binding%2520to%2520cytochrome%2520P450%25202D6%2520and%25202C9%253A%2520An%2520in%2520silico%2520protocol%2520for%2520generating%2520toxicity%2520alerts%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D2088%26epage%3D2101%26doi%3D10.1002%2Fcmdc.201000358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Dobler, M.</span>BioX, a Versatile Molecular-Modeling Software; B<span class="NLM_publisher-name">iographics Laboratory 3R</span>: <span class="NLM_publisher-loc">Basel, Switzerland</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.biograf.ch/index.php?id=software" class="extLink">http://www.biograf.ch/index.php?id=software</a> (Updated Nov 8, 2014).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Dobler&title=BioX%2C+a+Versatile+Molecular-Modeling+Software"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DDobler%26aufirst%3DM.%26jtitle%3DBioX%252C%2520a%2520Versatile%2520Molecular-Modeling%2520Software%26pub%3Diographics%2520Laboratory%25203R%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yun Wu, Beilei Wang, Junjie Wang, Shuang Qi, Fengming Zou, Ziping Qi, Feiyang Liu, Qingwang Liu, Cheng Chen, Chen Hu, Zhenquan Hu, Aoli Wang, Li Wang, Wenchao Wang, Tao Ren, Yujiao Cai, Mingfeng Bai, Qingsong Liu, <span class="NLM_string-name hlFld-ContribAuthor">Jing Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (13)
                                     , 6083-6101. <a href="https://doi.org/10.1021/acs.jmedchem.9b00280" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00280</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00280%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-%2525284-Chloro-3-%252528trifluoromethyl%252529phenyl%252529-N-%2525284-%252528%2525286%25252C7-dimethoxyquinolin-4-yl%252529oxy%252529phenyl%252529acetamide%252B%252528CHMFL-KIT-64%252529%252Bas%252Ba%252BNovel%252BOrally%252BAvailable%252BPotent%252BInhibitor%252Bagainst%252BBroad-Spectrum%252BMutants%252Bof%252Bc-KIT%252BKinase%252Bfor%252BGastrointestinal%252BStromal%252BTumors%26aulast%3DWu%26aufirst%3DYun%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D12022019%26date%3D28062019%26date%3D17062019%26volume%3D62%26issue%3D13%26spage%3D6083%26epage%3D6101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tingting  Lu</span>, <span class="hlFld-ContribAuthor ">Jiangyan  Cao</span>, <span class="hlFld-ContribAuthor ">Fengming  Zou</span>, <span class="hlFld-ContribAuthor ">Xixiang  Li</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Wenliang  Wang</span>, <span class="hlFld-ContribAuthor ">Huamin  Liang</span>, <span class="hlFld-ContribAuthor ">Qingwang  Liu</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Lili  Li</span>, <span class="hlFld-ContribAuthor ">Jian  Ge</span>, <span class="hlFld-ContribAuthor ">Yang  Shen</span>, <span class="hlFld-ContribAuthor ">Tao  Ren</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Ruixiang  Xia</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2021,</strong> <em>897 </em>, 173944. <a href="https://doi.org/10.1016/j.ejphar.2021.173944" title="DOI URL">https://doi.org/10.1016/j.ejphar.2021.173944</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2021.173944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2021.173944%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DDiscovery%252Bof%252Ba%252Bhighly%252Bpotent%252Bkinase%252Binhibitor%252Bcapable%252Bof%252Bovercoming%252Bmultiple%252Bimatinib-resistant%252BABL%252Bmutants%252Bfor%252Bchronic%252Bmyeloid%252Bleukemia%252B%252528CML%252529%26aulast%3DLu%26aufirst%3DTingting%26date%3D2021%26volume%3D897%26spage%3D173944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Wentao  Zhang</span>, <span class="hlFld-ContribAuthor ">Xuesong  Liu</span>, <span class="hlFld-ContribAuthor ">Fengming  Zou</span>, <span class="hlFld-ContribAuthor ">Junjie  Wang</span>, <span class="hlFld-ContribAuthor ">Qingwang  Liu</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Yongfei  Chen</span>, <span class="hlFld-ContribAuthor ">Shuang  Qi</span>, <span class="hlFld-ContribAuthor ">Zongru  Jiang</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112744. <a href="https://doi.org/10.1016/j.ejmech.2020.112744" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112744</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112744%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528E%252529-N-%2525284-methyl-5-%2525283-%2525282-%252528pyridin-2-yl%252529vinyl%252529-1H-indazol-6-yl%252529thiazol-2-yl%252529-2-%2525284-methylpiperazin-1-yl%252529acetamide%252B%252528IHMT-TRK-284%252529%252Bas%252Ba%252Bnovel%252Borally%252Bavailable%252Btype%252BII%252BTRK%252Bkinase%252Binhibitor%252Bcapable%252Bof%252Bovercoming%252Bmultiple%252Bresistant%252Bmutants%26aulast%3DWang%26aufirst%3DBeilei%26date%3D2020%26volume%3D207%26spage%3D112744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tingting  Lu</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Zongru  Jiang</span>, <span class="hlFld-ContribAuthor ">Ziping  Qi</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Feiyang  Liu</span>, <span class="hlFld-ContribAuthor ">Wenliang  Wang</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Shuang  Qi</span>, <span class="hlFld-ContribAuthor ">Jiaxin  Wu</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Jun  Tang</span>, <span class="hlFld-ContribAuthor ">Hezhong  Yan</span>, <span class="hlFld-ContribAuthor ">Mingfeng  Bai</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2019,</strong> <em>447 </em>, 105-114. <a href="https://doi.org/10.1016/j.canlet.2019.01.024" title="DOI URL">https://doi.org/10.1016/j.canlet.2019.01.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2019.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2019.01.024%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DRepurposing%252Bcabozantinib%252Bto%252BGISTs%25253A%252BOvercoming%252Bmultiple%252Bimatinib-resistant%252BcKIT%252Bmutations%252Bincluding%252Bgatekeeper%252Band%252Bactivation%252Bloop%252Bmutants%252Bin%252BGISTs%252Bpreclinical%252Bmodels%26aulast%3DLu%26aufirst%3DTingting%26date%3D2019%26volume%3D447%26spage%3D105%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei  Peng</span>, <span class="hlFld-ContribAuthor ">Jin  Liu</span>, <span class="hlFld-ContribAuthor ">Lili  Li</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-Catalyzed Tandem Reaction of Enamino Esters with
              ortho
              -Halogenated Aromatic Carbonyls: One-Pot Approach to Functionalized Quinolines. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>2018 </em>
                                    (5)
                                     , 666-672. <a href="https://doi.org/10.1002/ejoc.201701472" title="DOI URL">https://doi.org/10.1002/ejoc.201701472</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201701472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201701472%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DCopper-Catalyzed%252BTandem%252BReaction%252Bof%252BEnamino%252BEsters%252Bwith%252Bortho%252B-Halogenated%252BAromatic%252BCarbonyls%25253A%252BOne-Pot%252BApproach%252Bto%252BFunctionalized%252BQuinolines%26aulast%3DPeng%26aufirst%3DFei%26date%3D2018%26date%3D2018%26volume%3D2018%26issue%3D5%26spage%3D666%26epage%3D672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin  Prause</span>, <span class="hlFld-ContribAuthor ">Sabrina  Niedermoser</span>, <span class="hlFld-ContribAuthor ">Carmen  Wängler</span>, <span class="hlFld-ContribAuthor ">Clemens  Decristoforo</span>, <span class="hlFld-ContribAuthor ">Uwe  Seibold</span>, <span class="hlFld-ContribAuthor ">Stephanie  Riester</span>, <span class="hlFld-ContribAuthor ">Takahiro  Taguchi</span>, <span class="hlFld-ContribAuthor ">Ralf  Schirrmacher</span>, <span class="hlFld-ContribAuthor ">Gert  Fricker</span>, <span class="hlFld-ContribAuthor ">Björn  Wängler</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, in vitro and in vivo evaluation of 18 F-fluoronorimatinib as radiotracer for Imatinib-sensitive gastrointestinal stromal tumors. </span><span class="cited-content_cbyCitation_journal-name">Nuclear Medicine and Biology</span><span> <strong>2018,</strong> <em>57 </em>, 1-11. <a href="https://doi.org/10.1016/j.nucmedbio.2017.11.004" title="DOI URL">https://doi.org/10.1016/j.nucmedbio.2017.11.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nucmedbio.2017.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nucmedbio.2017.11.004%26sid%3Dliteratum%253Aachs%26jtitle%3DNuclear%2520Medicine%2520and%2520Biology%26atitle%3DSynthesis%25252C%252Bin%252Bvitro%252Band%252Bin%252Bvivo%252Bevaluation%252Bof%252B18%252BF-fluoronorimatinib%252Bas%252Bradiotracer%252Bfor%252BImatinib-sensitive%252Bgastrointestinal%252Bstromal%252Btumors%26aulast%3DPrause%26aufirst%3DMartin%26date%3D2018%26volume%3D57%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qian  Yan</span>, <span class="hlFld-ContribAuthor ">Ruxia  Li</span>, <span class="hlFld-ContribAuthor ">Aiyi  Xin</span>, <span class="hlFld-ContribAuthor ">Yin  Han</span>, <span class="hlFld-ContribAuthor ">Yanxia  Zhang</span>, <span class="hlFld-ContribAuthor ">Junxi  Liu</span>, <span class="hlFld-ContribAuthor ">Wenguang  Li</span>, <span class="hlFld-ContribAuthor ">Duolong  Di</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and anticancer properties of isocorydine derivatives. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (24)
                                     , 6542-6553. <a href="https://doi.org/10.1016/j.bmc.2017.10.027" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.10.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.10.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.10.027%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Banticancer%252Bproperties%252Bof%252Bisocorydine%252Bderivatives%26aulast%3DYan%26aufirst%3DQian%26date%3D2017%26volume%3D25%26issue%3D24%26spage%3D6542%26epage%3D6553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of the representative cKIT kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic illustration of discovery of compound <b>35</b> (CHMFL-KIT-8140).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Schematic illustration of SAR exploration rationale. (A) Binding mode of compound <b>1</b> with cKIT wt (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>). (B) Binding mode of compound <b>1</b> with cKIT T670I homology model (generated based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>). (C) Binding mode of compound <b>6</b> with cKIT wt (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>, docking model). (D) Binding mode of compound <b>6</b> with cKIT T670I homology model (generated based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>, docking model). (E) Illustration of the hydrophobic interaction between the CF3 group of compound <b>6</b> and Leu647, Ile653, Leu783 and Ile808. (F) Illustration of the chemical modification strategy of compound <b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Molecular modeling analysis of the binding modes of cKIT wt/T670I with compound <b>35</b>: (A) binding mode of compound <b>35</b> with cKIT wt (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>); (B) binding mode of compound <b>35</b> with cKIT T670I homology model (generated based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. ADP-Glo biochemical characterization of compound <b>35</b> against cKIT wt/T670I kinases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Kinome wide selectivity profiling of compound <b>35</b>. (A) KinomeScan profiling of compound <b>35</b> at a concentration of 1 μM against 468 kinases and mutants. (B) Kinases that maintained activity of less than 1% of control in the presence of 1 μM <b>35</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of compounds <b>1</b>, <b>2</b>, and <b>35</b> on cKIT mediated signaling pathways in GIST-T1 and GIST-5R cancer cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Effect of compounds <b>1</b>, <b>2</b>, and <b>35</b> on induction of apoptosis in GIST-T1 and GIST-5R cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0010.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>35</b>’s antitumor efficacy in BaF3-TEL-cKIT-T670I xenograft model. Female nu/nu mice bearing established BaF3-TEL-cKIT-T670I tumor xenografts were treated with compound <b>35</b> at 25, 50, 100 mg kg<sup>–1</sup> d<sup>–1</sup> or vehicle. Daily ip administration was initiated when BaF3-TEL-cKIT-T670I tumors had reached a size of 200–400 mm<sup>3</sup>. Each group contained seven animals. Data of mean ± SEM (A) body weight and (B) tumor size measurements from BaF3-TEL-cKIT-T670I xenograft mice after compound <b>35</b> administration. Initial body weight and tumor size were set as 100%. (C) Representative photographs of tumors in each group after 25, 50, 100 (mg/kg)/d compound <b>35</b> or vehicle treatment. (D) Comparison of the final tumor weight in each group after 10-day treatment period of <b>35</b>. Numbers in columns indicate the mean tumor weight in each group. (ns) <i>p</i> > 0.05, (∗) <i>p</i> < 0.05, (∗∗) <i>p</i> < 0.01. (E) Representative micrographs of hematoxylin and eosin (HE), Ki-67, and TUNEL staining of tumor tissues of <b>35</b> treatment groups in comparison with the vehicle group. Note the specific nuclear staining of cells with morphology consistent with proliferation and apoptosis (E, red arrow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0011.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>7</b>, <b>9</b>, <b>11</b>–<b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i><sup>t</sup></i>BuOK, K<sub>2</sub>CO<sub>3</sub>, DMSO, 100 °C, 12 h; (b) K<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 8 h; (c) H<sub>2</sub>, 10% Pd/C, MeOH, rt, 3 h; (d) triphosgene, Et<sub>3</sub>N, DMAP, DCM, 0 °C to rt, 1 h; (e) 4 M HCl in ethyl acetate, rt, 1 h. (f) For <b>7</b>, <b>9</b>, <b>11</b>–<b>13</b>, and <b>31</b>–<b>35</b>: acyl chloride, Et<sub>3</sub>N, DMF, −50 °C, 5 min. For <b>16</b>–<b>24</b>, <b>26</b>–<b>30</b>, and <b>36</b>: carboxylic acid, HATU, Et<sub>3</sub>N, DMF, rt, overnight. For <b>14</b>, <b>15</b>, and <b>25</b>: (i) carboxylic acid, HATU, Et<sub>3</sub>N, DMF, rt, overnight; (ii) 4 M HCl in ethyl acetate, rt, 1 h.</p></p></figure><figure data-id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0012.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 8 h; (b) 4 M HCl in ethyl acetate, rt, 1 h; (c) <b>37</b>, triphodgene, Et<sub>3</sub>N, DMAP, DCM, 0 °C to rt, 1 h; (d) H<sub>2</sub>, 10% Pd/C, MeOH, rt, 8 h; (e) propionyl chloride, Et<sub>3</sub>N, DMF, −50 °C, 5 min.</p></p></figure><figure data-id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/medium/jm-2016-00902s_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0013.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compound <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00902/20160916/images/large/jm-2016-00902s_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00902&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HATU, DIPEA, DMF, rt, overnight; (b) 1.0 M NaOH, MeOH, reflux, 2 h; (c) <b>40d</b>, HATU, DIPEA, DMF, rt, overnight; (d) 4 M HCl in ethyl acetate, rt, 1 h; (e) propionyl chloride, Et<sub>3</sub>N, DMF, −50 °C, 5 min.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i86">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63885" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63885" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 25 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Miettinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasota, J.</span><span> </span><span class="NLM_article-title">Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis</span> <span class="citation_source-journal">Virchows Arch.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">438</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.1007/s004280000338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1007%2Fs004280000338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=11213830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1Kquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2001&pages=1-12&author=M.+Miettinenauthor=J.+Lasota&title=Gastrointestinal+stromal+tumors%2D%2Ddefinition%2C+clinical%2C+histological%2C+immunohistochemical%2C+and+molecular+genetic+features+and+differential+diagnosis&doi=10.1007%2Fs004280000338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis</span></div><div class="casAuthors">Miettinen, Markku; Lasota, Jerzy</div><div class="citationInfo"><span class="NLM_cas:title">Virchows Archiv</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">438</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">VARCEM</span>;
        ISSN:<span class="NLM_cas:issn">0945-6317</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review with 81 refs.  Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal (GI) tract.  They are defined here as KIT (CD117, stem cell factor receptor)-pos. mesenchymal spindle cell or epithelioid neoplasms primary in the GI tract, omentum, and mesentery.  GISTs typically present in older individuals and are most common in the stomach (60-70%), followed by small intestine (20-25%), colon and rectum (5%), and esophagus (<5%).  Benign tumors outnumber the malignant ones by a wide margin.  Approx. 70% of GISTs are pos. for CD34, 20-30% are pos. for smooth muscle actin (SMA), 10% are pos. for S100 protein and <5% are pos. for desmin.  The expression of CD34 and SMA is often reciprocal.  GISTs commonly have activating mutations in exon 11 (or rarely exon 9 and exon 13) of the KIT gene that encodes a tyrosine kinase receptor for the growth factor named stem cell factor or mast cell growth factor.  Ligand-independent activation of KIT appears to be a strong candidate for mol. pathogenesis of GISTs, and it may be a target for future treatment for such tumors.  Other genetic changes in GISTs discovered using comparative genomic hybridization include losses in 14q and 22q in both benign and malignant GISTs and occurrence in various gains predominantly in malignant GISTs.  GISTs have phenotypic similarities with the interstitial cells of Cajal and, therefore, a histogenetic origin from these cells has been suggested.  An alternative possibility, origin of pluripotential stem cells, is also possible; this is supported by the same origin of Cajal cells and smooth muscle and by the common SMA expression in GISTs.  GISTs differ clin. and pathogenetically from true leiomyosarcomas (very rare in the GI tract) and leiomyomas.  The latter occur in the GI tract, predominantly in the esophagus (intramural tumors) and the colon and rectum (muscularis mucosae tumors).  They also differ from schwannomas that are benign S100-pos. spindle cell tumors usually presenting in the stomach.  GI autonomic nerve tumors (GANTs) are probably a subset of GIST.  Other mesenchymal tumors that have to be sepd. from GISTs include inflammatory myofibroblastic tumors in children, desmoid, and dedifferentiated liposarcoma.  Angiosarcomas and metastatic melanomas, both of which are often KIT-pos., should not be confused with GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeixqNq3cd-7Vg90H21EOLACvtfcHk0lgmKB_0U6jkxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1Kquw%253D%253D&md5=d2600b6aa118b36339ace603c1c9b87f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2Fs004280000338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs004280000338%26sid%3Dliteratum%253Aachs%26aulast%3DMiettinen%26aufirst%3DM.%26aulast%3DLasota%26aufirst%3DJ.%26atitle%3DGastrointestinal%2520stromal%2520tumors--definition%252C%2520clinical%252C%2520histological%252C%2520immunohistochemical%252C%2520and%2520molecular%2520genetic%2520features%2520and%2520differential%2520diagnosis%26jtitle%3DVirchows%2520Arch.%26date%3D2001%26volume%3D438%26spage%3D1%26epage%3D12%26doi%3D10.1007%2Fs004280000338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Lennartsson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronnstrand, L.</span><span> </span><span class="NLM_article-title">Stem cell factor receptor/c-Kit: from basic science to clinical implications</span> <span class="citation_source-journal">Physiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">1619</span><span class="NLM_x">–</span> <span class="NLM_lpage">1649</span><span class="refDoi"> DOI: 10.1152/physrev.00046.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1152%2Fphysrev.00046.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=23073628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhsl2lsbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=1619-1649&author=J.+Lennartssonauthor=L.+Ronnstrand&title=Stem+cell+factor+receptor%2Fc-Kit%3A+from+basic+science+to+clinical+implications&doi=10.1152%2Fphysrev.00046.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Stel cell factor receptor/c-Kit: from basic science to clinical implications</span></div><div class="casAuthors">Lennartsson, Johan; Roennstrand, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1619-1649</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  Stem cell factor (SCF) is a dimeric mol. that exerts its biol. functions by binding to and activating the receptor tyrosine kinase c-Kit.  Activation of c-Kit leads to its autophosphorylation and initiation of signal transduction.  Signaling proteins are recruited to activated c-Kit by certain interaction domains (e.g., SH2 and PTB) that specifically bind to phosphorylated tyrosine residues in the intracellular region of c-Kit.  Activation of c-Kit signaling has been found to mediate cell survival, migration, and proliferation depending on the cell type.  Signaling from c-Kit is crucial for normal hematopoiesis, pigmentation, fertility, gut movement, and some aspects of the nervous system.  Deregulated c-Kit kinase activity has been found in a no. of pathol. conditions, including cancer and allergy.  The observation that gain-of-function mutations in c-Kit can promote tumor formation and progression has stimulated the development of therapeutics agents targeting this receptor, e.g., the clin. used inhibitor imatinib mesylate.  Also other clin. used multiselective kinase inhibitors, for instance, sorafenib and sunitinib, have c-Kit included in their range of targets.  Furthermore, loss-of-function mutations in c-Kit have been obsd. and shown to give rise to a condition called piebaldism.  This review provides a summary of our current knowledge regarding structural and functional aspects of c-Kit signaling both under normal and pathol. conditions, as well as advances in the development of low-mol.-wt. mols. inhibiting c-Kit function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiAi_V1Wivd7Vg90H21EOLACvtfcHk0lgNxdyj-nrnDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhsl2lsbnK&md5=b874bfb881938c505b6718732950be51</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00046.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00046.2011%26sid%3Dliteratum%253Aachs%26aulast%3DLennartsson%26aufirst%3DJ.%26aulast%3DRonnstrand%26aufirst%3DL.%26atitle%3DStem%2520cell%2520factor%2520receptor%252Fc-Kit%253A%2520from%2520basic%2520science%2520to%2520clinical%2520implications%26jtitle%3DPhysiol.%2520Rev.%26date%3D2012%26volume%3D92%26spage%3D1619%26epage%3D1649%26doi%3D10.1152%2Fphysrev.00046.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Linnekin, D.</span><span> </span><span class="NLM_article-title">Early signaling pathways activated by c-Kit in hematopoietic cells</span> <span class="citation_source-journal">Int. J. Biochem. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1053</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span><span class="refDoi"> DOI: 10.1016/S1357-2725(99)00078-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1016%2FS1357-2725%2899%2900078-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10582339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADyaK1MXmsVWitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1999&pages=1053-1074&author=D.+Linnekin&title=Early+signaling+pathways+activated+by+c-Kit+in+hematopoietic+cells&doi=10.1016%2FS1357-2725%2899%2900078-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Early signaling pathways activated by c-Kit in hematopoietic cells</span></div><div class="casAuthors">Linnekin, D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1053-1074</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 171 refs.  C-Kit is a receptor tyrosine kinase that binds stem cell factor (SCF).  Structurally, c-Kit contains five Ig-like domains extracellularly and a catalytic domain divided into two regions by a 77 amino acid insert intracellularly.  Studies in white spotting and steel mice have shown that functional SCF and c-Kit are crit. in the survival and development of stem cells involved in hematopoiesis, pigmentation and reprodn.  Mutations in c-Kit are assocd. with a variety of human diseases.  Interaction of SCF with c-Kit rapidly induces receptor dimerization and increases in autophosphorylation activity.  Downstream of c-Kit, multiple signal transduction components are activated, including phosphatidylinositol-3-kinase, Src family members, the JAK/STAT pathway and the Ras-Raf-MAP kinase cascade.  Structure-function studies have begun to address the role of these signaling components in SCF-mediated responses.  This review will focus on the biochem. mechanism of action of SCF in hematopoietic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-8E1wr3VU-rVg90H21EOLACvtfcHk0lgNxdyj-nrnDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsVWitrc%253D&md5=f8fc51c696dbb65c6885bd55d0e0bde8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1357-2725%2899%2900078-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1357-2725%252899%252900078-3%26sid%3Dliteratum%253Aachs%26aulast%3DLinnekin%26aufirst%3DD.%26atitle%3DEarly%2520signaling%2520pathways%2520activated%2520by%2520c-Kit%2520in%2520hematopoietic%2520cells%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D1999%26volume%3D31%26spage%3D1053%26epage%3D1074%26doi%3D10.1016%2FS1357-2725%2899%2900078-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Hirota, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isozaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiguro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muhammad Tunio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, Y.</span><span> </span><span class="NLM_article-title">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">580</span><span class="refDoi"> DOI: 10.1126/science.279.5350.577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1126%2Fscience.279.5350.577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=9438854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=577-580&author=S.+Hirotaauthor=K.+Isozakiauthor=Y.+Moriyamaauthor=K.+Hashimotoauthor=T.+Nishidaauthor=S.+Ishiguroauthor=K.+Kawanoauthor=M.+Hanadaauthor=A.+Kurataauthor=M.+Takedaauthor=G.+Muhammad+Tunioauthor=Y.+Matsuzawaauthor=Y.+Kanakuraauthor=Y.+Shinomuraauthor=Y.+Kitamura&title=Gain-of-function+mutations+of+c-kit+in+human+gastrointestinal+stromal+tumors&doi=10.1126%2Fscience.279.5350.577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span></div><div class="casAuthors">Hirota, Seiichi; Isozaki, Koji; Moriyama, Yasuhiro; Hashimoto, Koji; Nishida, Toshirou; Ishiguro, Shingo; Kawano, Kiyoshi; Hanada, Masato; Kurata, Akihiko; Takeda, Masashi; Muhammad Tunio, Ghulam; Matsuzawa, Yuji; Kanakura, Yuzuru; Shinomura, Yasuhisa; Kitamura, Yukihiko</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5350</span>),
    <span class="NLM_cas:pages">577-580</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the human digestive tract, but their mol. etiol. and cellular origin are unknown.  Sequencing of c-kit complementary DNA, which encodes a proto-oncogenic receptor tyrosine kinase (KIT), from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains.  All of the corresponding mutant KIT proteins were constitutively activated without the KIT ligand, stem cell factor (SCF).  Stable transfection of the mutant c-kit complementary DNAs induced malignant transformation of Ba/F3 murine lymphoid cells, suggesting that the mutations contribute to tumor development.  GISTs may originate from the interstitial cells of Cajal (ICCs) because the development of ICCs is dependent on the SCF-KIT interaction and because, like GISTs, these cells express both KIT and CD34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLlGnWQ79KELVg90H21EOLACvtfcHk0lj24VuFgOgxhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D&md5=b66b6b8a389b064f73fba13ca84e8650</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.279.5350.577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.279.5350.577%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DS.%26aulast%3DIsozaki%26aufirst%3DK.%26aulast%3DMoriyama%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DIshiguro%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DK.%26aulast%3DHanada%26aufirst%3DM.%26aulast%3DKurata%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DMuhammad%2BTunio%26aufirst%3DG.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DShinomura%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26atitle%3DGain-of-function%2520mutations%2520of%2520c-kit%2520in%2520human%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D1998%26volume%3D279%26spage%3D577%26epage%3D580%26doi%3D10.1126%2Fscience.279.5350.577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duensing, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreevey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">PDGFRA activating mutations in gastrointestinal stromal tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">708</span><span class="NLM_x">–</span> <span class="NLM_lpage">710</span><span class="refDoi"> DOI: 10.1126/science.1079666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1126%2Fscience.1079666" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=708-710&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=A.+Duensingauthor=L.+McGreeveyauthor=C.+J.+Chenauthor=N.+Josephauthor=S.+Singerauthor=D.+J.+Griffithauthor=A.+Haleyauthor=A.+Townauthor=G.+D.+Demetriauthor=C.+D.+Fletcherauthor=J.+A.+Fletcher&title=PDGFRA+activating+mutations+in+gastrointestinal+stromal+tumors&doi=10.1126%2Fscience.1079666"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.1079666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1079666%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DDuensing%26aufirst%3DA.%26aulast%3DMcGreevey%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DJoseph%26aufirst%3DN.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DGriffith%26aufirst%3DD.%2BJ.%26aulast%3DHaley%26aufirst%3DA.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DPDGFRA%2520activating%2520mutations%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D708%26epage%3D710%26doi%3D10.1126%2Fscience.1079666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarlomo-Rikala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tervahartiala, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">1052</span><span class="NLM_x">–</span> <span class="NLM_lpage">1056</span><span class="refDoi"> DOI: 10.1056/NEJM200104053441404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1056%2FNEJM200104053441404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=11287975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=1052-1056&author=H.+Joensuuauthor=P.+J.+Robertsauthor=M.+Sarlomo-Rikalaauthor=L.+C.+Anderssonauthor=P.+Tervahartialaauthor=D.+Tuvesonauthor=S.+Silbermanauthor=R.+Capdevilleauthor=S.+Dimitrijevicauthor=B.+Drukerauthor=G.+D.+Demetri&title=Effect+of+the+tyrosine+kinase+inhibitor+STI571+in+a+patient+with+a+metastatic+gastrointestinal+stromal+tumor&doi=10.1056%2FNEJM200104053441404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor</span></div><div class="casAuthors">Joensuu H; Roberts P J; Sarlomo-Rikala M; Andersson L C; Tervahartiala P; Tuveson D; Silberman S; Capdeville R; Dimitrijevic S; Druker B; Demetri G D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1052-6</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYZ86Vmj15i5otVjB3IRIyfW6udTcc2ebHRTH0XfVH_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D&md5=d361debf544b136b28889449118225e3</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJM200104053441404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200104053441404%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DSarlomo-Rikala%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DL.%2BC.%26aulast%3DTervahartiala%26aufirst%3DP.%26aulast%3DTuveson%26aufirst%3DD.%26aulast%3DSilberman%26aufirst%3DS.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DEffect%2520of%2520the%2520tyrosine%2520kinase%2520inhibitor%2520STI571%2520in%2520a%2520patient%2520with%2520a%2520metastatic%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D1052%26epage%3D1056%26doi%3D10.1056%2FNEJM200104053441404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Abbeele, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiese, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span> </span><span class="NLM_article-title">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x">, </span> <span class="NLM_fpage">472</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span><span class="refDoi"> DOI: 10.1056/NEJMoa020461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1056%2FNEJMoa020461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=12181401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2002&pages=472-480&author=G.+D.+Demetriauthor=M.+von+Mehrenauthor=C.+D.+Blankeauthor=A.+D.+Van+den+Abbeeleauthor=B.+Eisenbergauthor=P.+J.+Robertsauthor=M.+C.+Heinrichauthor=D.+A.+Tuvesonauthor=S.+Singerauthor=M.+Janicekauthor=J.+A.+Fletcherauthor=S.+G.+Silvermanauthor=S.+L.+Silbermanauthor=R.+Capdevilleauthor=B.+Kieseauthor=B.+Pengauthor=S.+Dimitrijevicauthor=B.+J.+Drukerauthor=C.+Corlessauthor=C.+D.+Fletcherauthor=H.+Joensuu&title=Efficacy+and+safety+of+imatinib+mesylate+in+advanced+gastrointestinal+stromal+tumors&doi=10.1056%2FNEJMoa020461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span></div><div class="casAuthors">Demetri, George D.; von Mehren, Margaret; Blanke, Charles D.; Van den Abbeele, Annick D.; Eisenberg, Burton; Roberts, Peter J.; Heinrich, Michael C.; Tuveson, David A.; Singer, Samuel; Janicek, Milos; Fletcher, Jonathan A.; Silverman, Stuart G.; Silberman, Sandra L.; Capdeville, Renaud; Kiese, Beate; Peng, Bin; Dimitrijevic, Sasa; Druker, Brian J.; Corless, Christopher; Fletcher, Christopher D. M.; Joensuu, Heikki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">472-480</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Constitutive activation of KIT receptor tyrosine kinase is crit. in the pathogenesis of gastrointestinal stromal tumors.  Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclin. models and preliminary clin. studies to have activity against such tumors.  We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor.  We assessed antitumor response and the safety and tolerability of the drug.  Pharmacokinetics were assessed in a subgroup of patients.  A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily.  Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for tech. reasons, response could not be evaluated in 7 patients (4.8 percent).  No patient had a complete response to the treatment.  The median duration of response had not been reached after a median follow-up of 24 wk after the onset of response.  Early resistance to imatinib was noted in 20 patients (13.6 percent).  Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common.  Gastrointestinal or intraabdominal hemorrhage occurred in approx. 5 percent of patients.  There were no significant differences in toxic effects or response between the two doses.  Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia.  Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor.  Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVE0HpuuKXXrVg90H21EOLACvtfcHk0lg-eA7g-LLZzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D&md5=95c9ea076dd2b0e053ae2061cb3f5d24</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa020461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa020461%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DJanicek%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DSilverman%26aufirst%3DS.%2BG.%26aulast%3DSilberman%26aufirst%3DS.%2BL.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DKiese%26aufirst%3DB.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DCorless%26aufirst%3DC.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DJoensuu%26aufirst%3DH.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520imatinib%2520mesylate%2520in%2520advanced%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D347%26spage%3D472%26epage%3D480%26doi%3D10.1056%2FNEJMoa020461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalcberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeCesne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issels, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Oosterom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogendoorn, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Glabbeke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertulli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span> </span><span class="NLM_article-title">Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1127</span><span class="NLM_x">–</span> <span class="NLM_lpage">1134</span><span class="refDoi"> DOI: 10.1016/S0140-6736(04)17098-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1016%2FS0140-6736%2804%2917098-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2004&pages=1127-1134&author=J.+Verweijauthor=P.+G.+Casaliauthor=J.+Zalcbergauthor=A.+LeCesneauthor=P.+Reichardtauthor=J.+Y.+Blayauthor=R.+Isselsauthor=A.+van+Oosteromauthor=P.+C.+Hogendoornauthor=M.+Van+Glabbekeauthor=R.+Bertulliauthor=I.+Judson&title=Progression-free+survival+in+gastrointestinal+stromal+tumours+with+high-dose+imatinib%3A+randomised+trial&doi=10.1016%2FS0140-6736%2804%2917098-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2804%2917098-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252804%252917098-0%26sid%3Dliteratum%253Aachs%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DZalcberg%26aufirst%3DJ.%26aulast%3DLeCesne%26aufirst%3DA.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DIssels%26aufirst%3DR.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%26aulast%3DHogendoorn%26aufirst%3DP.%2BC.%26aulast%3DVan%2BGlabbeke%26aufirst%3DM.%26aulast%3DBertulli%26aufirst%3DR.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DProgression-free%2520survival%2520in%2520gastrointestinal%2520stromal%2520tumours%2520with%2520high-dose%2520imatinib%253A%2520randomised%2520trial%26jtitle%3DLancet%26date%3D2004%26volume%3D364%26spage%3D1127%26epage%3D1134%26doi%3D10.1016%2FS0140-6736%2804%2917098-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Antonescu, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besmer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hom, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koryotowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leversha, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desantis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMatteo, R. P.</span><span> </span><span class="NLM_article-title">Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">4182</span><span class="NLM_x">–</span> <span class="NLM_lpage">4190</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-2245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1158%2F1078-0432.CCR-04-2245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=15930355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=4182-4190&author=C.+R.+Antonescuauthor=P.+Besmerauthor=T.+Guoauthor=K.+Arkunauthor=G.+Homauthor=B.+Koryotowskiauthor=M.+A.+Levershaauthor=P.+D.+Jeffreyauthor=D.+Desantisauthor=S.+Singerauthor=M.+F.+Brennanauthor=R.+G.+Makiauthor=R.+P.+DeMatteo&title=Acquired+resistance+to+imatinib+in+gastrointestinal+stromal+tumor+occurs+through+secondary+gene+mutation&doi=10.1158%2F1078-0432.CCR-04-2245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation</span></div><div class="casAuthors">Antonescu, Cristina R.; Besmer, Peter; Guo, Tianhua; Arkun, Knarik; Hom, Glory; Koryotowski, Beata; Leversha, Margaret A.; Jeffrey, Philip D.; Desantis, Diann; Singer, Samuel; Brennan, Murray F.; Maki, Robert G.; DeMatteo, Ronald P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4182-4190</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GIST) have an activating mutation in either KIT or PDGFRA.  Imatinib is a selective tyrosine kinase inhibitor and achieves a partial response or stable disease in about 80% of patients with metastatic GIST.  It is now clear that some patients with GIST develop resistance to imatinib during chronic therapy.  To identify the mechanism of resistance, we studied 31 patients with GIST who were treated with imatinib and then underwent surgical resection.  There were 13 patients who were nonresistant to imatinib, 3 with primary resistance, and 15 with acquired resistance after initial benefit from the drug.  There were no secondary mutations in KIT or PDGFRA in the nonresistant or primary resistance groups.  In contrast, secondary mutations were found in 7 of 15 (46%) patients with acquired resistance, each of whom had a primary mutation in KIT exon 11.  Most secondary mutations were located in KIT exon 17.  KIT phosphorylation was heterogeneous and did not correlate with clin. response to imatinib or mutation status.  That acquired resistance to imatinib in GIST commonly occurs via secondary gene mutation in the KIT kinase domain has implications for strategies to delay or prevent imatinib resistance and to employ newer targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOQf6NfYqwnrVg90H21EOLACvtfcHk0lgU9Vto6NgdvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D&md5=f0f8000b2c362c7d1dcc74a2a7aaa067</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2245%26sid%3Dliteratum%253Aachs%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DArkun%26aufirst%3DK.%26aulast%3DHom%26aufirst%3DG.%26aulast%3DKoryotowski%26aufirst%3DB.%26aulast%3DLeversha%26aufirst%3DM.%2BA.%26aulast%3DJeffrey%26aufirst%3DP.%2BD.%26aulast%3DDesantis%26aufirst%3DD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DBrennan%26aufirst%3DM.%2BF.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26atitle%3DAcquired%2520resistance%2520to%2520imatinib%2520in%2520gastrointestinal%2520stromal%2520tumor%2520occurs%2520through%2520secondary%2520gene%2520mutation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D4182%26epage%3D4190%26doi%3D10.1158%2F1078-0432.CCR-04-2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Debiec-Rychter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciot, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mentens, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vranckx, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasag, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prenen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roesel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagemeijer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Oosterom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marynen, P.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span><span class="refDoi"> DOI: 10.1053/j.gastro.2004.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1053%2Fj.gastro.2004.11.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2005&pages=270-279&author=M.+Debiec-Rychterauthor=J.+Coolsauthor=H.+Dumezauthor=R.+Sciotauthor=M.+Stulauthor=N.+Mentensauthor=H.+Vranckxauthor=B.+Wasagauthor=H.+Prenenauthor=J.+Roeselauthor=A.+Hagemeijerauthor=A.+Van+Oosteromauthor=P.+Marynen&title=Mechanisms+of+resistance+to+imatinib+mesylate+in+gastrointestinal+stromal+tumors+and+activity+of+the+PKC412+inhibitor+against+imatinib-resistant+mutants&doi=10.1053%2Fj.gastro.2004.11.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2004.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2004.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DDebiec-Rychter%26aufirst%3DM.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DDumez%26aufirst%3DH.%26aulast%3DSciot%26aufirst%3DR.%26aulast%3DStul%26aufirst%3DM.%26aulast%3DMentens%26aufirst%3DN.%26aulast%3DVranckx%26aufirst%3DH.%26aulast%3DWasag%26aufirst%3DB.%26aulast%3DPrenen%26aufirst%3DH.%26aulast%3DRoesel%26aufirst%3DJ.%26aulast%3DHagemeijer%26aufirst%3DA.%26aulast%3DVan%2BOosterom%26aufirst%3DA.%26aulast%3DMarynen%26aufirst%3DP.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520imatinib%2520mesylate%2520in%2520gastrointestinal%2520stromal%2520tumors%2520and%2520activity%2520of%2520the%2520PKC412%2520inhibitor%2520against%2520imatinib-resistant%2520mutants%26jtitle%3DGastroenterology%26date%3D2005%26volume%3D128%26spage%3D270%26epage%3D279%26doi%3D10.1053%2Fj.gastro.2004.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDougall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Molecular correlates of imatinib resistance in gastrointestinal stromal tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4764</span><span class="NLM_x">–</span> <span class="NLM_lpage">4774</span><span class="refDoi"> DOI: 10.1200/JCO.2006.06.2265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1200%2FJCO.2006.06.2265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=16954519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFynsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=4764-4774&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=C.+D.+Blankeauthor=G.+D.+Demetriauthor=H.+Joensuuauthor=P.+J.+Robertsauthor=B.+L.+Eisenbergauthor=M.+von+Mehrenauthor=C.+D.+Fletcherauthor=K.+Sandauauthor=K.+McDougallauthor=W.+B.+Ouauthor=C.+J.+Chenauthor=J.+A.+Fletcher&title=Molecular+correlates+of+imatinib+resistance+in+gastrointestinal+stromal+tumors&doi=10.1200%2FJCO.2006.06.2265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular correlates of imatinib resistance in gastrointestinal stromal tumors</span></div><div class="casAuthors">Heinrich, Michael C.; Corless, Christopher L.; Blanke, Charles D.; Demetri, George D.; Joensuu, Heikki; Roberts, Peter J.; Eisenberg, Burton L.; von Mehren, Margaret; Fletcher, Christopher D. M.; Sandau, Katrin; McDougall, Karen; Ou, Wen-bin; Chen, Chang-Jie; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">4764-4774</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of the KIT or platelet-derived growth factor alpha (PDGFRA) kinases, which are targets for imatinib.  In clin. studies, 75% to 90% of patients with advanced GISTs experience clin. benefit from imatinib.  However, imatinib resistance is an increasing clin. problem.  Patients and Methods One hundred forty-seven patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clin. study of imatinib.  Specimens from pretreatment and/or imatinib-resistant tumors were analyzed to identify mol. correlates of imatinib resistance.  Secondary kinase mutations of KIT or PDGFRA that were identified in imatinib-resistant GISTs were biochem. profiled for imatinib sensitivity.  Results Mol. studies were performed using specimens from 10 patients with primary and 33 patients with secondary resistance.  Imatinib-resistant tumors had levels of activated KIT that were similar to or greater than those typically found in untreated GISTs.  Secondary kinase mutations were rare in GISTs with primary resistance but frequently found in GISTs with secondary resistance (10% v 67%, P = .002).  Evidence for clonal evolution and/or polyclonal secondary kinase mutations was seen in three (18.8%) of 16 patients.  Secondary kinase mutations were nonrandomly distributed and were assocd. with decreased imatinib sensitivity compared with typical KIT exon 11 mutations.  Using RNAi technol., we demonstrated that imatinib-resistant GIST cells remain dependent on KIT kinase activity for activation of crit. downstream signaling pathways.  Conclusion Different mol. mechanisms are responsible for primary and secondary imatinib resistance in GISTs.  These findings have implications for future approaches to the growing problem of imatinib resistance in patients with advanced GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw_n35sjCddLVg90H21EOLACvtfcHk0lguUcgU7yNbBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFynsrrN&md5=25f7b94dd02d55c2fb56cea499cb7ab8</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.06.2265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.06.2265%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DEisenberg%26aufirst%3DB.%2BL.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DSandau%26aufirst%3DK.%26aulast%3DMcDougall%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DW.%2BB.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DMolecular%2520correlates%2520of%2520imatinib%2520resistance%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D4764%26epage%3D4774%26doi%3D10.1200%2FJCO.2006.06.2265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNitto, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">English, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greig, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacques, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunney, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quenzer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmett, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">1542</span><span class="NLM_x">–</span> <span class="NLM_lpage">1547</span><span class="refDoi"> DOI: 10.1073/pnas.0812413106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1073%2Fpnas.0812413106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=19164557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=1542-1547&author=K.+S.+Gajiwalaauthor=J.+C.+Wuauthor=J.+Christensenauthor=G.+D.+Deshmukhauthor=W.+Diehlauthor=J.+P.+DiNittoauthor=J.+M.+Englishauthor=M.+J.+Greigauthor=Y.+A.+Heauthor=S.+L.+Jacquesauthor=E.+A.+Lunneyauthor=M.+McTigueauthor=D.+Molinaauthor=T.+Quenzerauthor=P.+A.+Wellsauthor=X.+Yuauthor=Y.+Zhangauthor=A.+Zouauthor=M.+R.+Emmettauthor=A.+G.+Marshallauthor=H.+M.+Zhangauthor=G.+D.+Demetri&title=KIT+kinase+mutants+show+unique+mechanisms+of+drug+resistance+to+imatinib+and+sunitinib+in+gastrointestinal+stromal+tumor+patients&doi=10.1073%2Fpnas.0812413106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span></div><div class="casAuthors">Gajiwala, Ketan S.; Wu, Joe C.; Christensen, James; Deshmukh, Gayatri D.; Diehl, Wade; DiNitto, Jonathan P.; English, Jessie M.; Greig, Michael J.; He, You-Ai; Jacques, Suzanne L.; Lunney, Elizabeth A.; McTigue, Michele; Molina, Dave; Quenzer, Terri; Wells, Peter A.; Yu, Xiu; Zhang, Yan; Zou, Aihua; Emmett, Mark R.; Marshall, Alan G.; Zhang, Hui-Min; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1542-1547</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GISTs) exhibit aberrant activation of the receptor tyrosine kinase (RTK) KIT.  The efficacy of the inhibitors imatinib mesylate and sunitinib malate in GIST patients has been linked to their inhibition of these mutant KIT proteins.  However, patients on imatinib can acquire secondary KIT mutations that render the protein insensitive to the inhibitor.  Sunitinib has shown efficacy against certain imatinib-resistant mutants, although a subset that resides in the activation loop, including D816H/V, remains resistant.  Biochem. and structural studies were undertaken to det. the mol. basis of sunitinib resistance.  Our results show that sunitinib targets the autoinhibited conformation of WT KIT and that the D816H mutant undergoes a shift in conformational equil. toward the active state.  These findings provide a structural and enzymol. explanation for the resistance profile obsd. with the KIT inhibitors.  Prospectively, they have implications for understanding oncogenic kinase mutants and for circumventing drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkwFxa-p-iWbVg90H21EOLACvtfcHk0lguUcgU7yNbBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D&md5=dd226c914c6f9a258426c0f4984a5258</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0812413106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0812413106%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DDeshmukh%26aufirst%3DG.%2BD.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DEnglish%26aufirst%3DJ.%2BM.%26aulast%3DGreig%26aufirst%3DM.%2BJ.%26aulast%3DHe%26aufirst%3DY.%2BA.%26aulast%3DJacques%26aufirst%3DS.%2BL.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMolina%26aufirst%3DD.%26aulast%3DQuenzer%26aufirst%3DT.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DA.%26aulast%3DEmmett%26aufirst%3DM.%2BR.%26aulast%3DMarshall%26aufirst%3DA.%2BG.%26aulast%3DZhang%26aufirst%3DH.%2BM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DKIT%2520kinase%2520mutants%2520show%2520unique%2520mechanisms%2520of%2520drug%2520resistance%2520to%2520imatinib%2520and%2520sunitinib%2520in%2520gastrointestinal%2520stromal%2520tumor%2520patients%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D1542%26epage%3D1547%26doi%3D10.1073%2Fpnas.0812413106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Wardelmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merkelbach-Bruse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schildhaus, H. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinicke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speidel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietsch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buettner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pink, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenberger, P.</span><span> </span><span class="NLM_article-title">Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1743</span><span class="NLM_x">–</span> <span class="NLM_lpage">1749</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-1211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1158%2F1078-0432.CCR-05-1211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=16551858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1Cjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1743-1749&author=E.+Wardelmannauthor=S.+Merkelbach-Bruseauthor=K.+Paulsauthor=N.+Thomasauthor=H.+U.+Schildhausauthor=T.+Heinickeauthor=N.+Speidelauthor=T.+Pietschauthor=R.+Buettnerauthor=D.+Pinkauthor=P.+Reichardtauthor=P.+Hohenberger&title=Polyclonal+evolution+of+multiple+secondary+KIT+mutations+in+gastrointestinal+stromal+tumors+under+treatment+with+imatinib+mesylate&doi=10.1158%2F1078-0432.CCR-05-1211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate</span></div><div class="casAuthors">Wardelmann, Eva; Merkelbach-Bruse, Sabine; Pauls, Katharina; Thomas, Nadja; Schildhaus, Hans-Ulrich; Heinicke, Thomas; Speidel, Nicola; Pietsch, Torsten; Buettner, Reinhard; Pink, Daniel; Reichardt, Peter; Hohenberger, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1743-1749</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GIST) are characterized by a strong KIT receptor activation most often resulting from KIT mutations.  In a smaller subgroup of tumors without KIT mutations, analogous activating mutations are found in the platelet-derived growth factor receptor α (PDGFRα) gene.  Both PDGFRα and KIT receptors are targets of the tyrosine kinase inhibitor imatinib (Glivec) which has improved the treatment of advanced GISTs significantly.  However, a subgroup of tumors show a secondary progress under therapy with imatinib after initial response.  One possible mechanism of secondary resistance is the development of newly acquired KIT mutations.  In the present study, we evaluated the frequency of such secondary KIT mutations in a series of GIST patients in which tumor tissue was resected under treatment.  We examd. one to seven different tumor areas in 32 cases (total of 104 samples) and found up to four newly acquired KIT mutations in 14 patients (43.8%).  These were always located in exons encoding the first or second tyrosine kinase domain (exon 13, 14, or 17).  Mutations were found only in a subset of samples analyzed from each case whereas others retained the wild-type sequence in the same region.  There was never more than one new mutation in the same sample.  Consistent with a secondary clonal evolution, the primary mutation was always detectable in all samples from each tumor.  According to our results, the identification of newly acquired KIT mutations in addn. to the primary mutation is dependent on the no. of tissue samples analyzed and has high implications for further therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhLaWTAFjP7Vg90H21EOLACvtfcHk0lhi1UcKZs_cpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1Cjs7Y%253D&md5=e39c95f452672224e49e8c5515b139c1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1211%26sid%3Dliteratum%253Aachs%26aulast%3DWardelmann%26aufirst%3DE.%26aulast%3DMerkelbach-Bruse%26aufirst%3DS.%26aulast%3DPauls%26aufirst%3DK.%26aulast%3DThomas%26aufirst%3DN.%26aulast%3DSchildhaus%26aufirst%3DH.%2BU.%26aulast%3DHeinicke%26aufirst%3DT.%26aulast%3DSpeidel%26aufirst%3DN.%26aulast%3DPietsch%26aufirst%3DT.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DPink%26aufirst%3DD.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DHohenberger%26aufirst%3DP.%26atitle%3DPolyclonal%2520evolution%2520of%2520multiple%2520secondary%2520KIT%2520mutations%2520in%2520gastrointestinal%2520stromal%2520tumors%2520under%2520treatment%2520with%2520imatinib%2520mesylate%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D1743%26epage%3D1749%26doi%3D10.1158%2F1078-0432.CCR-05-1211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenstein, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span><span class="refDoi"> DOI: 10.1016/j.ccr.2005.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1016%2Fj.ccr.2005.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=15710326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=129-141&author=E.+Weisbergauthor=P.+W.+Manleyauthor=W.+Breitensteinauthor=J.+Bruggenauthor=S.+W.+Cowan-Jacobauthor=A.+Rayauthor=B.+Huntlyauthor=D.+Fabbroauthor=G.+Fendrichauthor=E.+Hall-Meyersauthor=A.+L.+Kungauthor=J.+Mestanauthor=G.+Q.+Daleyauthor=L.+Callahanauthor=L.+Catleyauthor=C.+Cavazzaauthor=A.+Mohammedauthor=D.+Neubergauthor=R.+D.+Wrightauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Characterization+of+AMN107%2C+a+selective+inhibitor+of+native+and+mutant+Bcr-Abl&doi=10.1016%2Fj.ccr.2005.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Breitenstein, Werner; Brueggen, Josef; Cowan-Jacob, Sandra W.; Ray, Arghya; Huntly, Brian; Fabbro, Doriano; Fendrich, Gabriele; Hall-Meyers, Elizabeth; Kung, Andrew L.; Mestan, Juergen; Daley, George Q.; Callahan, Linda; Catley, Laurie; Cavazza, Cara; Mohammed, Azam; Neuberg, Donna; Wright, Renee D.; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL).  We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a no. of imatinib-resistant Bcr-Abl mutants.  Crystallog. anal. of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl.  Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.  AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow6QF3qX2uO7Vg90H21EOLACvtfcHk0lgiT1JanFEaBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D&md5=d28e1a54b982951f8d3e6ef1d2d3b2eb</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBruggen%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DHuntly%26aufirst%3DB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DCallahan%26aufirst%3DL.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DCavazza%26aufirst%3DC.%26aulast%3DMohammed%26aufirst%3DA.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DCharacterization%2520of%2520AMN107%252C%2520a%2520selective%2520inhibitor%2520of%2520native%2520and%2520mutant%2520Bcr-Abl%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D129%26epage%3D141%26doi%3D10.1016%2Fj.ccr.2005.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Adenis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bui-Nguyen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouche, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertucci, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isambert, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bompas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaigneau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domont, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray-Coquard, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blesius, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Tine, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulusu, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubreuil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansfield, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moussy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermine, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Cesne, A.</span><span> </span><span class="NLM_article-title">Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1762</span><span class="NLM_x">–</span> <span class="NLM_lpage">1769</span><span class="refDoi"> DOI: 10.1093/annonc/mdu237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1093%2Fannonc%2Fmdu237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=25122671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FhsFagtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1762-1769&author=A.+Adenisauthor=J.+Y.+Blayauthor=B.+Bui-Nguyenauthor=O.+Boucheauthor=F.+Bertucciauthor=N.+Isambertauthor=E.+Bompasauthor=L.+Chaigneauauthor=J.+Domontauthor=I.+Ray-Coquardauthor=A.+Blesiusauthor=B.+A.+Van+Tineauthor=V.+R.+Bulusuauthor=P.+Dubreuilauthor=C.+D.+Mansfieldauthor=Y.+Acinauthor=A.+Moussyauthor=O.+Hermineauthor=A.+Le+Cesne&title=Masitinib+in+advanced+gastrointestinal+stromal+tumor+%28GIST%29+after+failure+of+imatinib%3A+a+randomized+controlled+open-label+trial&doi=10.1093%2Fannonc%2Fmdu237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial</span></div><div class="casAuthors">Adenis A; Blay J-Y; Ray-Coquard I; Bui-Nguyen B; Bouche O; Bertucci F; Isambert N; Bompas E; Chaigneau L; Domont J; Blesius A; Le Cesne A; Van Tine B A; Bulusu V R; Dubreuil P; Mansfield C D; Acin Y; Moussy A; Hermine O</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1762-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Masitinib is a highly selective tyrosine kinase inhibitor with activity against the main oncogenic drivers of gastrointestinal stromal tumor (GIST).  Masitinib was evaluated in patients with advanced GIST after imatinib failure or intolerance.  PATIENTS AND METHODS:  Prospective, multicenter, randomized, open-label trial.  Patients with inoperable, advanced imatinib-resistant GIST were randomized (1 : 1) to receive masitinib (12 mg/kg/day) or sunitinib (50 mg/day 4-weeks-on/2-weeks-off) until progression, intolerance, or refusal.  Primary efficacy analysis was noncomparative, testing whether masitinib attained a median progression-free survival (PFS) (blind centrally reviewed RECIST) threshold of >3 months according to the lower bound of the 90% unilateral confidence interval (CI).  Secondary analyses on overall survival (OS) and PFS were comparative with results presented according to a two-sided 95% CI.  RESULTS:  Forty-four patients were randomized to receive masitinib (n = 23) or sunitinib (n = 21).  Median follow-up was 14 months.  Patients receiving masitinib experienced less toxicity than those receiving sunitinib, with significantly lower occurrence of severe adverse events (52% versus 91%, respectively, P = 0.008).  Median PFS (central RECIST) for the noncomparative primary analysis in the masitinib treatment arm was 3.71 months (90% CI 3.65).  Secondary analyses showed that median OS was significantly longer for patients receiving masitinib followed by post-progression addition of sunitinib when compared against patients treated directly with sunitinib in second-line [hazard ratio (HR) = 0.27, 95% CI 0.09-0.85, P = 0.016].  This improvement was sustainable as evidenced by 26-month follow-up OS data (HR = 0.40, 95% CI 0.16-0.96, P = 0.033); an additional 12.4 months survival advantage being reported for the masitinib treatment arm.  Risk of progression while under treatment with masitinib was in the same range as for sunitinib (HR = 1.1, 95% CI 0.6-2.2, P = 0.833).  CONCLUSIONS:  Primary efficacy analysis ensured the masitinib treatment arm could satisfy a prespecified PFS threshold.  Secondary efficacy analysis showed that masitinib followed by the standard of care generated a statistically significant survival benefit over standard of care.  Encouraging median OS and safety data from this well-controlled and appropriately designed randomized trial indicate a positive benefit-risk ratio.  Further development of masitinib in imatinib-resistant/intolerant patients with advanced GIST is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxkpR-5bcD_eb6AVA-44PTfW6udTcc2eZuMjdGtblUr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FhsFagtA%253D%253D&md5=a2aae8942a25c3f43682342282f40402</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu237%26sid%3Dliteratum%253Aachs%26aulast%3DAdenis%26aufirst%3DA.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DBui-Nguyen%26aufirst%3DB.%26aulast%3DBouche%26aufirst%3DO.%26aulast%3DBertucci%26aufirst%3DF.%26aulast%3DIsambert%26aufirst%3DN.%26aulast%3DBompas%26aufirst%3DE.%26aulast%3DChaigneau%26aufirst%3DL.%26aulast%3DDomont%26aufirst%3DJ.%26aulast%3DRay-Coquard%26aufirst%3DI.%26aulast%3DBlesius%26aufirst%3DA.%26aulast%3DVan%2BTine%26aufirst%3DB.%2BA.%26aulast%3DBulusu%26aufirst%3DV.%2BR.%26aulast%3DDubreuil%26aufirst%3DP.%26aulast%3DMansfield%26aufirst%3DC.%2BD.%26aulast%3DAcin%26aufirst%3DY.%26aulast%3DMoussy%26aufirst%3DA.%26aulast%3DHermine%26aufirst%3DO.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26atitle%3DMasitinib%2520in%2520advanced%2520gastrointestinal%2520stromal%2520tumor%2520%2528GIST%2529%2520after%2520failure%2520of%2520imatinib%253A%2520a%2520randomized%2520controlled%2520open-label%2520trial%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26spage%3D1762%26epage%3D1769%26doi%3D10.1093%2Fannonc%2Fmdu237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Guo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agaram, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hom, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Adamo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMatteo, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besmer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonescu, C. R.</span><span> </span><span class="NLM_article-title">Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">4874</span><span class="NLM_x">–</span> <span class="NLM_lpage">4881</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-0484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1158%2F1078-0432.CCR-07-0484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=17699867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGmtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=4874-4881&author=T.+Guoauthor=N.+P.+Agaramauthor=G.+C.+Wongauthor=G.+Homauthor=D.+D%E2%80%99Adamoauthor=R.+G.+Makiauthor=G.+K.+Schwartzauthor=D.+Veachauthor=B.+D.+Clarksonauthor=S.+Singerauthor=R.+P.+DeMatteoauthor=P.+Besmerauthor=C.+R.+Antonescu&title=Sorafenib+inhibits+the+imatinib-resistant+KITT670I+gatekeeper+mutation+in+gastrointestinal+stromal+tumor&doi=10.1158%2F1078-0432.CCR-07-0484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor</span></div><div class="casAuthors">Guo, Tianhua; Agaram, Narasimhan P.; Wong, Grace C.; Hom, Glory; D'Adamo, David; Maki, Robert G.; Schwartz, Gary K.; Veach, Darren; Clarkson, Bayard D.; Singer, Samuel; DeMatteo, Ronald P.; Besmer, Peter; Antonescu, Cristina R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4874-4881</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Resistance is commonly acquired in patients with metastatic gastrointestinal stromal tumor who are treated with imatinib mesylate, often due to the development of secondary mutations in the KIT kinase domain.  We sought to investigate the efficacy of second-line tyrosine kinase inhibitors, such as sorafenib, dasatinib, and nilotinib, against the commonly obsd. imatinib-resistant KIT mutations (KITV654A, KITT670I, KITD820Y, and KITN822K) expressed in the Ba/F3 cellular system.  EXPTL. DESIGN: In vitro drug screening of stable Ba/F3 KIT mutants recapitulating the genotype of imatinib-resistant patients harboring primary and secondary KIT mutations was investigated.  Comparison was made to imatinib-sensitive Ba/F3 KIT mutant cells as well as Ba/F3 cells expressing only secondary KIT mutations.  The efficacy of drug treatment was evaluated by proliferation and apoptosis assays, in addn. to biochem. inhibition of KIT activation.  RESULTS: Sorafenib was potent against all imatinib-resistant Ba/F3 KIT double mutants tested, including the gatekeeper secondary mutation KITWK557-8del/T670I, which was resistant to other kinase inhibitors.  Although all three drugs tested decreased cell proliferation and inhibited KIT activation against exon 13 (KITV560del/V654A) and exon 17 (KITV559D/D820Y) double mutants, nilotinib did so at lower concns.  CONCLUSIONS: Our results emphasize the need for tailored salvage therapy in imatinib-refractory gastrointestinal stromal tumors according to individual mol. mechanisms of resistance.  The Ba/F3 KITWK557-8del/T670I cells were sensitive only to sorafenib inhibition, whereas nilotinib was more potent on imatinib-resistant KITV560del/V654A and KITV559D/D820Y mutant cells than dasatinib and sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqllTJoDeevKbVg90H21EOLACvtfcHk0ljAD0YoFIX_Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGmtLw%253D&md5=f1643671ada85f1bcd05faa04cd88b52</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0484%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DAgaram%26aufirst%3DN.%2BP.%26aulast%3DWong%26aufirst%3DG.%2BC.%26aulast%3DHom%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Adamo%26aufirst%3DD.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DVeach%26aufirst%3DD.%26aulast%3DClarkson%26aufirst%3DB.%2BD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26atitle%3DSorafenib%2520inhibits%2520the%2520imatinib-resistant%2520KITT670I%2520gatekeeper%2520mutation%2520in%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D4874%26epage%3D4881%26doi%3D10.1158%2F1078-0432.CCR-07-0484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1230</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span><span class="refDoi"> DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+type+II+binding+mode%3A+A+privileged+approach+for+kinase+inhibitor+focused+drug+discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0ljAD0YoFIX_Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520type%2520II%2520binding%2520mode%253A%2520A%2520privileged%2520approach%2520for%2520kinase%2520inhibitor%2520focused%2520drug%2520discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1051</span><span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0lgOCdC9FZmpwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Grunewald, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mühlenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuler, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span> </span><span class="NLM_article-title">Effect of secondary KIT mutations on growth of GIST cells in the absence of selective pressure by imatinib in isogenic models of imatinib resistance</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">No. 15, May 20 Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">10555</span><div class="note"><p class="first last">(ASCO Annual Meeting Abstracts)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=10555&issue=No.+15%2C+May+20+Suppl.&author=S.+Grunewaldauthor=T.+M%C3%BChlenbergauthor=B.+Rubinauthor=M.+H.+Schulerauthor=J.+A.+Fletcherauthor=S.+Bauer&title=Effect+of+secondary+KIT+mutations+on+growth+of+GIST+cells+in+the+absence+of+selective+pressure+by+imatinib+in+isogenic+models+of+imatinib+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrunewald%26aufirst%3DS.%26aulast%3DM%25C3%25BChlenberg%26aufirst%3DT.%26aulast%3DRubin%26aufirst%3DB.%26aulast%3DSchuler%26aufirst%3DM.%2BH.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DBauer%26aufirst%3DS.%26atitle%3DEffect%2520of%2520secondary%2520KIT%2520mutations%2520on%2520growth%2520of%2520GIST%2520cells%2520in%2520the%2520absence%2520of%2520selective%2520pressure%2520by%2520imatinib%2520in%2520isogenic%2520models%2520of%2520imatinib%2520resistance%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26issue%3DNo.%252015%252C%2520May%252020%2520Suppl%26spage%3D10555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Duensing, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medeiros, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McConarty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panigrahy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3999</span><span class="NLM_x">–</span> <span class="NLM_lpage">4006</span><span class="refDoi"> DOI: 10.1038/sj.onc.1207525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1038%2Fsj.onc.1207525" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=3999-4006&author=A.+Duensingauthor=F.+Medeirosauthor=B.+McConartyauthor=N.+E.+Josephauthor=D.+Panigrahyauthor=S.+Singerauthor=C.+D.+Fletcherauthor=G.+D.+Demetriauthor=J.+A.+Fletcher&title=Mechanisms+of+oncogenic+KIT+signal+transduction+in+primary+gastrointestinal+stromal+tumors+%28GISTs%29&doi=10.1038%2Fsj.onc.1207525"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207525%26sid%3Dliteratum%253Aachs%26aulast%3DDuensing%26aufirst%3DA.%26aulast%3DMedeiros%26aufirst%3DF.%26aulast%3DMcConarty%26aufirst%3DB.%26aulast%3DJoseph%26aufirst%3DN.%2BE.%26aulast%3DPanigrahy%26aufirst%3DD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DMechanisms%2520of%2520oncogenic%2520KIT%2520signal%2520transduction%2520in%2520primary%2520gastrointestinal%2520stromal%2520tumors%2520%2528GISTs%2529%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D3999%26epage%3D4006%26doi%3D10.1038%2Fsj.onc.1207525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Pollard, J. W.</span><span> </span><span class="NLM_article-title">Trophic macrophages in development and disease</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1038/nri2528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1038%2Fnri2528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=19282852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFCisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=259-270&author=J.+W.+Pollard&title=Trophic+macrophages+in+development+and+disease&doi=10.1038%2Fnri2528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Trophic macrophages in development and disease</span></div><div class="casAuthors">Pollard, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">259-270</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Specialized phagocytes are found in the most primitive multicellular organisms.  Their roles in homeostasis and in distinguishing self from non-self have evolved with the complexity of organisms and their immune systems.  Equally important, but often overlooked, are the roles of macrophages in tissue development.  As discussed in this Review, these include functions in branching morphogenesis, neuronal patterning, angiogenesis, bone morphogenesis and the generation of adipose tissue.  In each case, macrophage depletion impairs the formation of the tissue and compromises its function.  I argue that in several diseases, the unrestrained acquisition of these developmental macrophage functions exacerbates pathol.  For example, macrophages enhance tumor progression and metastasis by affecting tumor-cell migration and invasion, as well as angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR03M07hzbU7Vg90H21EOLACvtfcHk0ljQmOjzC6TpsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFCisbc%253D&md5=d29685d4cbb8d8bdd296f8b8ff869d36</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnri2528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2528%26sid%3Dliteratum%253Aachs%26aulast%3DPollard%26aufirst%3DJ.%2BW.%26atitle%3DTrophic%2520macrophages%2520in%2520development%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D9%26spage%3D259%26epage%3D270%26doi%3D10.1038%2Fnri2528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Case, D. A.; Babin, V.; Berryman, J. T.; Betz, R. M.; Cai, Q.; Cerutti, D. S.; Cheatham, T. A.,  III; Darden, T. A.; Duke, R. E.; Gohlke, H.; Gietz, A. W.; Gusarov, S.; Homeyer, N.; Jonowski, P.; Kaus, J.; Kolossváry, I.; Kovalenko, A.; Lee, T. S.; LeGrand, S.; Luchko, T.; Luo, R.; Madei, B.; Merz, K. M.; Paesani, F.; Roe, D. R.; Roitberg, A.; Sagui, C.; Salomon-Ferrer, R.; Seabra, G.; Simmerling, C. L.; Smith, W.; Swails, J.; Walker, R. C.; Wang, J.; Wolf, R. M.; Wu, X.; Kollman, P. A.</span>AMBER14; <span class="NLM_publisher-name">University of California</span>: <span class="NLM_publisher-loc">San Francisco, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=D.+A.+Case&author=V.+Babin&author=J.+T.+Berryman&author=R.+M.+Betz&author=Q.+Cai&author=D.+S.+Cerutti&author=T.+A.+Cheatham&author=T.+A.+Darden&author=R.+E.+Duke&author=H.+Gohlke&author=A.+W.+Gietz&author=S.+Gusarov&author=N.+Homeyer&author=P.+Jonowski&author=J.+Kaus&author=I.+Kolossv%C3%A1ry&author=A.+Kovalenko&author=T.+S.+Lee&author=S.+LeGrand&author=T.+Luchko&author=R.+Luo&author=B.+Madei&author=K.+M.+Merz&author=F.+Paesani&author=D.+R.+Roe&author=A.+Roitberg&author=C.+Sagui&author=R.+Salomon-Ferrer&author=G.+Seabra&author=C.+L.+Simmerling&author=W.+Smith&author=J.+Swails&author=R.+C.+Walker&author=J.+Wang&author=R.+M.+Wolf&author=X.+Wu&author=P.+A.+Kollman&title=AMBER14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DCase%26aufirst%3DD.%2BA.%26jtitle%3DAMBER14%26pub%3DUniversity%2520of%2520California%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Word, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovell, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. C.</span><span> </span><span class="NLM_article-title">Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">1735</span><span class="NLM_x">–</span> <span class="NLM_lpage">1747</span><span class="refDoi"> DOI: 10.1006/jmbi.1998.2401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1006%2Fjmbi.1998.2401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=9917408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=1%3ACAS%3A528%3ADyaK1MXhtV2ht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1999&pages=1735-1747&author=J.+M.+Wordauthor=S.+C.+Lovellauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=Asparagine+and+glutamine%3A+using+hydrogen+atom+contacts+in+the+choice+of+side-chain+amide+orientation&doi=10.1006%2Fjmbi.1998.2401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Asparagine and Glutamine: Using Hydrogen Atom Contacts in the Choice of Side-chain Amide Orientation</span></div><div class="casAuthors">Word, J. Michael; Lovell, Simon C.; Richardson, Jane S.; Richardson, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1735-1747</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Small-probe contact dot surface anal., with all explicit hydrogen atoms added and their van der Waals contacts included, was used to choose between the two possible orientations for each of 1554 asparagine (Asn) and glutamine (Gln) side-chain amide groups in a dataset of 100 unrelated, high-quality protein crystal structures at 0.9 to 1.7 Å resoln.  For the movable-H groups, each connected, closed set of local H-bonds was optimized for both H-bonds and van der Waals overlaps.  In addn. to the Asn/Gln "flips", this process included rotation of OH, SH, NH3+, and methionine Me H atoms, flip and protonation state of histidine rings, interaction with bound ligands, and a simple model of water interactions.  However, except for switching N and O identity for amide flips (or N and C identity for His flips), no non-H atoms were shifted.  Even in these very high-quality structures, about 20 % of the Asn/Gln side-chains required a 180° flip to optimize H-bonding and/or to avoid NH2 clashes with neighboring atoms (incorporating a conservative score penalty which, for marginal cases, favors the assignment in the original coordinate file).  The programs Reduce, Probe, and Mage provide not only a suggested amide orientation, but also a numerical score comparison, a categorization of the marginal cases, and a direct visualization of all relevant interactions in both orientations.  Visual examn. allowed confirmation of the raw score assignment for about 40 % of those Asn/Gln flips placed within the "marginal" penalty range by the automated algorithm, while uncovering only a small no. of cases whose automated assignment was incorrect because of special circumstances not yet handled by the algorithm.  It seems that the H-bond and the at.-clash criteria independently look at the same structural realities: when both criteria gave a clear answer, they agreed every time.  But consideration of van der Waals clashes settled many addnl. cases for which H-bonding was either absent or approx. equiv. for the two main alternatives.  With this extra information, 86 % of all side-chain amide groups could be oriented quite unambiguously.  In the absence of further exptl. data, it would probably be inappropriate to assign many more than this.  Some of the remaining 14 % are ambiguous because of coordinate error or inadequacy of the theor. model, but the great majority of ambiguous cases probably occur as a dynamic mix of both flip states in the actual protein mol.  The software and the 100 coordinate files with all H atoms added and optimized and with amide flips cor. are publicly available.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC6MEkiSKy07Vg90H21EOLACvtfcHk0ljQmOjzC6TpsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhtV2ht7g%253D&md5=a3bd044a8652a5ac03e2eb7b9414c2e0</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1998.2401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1998.2401%26sid%3Dliteratum%253Aachs%26aulast%3DWord%26aufirst%3DJ.%2BM.%26aulast%3DLovell%26aufirst%3DS.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DAsparagine%2520and%2520glutamine%253A%2520using%2520hydrogen%2520atom%2520contacts%2520in%2520the%2520choice%2520of%2520side-chain%2520amide%2520orientation%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1999%26volume%3D285%26spage%3D1735%26epage%3D1747%26doi%3D10.1006%2Fjmbi.1998.2401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Rossato, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smieško, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spreafico, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vedani, A.</span><span> </span><span class="NLM_article-title">Probing small-molecule binding to cytochrome P450 2D6 and 2C9: An in silico protocol for generating toxicity alerts</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">2088</span><span class="NLM_x">–</span> <span class="NLM_lpage">2101</span><span class="refDoi"> DOI: 10.1002/cmdc.201000358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;key=10.1002%2Fcmdc.201000358" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=2088-2101&author=G.+Rossatoauthor=B.+Ernstauthor=M.+Smie%C5%A1koauthor=M.+Spreaficoauthor=A.+Vedani&title=Probing+small-molecule+binding+to+cytochrome+P450+2D6+and+2C9%3A+An+in+silico+protocol+for+generating+toxicity+alerts&doi=10.1002%2Fcmdc.201000358"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000358%26sid%3Dliteratum%253Aachs%26aulast%3DRossato%26aufirst%3DG.%26aulast%3DErnst%26aufirst%3DB.%26aulast%3DSmie%25C5%25A1ko%26aufirst%3DM.%26aulast%3DSpreafico%26aufirst%3DM.%26aulast%3DVedani%26aufirst%3DA.%26atitle%3DProbing%2520small-molecule%2520binding%2520to%2520cytochrome%2520P450%25202D6%2520and%25202C9%253A%2520An%2520in%2520silico%2520protocol%2520for%2520generating%2520toxicity%2520alerts%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D2088%26epage%3D2101%26doi%3D10.1002%2Fcmdc.201000358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Dobler, M.</span>BioX, a Versatile Molecular-Modeling Software; B<span class="NLM_publisher-name">iographics Laboratory 3R</span>: <span class="NLM_publisher-loc">Basel, Switzerland</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.biograf.ch/index.php?id=software" class="extLink">http://www.biograf.ch/index.php?id=software</a> (Updated Nov 8, 2014).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Dobler&title=BioX%2C+a+Versatile+Molecular-Modeling+Software"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DDobler%26aufirst%3DM.%26jtitle%3DBioX%252C%2520a%2520Versatile%2520Molecular-Modeling%2520Software%26pub%3Diographics%2520Laboratory%25203R%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46','PDB','1T46'); return false;">PDB: 1T46</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i81"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00902">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_65102"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00902">10.1021/acs.jmedchem.6b00902</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Table S1 listing DiscoverX’s KinomeScan selectivity profiling data of compound <b>35</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00902/suppl_file/jm6b00902_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00902/suppl_file/jm6b00902_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00902/suppl_file/jm6b00902_si_001.pdf">jm6b00902_si_001.pdf (745.73 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00902/suppl_file/jm6b00902_si_002.csv">jm6b00902_si_002.csv (5.09 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00902%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-18" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00902" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0ec7588ba221c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
